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PROJECT ABSTRACT 
 
This project was designed to investigate the mechanisms by which recombinant human 
growth hormone (rhGH) and recombinant insulin-like growth factor-1 (rIGF-1), over a 
range of physiological and supra-physiological concentrations, regulate key components 
of mitochondrial function in addition to determining the subsequent impact of this 
regulation on cellular viability. The project was divided into three studies. 
Study One investigated whether rhGH and rIGF-1 exert a direct effect on the function of 
mitochondria over a range of physiological and supra-physiological concentrations in 
peripheral blood mononuclear cells (PBMCs) from healthy male subjects. PBMCs were 
incubated for 4 hours with either rhGH (Range = 0.25 – 100µg/L) or IGF-1 (Range = 
100 – 600µg/L) and subsequently analysed for the determination of cellular viability, 
mitochondrial membrane potential (Δψm), mitochondrial superoxide (O2−) generation 
and mitochondrial transition pore activity (mtPTP) activity. Levels of mitochondrial 
superoxide generation were found to be significantly reduced compared to control 
samples (lymphocytes – 21.5±1.6AU / monocytes – 230.2±9.8AU) following rhGH 
treatment at concentrations of 5µg/L (13.5±1.3AU, P≤0.05) and 10µg/L (12.3±1.5AU, 
P≤0.05) in lymphocytes and at concentrations of 10µg/L (153.4±11.4AU, P≤0.05) in 
monocytes, while no significant effect was found at higher concentrations or following 
treatment with IGF-1. Treatment with either hormone was not found to have any 
significant effect on Δψm, mtPTP activity or percentages of cellular viability. 
Study Two investigated the mitochondrial effects exerted by physiological and supra-
physiological concentrations of rhGH (Range = 0.5 – 50µg/L) and rIGF-1 (Range = 100 
– 500µg/L) under various respiratory conditions of substrate saturation in PBMCs from 
healthy male subjects. The level of mitochondrial highly reactive oxygen species 
(hROS) production and Δψm were determined in digitonin permeabilized cells, in the 
presence of the following respiratory substrates 1) pyruvate / malate 2) succinate / 
rotenone 3) pyruvate / malate / succinate and 4) octanoate / malate. Neither rhGH nor 
rIGF-1 exerted any significant effect on hROS levels in either lymphocyte (P=0.90) or 
monocyte (P=0.85) sub-populations at any concentration administered. Similarly, 
neither rhGH nor rIGF-1 exerted any significant effect on Δψm in either lymphocyte 
(P=0.97) or monocyte (P=0.78) sub-populations at any concentration administered. 
21 
 
Study Three was designed to determine the effect of the administration of rhGH for one 
week on the regulation of mitochondrial mediated apoptosis in PBMCs from healthy 
male subjects who undertake regular physical activity. Blood sampling was undertaken 
before rhGH administration and over a period of three weeks (Days 8, 15, 22 & 29) 
following the final injection of rhGH. PBMCs were isolated for the determination of 
miRNA, mRNA and protein expression levels in both placebos and cases. Results 
showed that rhGH had no effects on the mRNA and protein expression of the anti-
apoptotic Bcl-2. However, post rhGH administration showed a significant effect on the 
pro-apoptotic Bak which exhibited decreased protein concentrations compared to 
baseline and following correction with placebos. This effect was observed up to 8 days 
following the last rhGH treatment. Cytosolic miRNA expression was not found to be 
significantly affected by rhGH. However, measurement of the expression of miR-125b, 
a known target of Bak, in mitochondrial fractions showed a significant down-regulation 
8 days post rhGH administration. 
The evidence presented in this thesis points towards the mitochondrial effects elicited 
by rhGH being beneficial at physiological concentrations. However, it appears that 
these benefits are negated following rhGH treatment within the supra-physiological 
range. In addition, rhGH was found to be incapable of countering mitochondrial 
dysfunction induced in the presence of saturating substrate conditions at any 
administered concentration. These findings could have important health implications for 
any individual intent on improving their athletic capabilities through the administration 
of rhGH at supra-physiological dosages. 
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1.1 – Project Introduction  
The aim of this project was two-fold, firstly to investigate how recombinant human 
growth hormone (rhGH), the genetically engineered form of GH, and insulin-like 
growth factor-1 (IGF-1), over a range of physiological and supra-physiological 
concentrations, regulate key components of mitochondrial function, and secondly to 
determine the consequences of this regulation for cellular viability. The physiological 
role of growth hormone (GH), a peptide growth factor produced in the anterior pituitary, 
involves the regulation of cell growth via activation of proliferation and differentiation 
pathways in multiple tissue types, including bone, connective, adipose and muscle 
tissue [1, 2]. Its biological actions consist of metabolic effects, including a stimulation 
of protein synthesis and a promotion of lipolysis [3]. IGF-1, a downstream mediator of 
many of GH’s anabolic effects is released from the liver in response to GH signalling 
[4, 5]. 
Growth, protein synthesis and many components of fuel metabolism require the 
utilization of cellular energy that is obtained through the dephosphorylation of the high 
energy phosphate nucleotide adenosine triphosphate (ATP) [6].  ATP is primarily 
generated in mitochondria via oxidative phosphorylation [6-8]. Mitochondria are oval 
shaped intracellular organelles consisting of an outer membrane and an inner membrane 
which folds to form cristae in the mitochondrial matrix [8]. Enzymes of the Krebs cycle 
and oxidative phosphorylation are located in the mitochondrial matrix and within the 
inner mitochondrial membrane (IMM) respectively allowing for the generation of ATP 
from the substrates adenosine diphosphate (ADP) and inorganic phosphate (Pi) [6-8]. 
Oxidative phosphorylation utilizes the potential energy across the IMM, termed the 
mitochondrial membrane potential (Δψm), which is generated via proton pumping 
powered by the transfer of electrons along the electron transport chain (ETC), to drive 
the phosphorylation of ADP [6-8]. A consequence of this process is the generation of 
reactive oxygen species (ROS), metabolites of molecular oxygen (O2) formed as a result 
of the leakage of electrons from the ETC [9]. If not countered by the cell’s antioxidant 
defences, ROS will react with key cellular components, causing damage to intracellular 
lipids, proteins and nucleic acids [9, 10]. This has negative implications for optimum 
cellular function in terms of increased oxidative damage to key mitochondrial 
components and mitochondrially mediated activation of apoptosis, a regulated form of 
cell death [9-11].   
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In higher organisms, cells must adapt to constantly changing metabolic environments 
where the demand for energy can fluctuate widely depending on the functional activity 
of the cell [6]. Any stimulation of cellular activity that changes either the anabolic or 
catabolic environment of the cell requires an adjustment in the rate of energy production 
in order to match physiological demand [6]. Thus, the rate and efficiency of oxidative 
phosphorylation has to be tightly regulated [6]. It has been proposed that this regulation 
is principally mediated by the same extracellular agonists that modulate cellular activity 
via nuclear directed signalling pathways, through the parallel activation of cell 
signalling cascades targeted towards mitochondria [6]. Research has demonstrated that 
while some hormones such as epidermal growth factor (EGF) act through the targeting 
of their receptor to the organelle via endocytosis, the effects of other hormones, such as 
insulin and IGF-1, are mediated via the downstream activation of protein kinases [6, 7, 
12, 13].  
Under optimum conditions mitochondria function in an efficient manner, maintaining a 
tight coupling between O2 consumption and ATP synthesis, down-regulating the 
activity of the ETC in order to avoid the development of high Δψm values and keep the 
rate of ROS production at a low level [14]. This is proposed to be achieved through 
signal transduction mediated phosphorylation of ETC complexes, under which allosteric 
feedback inhibits key components of the ETC through elevations in the ATP/ADP ratio 
[14]. This allows Δψm values to be adjusted in line with the demand for ATP [14]. 
Under conditions of high ATP utilization, increased rates of ATP synthase activity will 
decrease Δψm to values insufficient for the rate of ATP production to be maintained 
[14]. Thus, the activity of the ETC must be raised in order to prevent a decrease of Δψm 
below values necessary to match the required rate of ATP production [14]. Signal 
transduction mediated de-phosphorylation of ETC complexes is suggested to both, 
inactivate allosteric ATP inhibition and, up-regulate the activity of individual ETC 
complexes [14]. However, excessive stimulation of ETC activity can result in 
hyperpolarization of Δψm to values that do not further accelerate ATP production but at 
which elevated levels of ROS are generated [14]. 
The project consisted of three studies which examined the impact rhGH and IGF-1 have 
on mitochondrial function in peripheral blood mononuclear cell’s (PBMCs). PBMCs, 
which consist of lymphocyte and monocyte cell sub-populations, are easily isolated 
from whole blood, exhibit both GH and IGF-1 cell surface receptors, and have 
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previously been demonstrated to incur changes in gene and protein expression in 
response to rhGH and IGF-1 (15-19). Study One investigated whether rhGH and IGF-1 
over a range of physiological and supra-physiological concentrations exerted a direct 
effect on Δψm and levels of mitochondrial ROS production in PBMCs in-vitro. The 
implications of this regulation in terms of its impact on mitochondrial mediated 
apoptosis and levels of cellular viability were also addressed. Mitochondrial responses 
to rhGH and IGF-1 administration in PBMCs at physiological and supra-physiological 
concentrations in-vitro were further addressed in Study Two, again through the analysis 
of Δψm and levels of mitochondrial ROS production. The examination of these variables 
was conducted under several respiratory conditions, which to varying degrees, gave 
control over the sites of electron entry into the ETC, allowing for interpretation of the 
role played by individual complexes in mediating the effects of both rhGH and IGF-1. 
These two hormones are suspected to induce an up-regulation of oxidative 
phosphorylation in order to meet the energy demands associated with their anabolic 
effects. It is proposed that, at supra-physiological concentrations, this increment in the 
rate of ATP production is produced at the expense of the efficiency of electron transport 
along the respiratory chain leading to an augmented production of ROS and that this has 
negative implications for cellular viability [20].  
While rhGH and IGF-1 exhibit well documented anti-apoptotic affects in-vitro, whether 
long-term effects persist in-vivo following the cessation of treatment is currently 
unknown. Furthermore, GH is associated with the development of pro-apoptotic 
conditions at supra-physiological concentrations in-vivo [21-23]. Study Three 
investigated the effect of rhGH administration on the regulation of mitochondrial 
mediated apoptosis in PBMCs in-vivo for up to three weeks post-treatment with the 
intent of determining how long purported anti-apoptotic benefits of elevated GH 
concentrations persist following the cessation of treatment. Potential implications for 
cellular viability were addressed through analysis of the GH mediated effects on the 
expression of apoptotic regulatory proteins. It is proposed that the initial anti-apoptotic 
effects induced by GH are attenuated following the cessation of treatment, leaving the 
cells susceptible to oxidative insult. Finally, potential mechanisms for the regulation of 
mitochondrial mediated apoptosis following rhGH administration in-vivo were 
investigated through the examination of the hormones effects on the expression of a 
class of regulatory RNA molecules, termed microRNA (miRNA), which target specific 
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apoptotic-regulatory genes [24]. This included the investigation of a novel 
mitochondrial associated miRNA signalling pathway. In light of the significant interest 
that peptide growth factors, such as GH and IGF-1, garner in athletic populations, the 
overriding aim of this research project was to elucidate any potential consequences at 
the molecular level from the administration of these hormones in healthy populations 
[25, 26]. 
1.2 – Project Rationale  
Despite the lack of any scientific evidence from peer reviewed journals in regard to the 
performance enhancing effects of rhGH, its use is reported to be widespread among 
athletes as well as health and fitness orientated populations [25, 26]. Individuals thought 
to abuse rhGH consist of elite competitive athletes in addition to both competitive and 
recreational bodybuilders who often self-administer large doses without supervision and 
in combination with other anabolic substances [27]. Evidence from the United States 
indicates that the use of rhGH as well as other anabolic substances such or androgenic 
steroids is not confined to professional athletes [26]. A report from the National 
Collegiate Athletic Association (NCAA) in 2001 claimed that 3.5% of college level 
athletes used GH that year [28], while Rickert et al. [29] estimated that 5% of male 
American high school students are either using or have previously used GH in order to 
induce an anabolic effect.  
The practice of administering rhGH for the purposes of enhancing athletic performance 
has been banned by most professional sports leagues and associations including the 
International Olympic Committee, as well as Major League Baseball and the National 
Football League in America [30]. The World Anti-Doping Agencies (WADA) classifies 
both GH and IGF-1 as prohibited substances (Class S2 – Peptide hormones, growth 
factors and related substances), both in and out of competition [31]. In addition the 
NCAA, the organization representing college athletes in America has also banned the 
use of rhGH by its members citing the dangerous nature of the drug’s many side effects 
[32]. Noted adverse effects include swelling of the hands and feet, coarsened facial 
features, dentition abnormalities, arthralgia (joint pain) and fluid retention, in addition 
to an increased risk of the development of diabetes mellitus, hypertension, 
cardiomyopathy and osteoporosis [33]. Although it is believed that the use of rhGH is 
widespread in sports, evidence of its abuse is largely anecdotal [25]. However athletes 
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from a wide range of sports, including baseball, cycling and athletics have been 
implicated in, or have confessed to, illicit rhGH use [30]. At the 1998 Tour de France, a 
large number of vials of rhGH were detected in the possession of cycling teams [25]. In 
2006 the commissioner of Major League Baseball (MLB) recruited former US senator 
George Mitchell to conduct an independent investigation into the illegal use of steroids 
and other performance enhancing substances in MLB [34]. The subsequent 
investigation reported on former MLB club employees and personal trainers of Major 
League players who allegedly used performance enhancing drugs, with some of these 
players having subsequently admitted to using rhGH [34-36].  
A limitation of the clinical trials conducted to date into the performance enhancing 
effects of rhGH is that the number of subjects who have participated in those trials has 
been small [37]. In addition, clinical trials are developed in order to detect relatively 
large changes in variables that effect athletic performances and would need many study 
participants to detect even a 1% change in performance [37]. Thus the enhancement 
required by professional athletes in order to make up the difference between winning 
and losing may not be adequately evaluated by such studies [37]. Doping regimes 
reported in rhGH abusing athletes can range from 3.3 to 8.3mg per day (10 – 25 
IU/day), 3 to 4 days per week, which is far in excess of the 0.3 to 0.6mg per day (1-2 
IU/day) usually prescribed to adult patients with growth hormone deficiency (GHD) 
[38]. Liu et al. [30] claim that reported rhGH doses used by athletes can be up to five 
times higher than those used in clinical studies.  Such high doses could have negative 
health implications.  
Acromegaly, a disorder which is commonly associated with a GH producing tumour 
known as a pituitary adenoma, is related to excessive production of GH and is 
characterized by marked abnormalities in protein and carbohydrate metabolism [21, 22]. 
The available data indicates that acromegaly consists of an initial anabolic phase leading 
to an increase in net protein synthesis and lean body mass and a later phase where 
protein mass is sustained but is subject to a negative effects of protein remodelling [21]. 
Long standing acromegaly is characterized by impairment of strength, aerobic exercise 
capacity and cardiac performance [21]. The development of cardiomyopathy and heart 
failure, conditions associated with a deregulated apoptosis, are also prevalent in 
acromegalic patients [22]. Acromegaly is associated with increased mortality with data 
indicating that about 60% of patients die from cardiovascular disease, 25% from 
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respiratory complications and 15% from cancer [22]. If left untreated, patients with 
acromegaly would die about 10 years earlier than healthy subjects [22]. In addition, life-
span studies on rodents have shown that growth hormone receptor (GHR) knockout 
mice and Ames dwarf mice, both exhibiting GHD, live longer than their wild-type 
siblings [39-41]. In contrast,  transgenic mice that over express GH live only half has 
long as normal wild type siblings [40]. 
Thus, interpretation of how exogenous GH administration affects the rate of cellular 
energy production will have implications in terms of the relevance of using rhGH as a 
performance enhancing aid. In addition, determining whether or not GH negatively 
impacts on mitochondrial function, by enhancing rates of ROS production and 
augmenting oxidatively induced cellular damage will enhance knowledge in regard to 
the risks involved in administering rhGH to individuals who exhibit normal rates of GH 
secretion. This research will also provide insight into the implications of long term 
rhGH abuse by athletes or anyone looking to benefit from the purported performance 
enhancing and anti-aging effects of the hormone. 
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2.1 – The Roles and Regulation of Mitochondrial Function 
 Mitochondria play a key role in the production of cellular energy, the generation of 
ROS and the regulation of apoptosis [6, 42]. Several studies have demonstrated that 
skeletal muscle mitochondria which tightly couple ATP production to oxygen 
consumption and which maintains a low rate of ROS generation are necessary for 
optimum physiological function and a prolonged life expectancy [9, 43, 44]. In contrast, 
a lack of cellular energy, excessive ROS production and deregulated apoptosis are 
exhibited either as isolated or combined features in many human diseases including 
neurodegenerative diseases, stroke, cardiovascular disorders, ischemia/reperfusion 
injury and cancer [6].  
2.1.1 – Regulation of Oxidative Phosphorylation 
Oxidative phosphorylation provides up to 90% of cellular ATP with the remainder 
derived from substrate level phosphorylation [45]. Oxidative phosphorylation is the 
formation of ATP from the substrates ADP and Pi in association with the transfer of 
electrons from fuel molecules along a group of trans-membrane protein complexes 
known as the ETC which is located in the IMM [45]. Carbohydrate and lipid substrates 
are metabolized in order to provide reducing equivalents in the form of the reduced co-
enzymes, nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide 
(FADH2) to the ETC. Through a series of redox reactions, electrons are transported 
along the enzyme complexes of the ETC, stimulating the activity of the three complexes 
which function as proton pumps (NADH dehydrogenase – Complex I, Cytochrome c 
reductase – Complex III and Cytocrome c oxidase – Complex IV) [6, 20]. The activity 
of these enzymes generates a proton motive force across the IMM which is composed of 
both an electrical (Δψm) and chemical (ΔPH) component [14]. Cytochrome c oxidase 
(COX) accepts electrons from the reduced co-enzyme cytochrome c (cyt c) and transfers 
them to molecular oxygen which is subsequently reduced to water (H20) in a reaction 
that involves four electrons, four hydrogen ions and a single O2 molecule [6]. The trans-
membrane potential that is generated by the active pumping of H+ out of the 
mitochondrial matrix facilitates the generation of ATP by Complex V of the ETC, ATP 
synthase [6]. ATP synthase is composed of an F1 matrix bound subunit that contains the 
catalytic ATP / ADP / Pi binding sites and a trans-membrane F0 subunit that couples the 
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backflow of protons into the mitochondrial matrix with the catalytic activity of the F1 
subunit through a peripheral and rotating mechanical mechanism [6].  
 
 
Figure 2.1: Electron Transport Chain, image adapted from Nelson et al. [46]. 
 
Whether an increase in the rate of oxygen consumption results in a concomitant increase 
in the yield of ATP is dependent on the efficiency of oxidative phosphorylation [47]. 
The efficiency of ATP synthesis is highly regulated and several mechanisms may affect 
it, including the nature of the substrate provided to the respiratory chain, proton leak 
across the IMM and the “slipping” of the coupling between redox reactions and proton 
pumping [48]. The free energy of electron transport within the proton pumps is 
sufficient to generate a proton motive force (ΔP) of approximately 240 millivolts (mV) 
[14]. However, the proton permeability of biological membranes increases 
exponentially above 130mV, leading to a waste of energy at high values [14]. 
Uncoupling, through proton leak, results in a dissociation of the rate of oxidation from 
that of phosphorylation and thus to a decrease in the yield of oxidative phosphorylation, 
with the additional energy being dissipated as heat [48]. Electron transport and oxygen 
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consumption are accelerated when control exerted by ADP is lost and ATP utilization 
exceeds ATP synthesis [7]. In addition, at Δψm above 140mV, production of the ROS 
superoxide anion (O2−) at complexes I and III of the respiratory chain has been reported 
to increase exponentially with increasing Δψm [14]. 
2.1.2 – Generation of Reactive Oxygen Species 
The accumulation of oxidative damage caused by ROS contributes to impaired 
physiological function, increased incidence of disease and a reduction in maximum life-
span potential [10]. In healthy tissue, mitochondria are the principal organelles 
responsible for the generation of ROS [9]. ROS are metabolites of molecular O2 that 
have a higher reactivity than O2 [10]. While the process of oxidative phosphorylation 
ultimately involves a four-electron reduction of O2 to H2O, during this process one or 
two electron reductions of O2 can occur, leading to the formation of O2−, from which 
other ROS can be generated [10]. These include hydroperoxyl (HO2.), hydroxyl (.OH), 
peroxyl (RO2.) and alkoxyl (RO.) radicals, molecules containing unpaired electrons, as 
well as non-radical species such as hydrogen peroxide (H2O2) and singlet oxygen [49]. 
In addition peroxynitrate (ONOO-) is formed from the reaction of O2− with nitric oxide 
(NO) [49]. H2O2 may be converted into the highly reactive .OH, resulting from a 
reaction with transition metals, namely with ferrous iron (Fe2+) [49].  .OH is an 
extremely reactive oxidizing radical that will react with most biomolecules at diffusion 
controlled rates [49]. ROS can react directly with DNA at the sugar phosphate backbone 
or at the bases, producing many different oxidatively modified purines and pyrimidines 
[9]. Mitochondrial DNA (mtDNA) is especially prone to oxidative damage due to its 
proximity to this primary source of ROS generation and its deficient repair capacity 
compared with nuclear DNA [10]. The direct consequence of oxidative stress is damage 
to various intracellular constituents. Changes in cellular membrane permeability and 
even membrane leakage can be manifested when lipid peroxidation occurs [10]. Protein 
oxidation has many important physiological consequences that affect normal cellular 
functions, while oxidative damage to both nuclear and mtDNA has detrimental effects, 
ranging from uncontrolled cell proliferation to accelerated cell death [10]. 
The source of ROS generation along the ETC has classically been attributed to the co-
enzyme of complex III, ubiquinone  or Coenyme_Q (CoQ) which produces the free 
radical semiquinone through the acquisition of a single electron; however recent 
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research also implicates complex I as a key site of electron “slippage” [9]. Flavin 
mononucleotide, semiquinones or iron-sulphur (Fe-S) clusters have been proposed as 
sites of ROS generation in complex I [9]. Both flavin and Fe-S clusters are situated in 
the hydrophilic domain of complex I facing the mitochondrial matrix compartment 
where mtDNA is located [9]. In contrast, ROS generated at complex III seem to be 
mainly directed to the cytosolic side of the IMM [9]. The prolonged exposure of these 
sites to electrons occurs when the ETC is inhibited, leading to an augmentation in the 
production of O2− [42]. Jaburek et al. [49] reported that significant elevations in the 
generation of ROS occur when mitochondria approach a non-phosphorylating state, 
such as when the efficiency of the coupling between ATP production and oxygen 
consumption is decreased. Under optimum physiological conditions, the oxidized form 
of the co-enzyme CoQ-, arising when complex III non-haem iron is reduced, is a short-
term intermediate that is rapidly reduced to CoQ as its electron is passed on to the 
cytochrome b1 subunit of complex IV [50]. In the absence of respiratory control, exerted 
by the supply of ADP, cytochrome b1 is highly reduced since its oxidation is prevented 
by high trans-membrane electrochemical proton potential, which leads to CoQ- 
becoming a long lasting component [50].  
2.1.3 – Mitochondrial Regulation of Cell Death Pathways 
Programmed cell death, termed apoptosis, functions as a homeostatic mechanism 
responsible for the ordered removal of superfluous, aged or damaged cells [51]. 
Apoptotic cell death is characterized by cell shrinkage, chromatin condensation, nuclear 
defragmentation, plasma membrane blebbing and the separation of cell fragments into 
apoptotic bodies [51]. There is essentially no inflammatory reaction associated with the 
process of apoptosis as apoptotic cells do not release their cellular constituents into the 
surrounding interstitial fluid and they are quickly phagocytised by surrounding 
macrophages [51]. The mechanisms that initiate apoptosis are highly complex, 
involving an energy-dependent cascade of signalling events which can be mediated via 
both intrinsic and extrinsic pathways [51]. Intrinsic signalling pathways involve a 
diverse range of non-receptor mediated stimuli that produce signals in response to 
intracellular damage caused by radiation, toxins, hypoxia, viral infections and oxidative 
stress [51]. The extrinsic death receptor pathway is characterised by ligand activation of 
trans-membrane receptors, such as the Fas receptor, tumour necrosis factor receptor 
1(TNFR1), TNF-related apoptosis-inducing ligand (TRAIL) receptor and death 
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receptors (DR) 3-6, which mediate caspase activation in response to extracellular 
stimuli [51].  
Mitochondria have been demonstrated to participate in intrinsic apoptotic signalling and 
to play an important role in extrinsic-receptor mediated apoptosis and non-apoptotic 
forms of cell death [52, 53]. In recent years, research investigating the role that 
mitochondria play in cell death pathways has focused attention on the regulation of 
mitochondrial membrane permeability as the potential mechanism linking key cellular 
signalling pathways to the execution of cell death [54]. Permeability transition is 
regulated by a unique supra-molecular complex known as the mitochondrial 
permeability transition pore (mtPTP), whose 3nm diameter increases the permeability of 
the IMM to solutes with a molecular mass of up to 15kDa [54]. While formation of the 
mtPTP is thought to arise from the apposition of multiple mitochondrial protein 
components at IMM and outer mitochondrial membrane (OMM) contact sites, at 
present the precise molecular composition of the pore is unresolved [54, 55]. However, 
a restricted set of proteins have been proposed to play a role in the composition of the 
mtPTP [54]. These include the OMM protein, voltage-dependent anion channel 
(VDAC), the IMM protein, adenine nucleotide translocator (ANT), the mitochondrial 
matrix protein, cyclophilin-D (Cyp-D) and the inter-membrane proteins, mitochondrial 
hexokinase (mtHK) and mitochondrial creatine kinase (mtCK) [54, 55]. Opening of the 
mtPTP has dramatic consequences for mitochondrial physiology, including the collapse 
of the mitochondrial trans-membrane potential, uncoupling of the respiratory chain, 
hyper-production of O2-., disruption of mitochondrial biogenesis, the efflux of small 
molecules such as calcium and glutathione from the mitochondrial matrix and the 
release of soluble inter-membrane proteins into the cytosol [11, 55]. Among the 
peptides released from mitochondria upon mtPTP opening are proteases and protease 
activators with key apoptogenic functions such as cyt c and apoptosis inducing factor 
(AIF) [11, 54]. The subsequent activation of down-stream caspase enzymes leads to a 
cytosolic cascade of endonuclease activity targeted towards to nucleus [11]. 
The mtPTP complex has been found to be subject to modulation by numerous 
endogenous physiological effectors including ions (Ca2+), the proton gradient (Δψm), the 
matrix concentration of adenine nucleotides (ATP/ADP), the redox state of electron 
carriers (NAD+/NADH), the redox state of matrix thiols (which is in equilibrium with 
the redox status of gluthathione – an indicator of the overall oxidative state of the cell), 
35 
 
ROS, NO and the concentration of lipoids (such as ceramide) [11]. From the nature of 
the factors that have been demonstrated as capable of inducing mtPTP opening, it is 
apparent that any major change in energy balance (e.g.: absence of oxygen, decrease in 
ATP/ADP, depletion of NADH and dissipation of the trans-membrane potential) or 
changes in the redox balance (e.g.: oxidation, leading to depletion of reduced 
glutathione concentrations or hyper-production of ROS) can provoke opening of the 
mtPTP [11]. This implies that the mtPTP complex integrates stress responses and that 
major damage of cells will invariably cause permeability transition [11].  
The regulation of mitochondrial apoptotic events is mediated through members of the 
B-cell CLL/Lymphoma protein 2 (Bcl-2) family of proteins which exhibit control over 
mitochondrial membrane permeability [51, 56]. To date, a total of 25 genes have been 
identified in the Bcl-2 family, which are divided into three groups based on the presence 
of up to four Bcl-2 homology domains (BH1-4 domains) [51, 56]. The anti-apoptotic 
Bcl-2 proteins, such as Bcl-2, Bcl-2 related gene – long isoform (Bcl-xL), and myeloid 
cell leukemia-1 (Mcl-1) contain all four BH domains and function to preserve 
mitochondrial integrity, preventing cyt c efflux in response to apoptotic stimuli [51, 56]. 
The pro-apoptotic Bcl-2 proteins are functionally divided into two groups [56]. The 
multi-domain (BH1-3) Bcl-2 associated x protein (Bax) and Bcl-2 antagonist killer 1 
(Bak) are pro-apoptotic effector molecules responsible for inducing mitochondrial 
permeabilization via the formation of proteolipid pores on the OMM [56]. The third 
class of Bcl-2 proteins, BH3-only molecules such as Bcl-2 antagonist of cell death 
(Bad), Bcl-2 interacting domain death agonist (Bid), Bcl-2 interacting mediator of cell 
death (Bim) and p53 up-regulated modulator of apoptosis (PUMA), function as 
activator molecules in distinct cellular stress pathways via interactions with other Bcl-2 
family members [56]. 
Upon activation, Bax and Bak form higher order oligomers in the OMM which are 
implicated in the induction of mitochondrial permeabilization [57-59]. Bax exists as a 
monomer in the cytosol with its C-terminal α-9 helix occupying the dimerization pocket 
to prevent mitochondrial targeting and homo-oligomerization [59]. In contrast, Bak is 
perennially located in the OMM, where its activity is restricted by the VDAC isoform, 
VDAC2, which occupies its dimerization binding site [59]. The pro-apoptotic activity of 
Bax and Bak is triggered by the BH3 activator proteins whose activity in turn falls 
under the regulation of upstream death signalling cascades [57-59]. For example, 
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following activation of Fas or TNFR1 receptors, Bid (21kDa) is cleaved by caspase 8 to 
its active truncated form tBid (15kDa) which subsequently interacts with the pro-
apoptotic effector molecules [57]. Furthermore, the phosphatidylinositol 3-kinase-
protein kinase B (PI3K-Akt) signalling pathway, which plays a critical role in mediating 
cell survival signals, has been implicated in the regulation of BH3 activators [60]. Akt 
has been shown to phosphorylate serine residues on Bad leading to its sequestration and 
inactivation by 14-3-3, a phosphoserine binding molecule [60]. Withdrawal of survival 
signals have been demonstrated to result in the translocation of monomeric Bax from 
the cytosol to the mitochondria via activation by de-phosphorylated Bad [60]. The BH3 
activators, tBid, Bim and PUMA have been demonstrated to bind to the α-1 helix on the 
N-terminal of Bax, inducing conformational changes which expose the dimerization 
binding site and allow the C-terminal trans-membrane domain to become available for 
insertion into the OMM [59]. Bak also requires BH3 mediated activation to trigger its 
homo-oligomerization by inducing conformational changes that disrupt Bak-VDAC2 
interactions [59]. Conversely, anti-apoptotic Bcl-2 proteins sequester BH3 activators 
into inert complexes, preventing Bax/Bak activation [59]. Thus, the ratio of expressed 
anti-apoptotic to pro-apoptotic Bcl-2 proteins is acknowledged to dictate the immediate 
fate of a cell in response to apoptotic stimuli [57]. 
2.1.4 – The Regulation of Mitochondrial Respiration through Cell Signalling Pathways 
The most basic level of regulation of oxidative phosphorylation, termed respiratory 
control, is dependent upon substrate availability and Δψm [61, 62]. Oxidative 
phosphorylation is limited by the rate at which substrates can supply reducing 
equivalents to complexes I and II of the ETC and the availability of ADP and phosphate 
to allow for ATP synthase activity, while increases in Δψm inhibits proton pumping 
across the respiratory complexes at high values, slowing the rate of ATP synthesis 
under resting conditions [61, 62]. While respiratory control serves as the principal form 
of regulation in bacteria and lower eukaryotic organisms, this level of control is 
insufficient in higher organisms where the rate of ATP utilization ranges widely (up to 
10 fold) depending on functional activity [14]. Thus, a hierarchy of additional 
regulatory mechanisms have developed, allowing for the adjustment of energy 
production to physiological demand [6, 14, 61, 62]. Further levels of control include 
allosteric regulation and post-translational modifications of ETC proteins [6, 61, 62]. 
Allosteric regulation represents an intracellular process allowing for the fine tuning of 
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energy production within the cell [6]. In contrast, regulation of the level of 
phosphorylation of respiratory complexes is mediated via hormonal and electrical 
signals that activate signal transduction cascades targeting mitochondria [6]. This 
represents a higher order of regulation, allowing for communication to take place 
between cells and organs [6].   
Allosteric regulation allows for fine tuning of the kinetic properties of metabolic 
enzymes through the binding of respiratory substrates, products and intermediates [61]. 
In particular, cyt c and COX represent key targets for this mode of regulation with the 
activity of both being adjusted via the binding of adenine nucleotides [14, 61]. At 
physiological concentrations ATP binds to cyt c leading to an inhibition of electron 
transfer between cyt c and COX [14, 61]. In addition, an ATP/ADP binding site is 
located on the matrix side of COX subunit IV leading to allosteric inhibition of COX in 
the presence of ATP and allosteric stimulation at high concentrations of ADP [14].  
Optimal rates of ATP synthesis are dependent upon Δψm values above 100mV, with 
maximal rates of ATP synthase activity observed at approximately 120mV [14]. At 
higher Δψm values the efficiency of oxidative phosphorylation decreases while the rate 
of ROS production is enhanced owing to an increase in basal proton leak across the 
IMM [14]. Allosteric inhibition of cyt c and COX in the presence of high intracellular 
ATP/ADP ratios serves to prevent an increase in Δψm to values above 120mV, 
maintaining tightly coupled rates of oxidative phosphorylation and keeping ROS 
production low under resting conditions [14]. It should be noted however that cell 
signalling mediated phosphorylation of ETC components is considered to be the 
overarching regulatory mechanism preventing the development of high Δψm values [6]. 
Indeed, the ability of ATP to allosterically inhibit COX has only been demonstrated in 
phosphorylated forms of the enzyme [14]. While Δψm values are kept low under resting 
conditions, under conditions of increased ATP utilization augmented rates of ATP 
synthase activity will attenuate resting Δψm values [14]. This is due to an increased flow 
of protons back into the mitochondrial matrix through its F0 subunit, resulting in 
submaximal values (< 120mV) for further ATP synthesis [14].  The mechanism of Δψm 
hyperpolarization serves to counteract this process [14]. However, in order for 
hyperpolarization of Δψm values to occur, cell signalling mediated de-phosphorylation 
of ETC components must first negate allosteric ATP mediated inhibition, further 
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demonstrating the higher order of control elicited on mitochondrial respiration by 
extracellular effector molecules such as hormones [14].  
While phosphorylation sites have been identified on all ETC complexes, in most cases 
the signalling pathways involved and the functional consequences of specific 
phosphorylation events have not been elucidated [6, 14, 61, 62]. To date, four serine 
(Ser) residues have been identified as phosphorylation sites on complex I, all from 
bovine heart mitochondria, including Ser20 of the NDUFB11-18kDa subunit, Ser55 of 
the 10kDa-NDUFA1 subunit, Ser59 of the NDUFA10 (42kDa)  subunit and Ser95 of 
the B14.5a subunit [6]. Furthermore, seven additional complex I subunits (75kDa Fe-S 
protein 1, flavoprotein 1, 39kDa 1α subcomplex, 24kDa subunit, 23kDa subunit, 22kDa 
1β subcomplex and 15kDa subunit) have been identified as phosphorylated proteins 
through mass spectrometry on isolated porcine mitochondria, although no phosphate 
groups were assigned to specific amino acids [63]. Tissue specific differences in the 
efficiency of respiratory rates have been attributed to the activity of complex I, with 
Cocco et al. [64] observing variable P/O ratios between rat brain, heart and liver 
mitochondria with complex I substrates while no differences were observed with 
complex II substrates. Thus, while no study to date has examined the functional 
consequences of the phosphorylation of any of the identified complex I sites, it is likely 
their regulation plays a role in mediating changes in the efficiency of respiratory control 
[64]. Identification of phosphorylated proteins via mass spectrometry on porcine 
mitochondria has also indicated the flavoprotein precursor subunit and the iron sulphur 
cluster containing B subunit of complex II in addition to the core protein I precursor, 
core protein II, Riesk iron sulphur protein precursor and the ubiquinone binding protein 
of complex III as targets for phosphorylation [6]. However, the specific amino acids 
phosphorylated, together with the relevant signalling pathways and mediated effects 
remain elusive [6]. 
Cyt c and COX represent the most extensively characterized of the ETC components to 
date, with four and 14 phospho-epitopes having been identified, respectively [61]. 
Tyrosine (Tyr) residues 48 and 97 are confirmed phosphorylation sites on cyt c, from 
bovine liver and heart mitochondria respectively, whose phosphorylation has been 
demonstrated to inhibit the activity of the electron carrier [65, 66]. Maximal rates of 
turnover for Tyr48-phosphorlated cyt c was found to be more than 50% reduced 
compared to unphosphorylated cyt c [65]. Half maximal turnover was demonstrated at a 
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substrate concentration of 5.5µM for Tyr97-phosphorylated cyt c compared to 2.5µM 
for unphosphorylated cyt c, indicating that phosphorylation inhibited the reaction with 
COX by shifting the Km of COX for cyt c [66]. In addition, threonine (Thr) 28 and 
serine (Ser) 47 have also been identified as phosphorylation sites on cyt c from human 
skeletal muscle mitochondria, however their specific functions remain unknown [61]. 
Several phosphorylation sites have been identified on COX subunits which likely play a 
pre-eminent role in regulating its enzymatic activity [61]. One site of phosphorylation, 
identified from bovine liver tissue as Tyr residue 304 on COX subunit I, is located 
adjacent to the oxygen binding site on the complex [67]. Tyr304-phosphorylated COX 
was found to be strongly inhibited with cyt c substrate concentrations of up to 10µM, 
even in the presence of the allosteric activator ADP [67]. While it was demonstrated 
that high cyclic adenosine monophosphate (cAMP) levels lead to Tyr304-
phosphorylation of COX subunit I, it is evident that this phosphorylation cannot be 
directly mediated through the cAMP dependent protein kinase A (PKA) which is a 
Ser/Thr-specific protein kinase [67]. It is suggested that PKA activates an as yet 
unidentified down-stream tyrosine kinase which in turn is responsible for the 
phosphorylation of COX subunit I [67]. COX inhibition through phosphorylation has 
also been demonstrated following the induction of ischemic stress in leporine heart 
tissue with identified phosphorylation sites including Ser115 and Ser116 of subunit I, 
Thr52 of subunit IV and Ser40 of subunit Vb [68]. Although phosphorylation of these 
sites was originally attributed to PKA owing to the abolishment of phosphorylation in 
the presence of alleged PKA inhibitor H89, the identified sites do not exhibit consensus 
phosphorylation site motifs for PKA, indicating that it is unlikely this kinase is directly 
involved in mediating their phosphorylation [61]. Thus, the specific kinases involved in 
the phosphorylation’s observed following ischemia remain undetermined [61]. 
Additional phosphorylation sites mapped on COX include Tyr11 of subunit IV-1 in 
bovine liver COX, Ser126 of subunit II, Ser34 of subunit IV-1, Ser4 and Thr35 subunit 
Va and Thr11 of subunit VIa in bovine heart COX, and Ser67 and Ser136 of subunit IV-
1 and Thr38 of subunit Va in human HeLa cells, although the signalling pathways 
involved in their regulation and their functional consequences remain unknown [61]. In 
regard to ATP synthase, identified phosphorylated sites include Ser76 of the α subunit, 
Thr213 of the β subunit and Tyr75 of the δ subunit, however once again their mode of 
regulation by cell signalling and the impact of their phosphorylation remains to be 
determined [6]. 
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It is apparent that cell signalling regulates mitochondrial metabolism through direct 
phosphorylation and de-phosphorylation of mitochondrial proteins, however little is 
known about the mitochondrial targeting of signal transduction pathways or the specific 
mitochondrial kinases and phosphatases which mediate these effects [6, 61, 62]. While 
an increasing number of effector molecules including PKA, Akt, and protein kinase Cδ 
(PKCδ), all of which are Ser/Thr specific kinases, and the non-receptor Tyr kinase c-Src 
have been demonstrated to be translocated into mitochondria upon their activation, the 
mechanism behind their subcellular relocation remains unelucidated [6]. Translocation 
of PKA to the mitochondria is associated with an inhibition of the activity of COX 
while the translocation of PKCδ is followed by the loss of Δψm and the release of cyt c 
[6]. Cellular stimulation with IGF-1 resulted in the translocation of phosphorylated Akt 
into the mitochondria where it was found to phosphorylate the β subunit of ATP 
synthase, although the functional consequences of this effect were not determined [12]. 
Meanwhile, the localization of c-Src to the mitochondrial inter-membrane space has 
been shown to result in the phosphorylation of COX at subunit II in osteoblasts, leading 
to an increase in COX activity [69]. The mitochondrial localization of kinases which 
target ETC components necessitates the presence of mitochondrial phosphates to 
counter their activity [61]. The protein tyrosine phosphatase Shp-2 was the first 
identified tyrosine phosphatase that localizes to the mitochondrial inter-membrane space 
and the OMM [70]. Although mitochondrial targets of Shp-2 are currently unknown, it 
is hypothesized to target cyt c and COX, the only two components of the ETC with 
mapped tyrosine phosphorylation sites [6]. Calcium (Ca2+) signalling represents another 
mechanism by which extracellular signals have been demonstrated to target 
mitochondria [6, 61]. Indeed, Ca2+ has been demonstrated to play an important role in 
signal transduction between cytosol and mitochondria, with spikes in intra-
mitochondrial Ca2+ concentrations leading to an up-regulation of mitochondrial 
oxidative metabolism [6, 61, 62]. Mammalian COX is known to contain a calcium-
sodium exchange site in subunit I which is speculated to affect COX activity, although 
the function of reversible Ca2+ binding at this site is unknown [6, 61, 62]. In addition, 
Ca2+ has been found to cause de-phosphorylation of most mitochondrial proteins, an 
effect which is widely attributed to the activation of as yet unidentified calcium-
dependent mitochondrial phosphatases [6, 61, 62]. In addition to affecting the activity of 
individual ETC complexes it has been suggested that cell signalling mediated 
phosphorylation plays a role in organizing the ETC proteins into hetero-oligomeric 
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supercomplexes termed respirasomes [6, 62]. The arrangement of ETC components into 
higher order complexes makes possible a more efficient electron transfer due to 
substrate channelling which is especially beneficial under conditions that require 
increased rates of ATP production [6, 62]. Thus, elucidation of the signalling pathways 
responsible for regulating respirasome stoichiometry represents an important direction 
for future research [6, 62].  
2.1.5 – Regulation of Mitochondrial Gene Expression 
While the majority of mitochondrial proteins are encoded by the nucleus, key elements 
of the ETC are also encoded by the mitochondrial genome [71, 72]. Co-ordinated 
regulation of the expression of both nuclear and mitochondrial encoded genes is 
required to give rise to a fully operational ETC [71, 72]. The expression of 
mitochondrial proteins is regulated at both the transcriptional and post-transcriptional 
level. 
2.1.5.1 – Transcriptional Regulation 
While transient changes in mitochondrial activity are regulated through post-translation 
modifications of mitochondrial proteins, in the long term cell signalling affects 
mitochondria through the regulation of changes in the gene expression of proteins that 
localize to the organelle [6]. It is well established that Ca2+ mediated signalling plays an 
active role in this regulation [73]. Increases in the concentration of cytosolic Ca2+ leads 
to the activation of a series of kinases, including Ca2+ dependent protein kinase C (PKC) 
isoforms [74], c-Raf [75], the extra-cellular signal-regulated kinase (ERK)-1 and ERK-2 
[76], mitogen-activated protein kinase (MAPK), mitogen-activated protein kinase 
kinase (MEK) [77] and the p90 ribosomal S6 kinase [78], which translocate their 
signals to the nucleus to alter the rate of gene transcription [7]. Freyssenet et al. [73] 
found that increases in intracellular Ca2+ concentrations trigger the activation of a 
PKC/MEK/MAPK dependent pathway which leads to an up-regulation of the 
expression of cyt c. Additionally, modifications in cytosolic Ca2+ concentrations have 
been reported to enhance the expression of a number of genes encoding mitochondrial 
proteins, including malate dehydrogenase and the β subunit of ATP synthase [7]. 
However, not all mitochondrial proteins are transcribed via Ca2+ signalling [7]. Indeed it 
has been reported that increases in cytosolic Ca2+ concentrations fail to induce changes 
in messenger RNA (mRNA) levels encoding COX subunits (IV, Vb and VIc), 
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indicating that a broader range of signalling molecules likely play a role in mediating 
changes in the synthesis of mitochondrial components [7].  
Nuclear genes encoding mitochondrial proteins possess upstream responsive elements 
to which proteins termed “transcription factors” bind in order to induce transcriptional 
activation [7]. Transcription factors implicated in up-regulating the expression of 
nuclear encoded mitochondrial proteins include nuclear respiratory factor (NRF)-1 and 
NRF-2 [71], peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ [72], c-
Jun, c-Fos and Sp1 [79]. Nuclear binding of NRF-1 and NRF-2 is critical to the 
transcriptional activation of multiple genes that encode components of the respiratory 
chain [71]. In addition to nuclear encoded mitochondrial proteins, mitochondria contain 
their own genome from which genes are transcribed, including 13 mRNA molecules 
that all encode protein components of the respiratory chain [7]. Mitochondrial DNA 
(mtDNA) also encodes 22 tRNA and 2 rRNA molecules that are essential for 
mitochondrial function [7]. The transcription of genes from mtDNA requires the import 
of nuclear encoded transcription factors into the organelle [7]. NRF-1 is known to bind 
to and activate the promoter of the nuclear encoded mitochondrial transcription factor A 
(Tfam) which localizes to the mitochondria to regulate the expression of mtDNA [7]. 
Tfam expression correlates strongly with alterations in mitochondrial transcriptional 
activation and oxidative capacity and its loss has been demonstrated to result in either 
partial or total depletion of mtDNA [80, 81].  
A coordinated increase in the transcription of nuclear and mitochondrial encoded genes 
requires the activation of higher order regulatory proteins capable of simultaneously 
adjusting transcriptional activation at multiple sites [7]. Induction of the regulatory 
factor PPAR co-activator 1α (PGC-1α) is known to play a critical role in coordination of 
the activation of genes involved in oxidative metabolism [82]. PGC-1α does not bind 
DNA directly, instead mediating its effects through interactions with transcription 
factors already bound to the promoter region of select genes [82]. The transcriptional 
co-activator enhances the overall efficiency of transcriptional activation by binding to 
specific transcription factors and recruiting additional co-activators, RNA polymerase II 
and various splicing factors [82]. Up-regulation of PGC-1α has been demonstrated to 
cause dramatic increases in the expression of NRF-1, NRF-2 and Tfam in addition to 
nuclear and mitochondrial encoded COX subunits and cyt c [82]. 
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The expression of Bcl-2 family proteins falls under the regulation of numerous 
transcription factors, demonstrating the complex mechanisms that underlie the control 
of mitochondrial mediated apoptotic pathways [83-88]. The nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) protein complex is a transcription factor 
which rapidly translocates to the nucleus upon activation via growth factor, cytokine, 
viral or stress mediated pathways [83]. Nuclear localization of NF-κB is associated with 
up-regulated expression of anti-apoptotic Bcl-2 proteins [83]. In particular, NF-κB 
contains specific motifs for both Bcl-2 and Bcl-xL transcription [83, 84]. Intriguingly, 
NF-κB has also been shown to play with positively associated with expression of the 
pro-apoptotic Bax protein, further demonstrating the complex nature of the interplay 
involved in the regulation of apoptotic pathways [83]. Bcl-2 expression is also found to 
be under the control of activating transcription factor-2 (ATF-2) and the cAMP-
response -element-binding protein (CREB), transcriptional regulators whose effects are 
mediated through the PI3K/Akt and ERK signalling pathways [85, 86]. Furthermore, 
nuclear factor (erythroid-derived 2)-like 2 (Nrf2) has recently been demonstrated to up-
regulate Bcl-2 levels in response to high levels of oxidative stress [87]. The regulation 
of Bcl-xL expression appears to diverge from that of Bcl-2 with the activation of E-
twenty six (Ets), signal transducers and activators of transcription (STATs) and the 
activator protein-1 (AP-1) transcription factors, following stimulation with a variety of 
extracellular signalling molecules, positively correlating with the proteins up-regulation 
[84]. The p53 tumour suppressor protein, upon exposure to stress mediated stimuli such 
as DNA damage and oxidative stress, is phosphorylated via MAPK dependent 
pathways, resulting in its activation as a transcription factor [89]. Activation of p53 
triggers a number of signalling pathways that lead to cell cycle arrest, cellular 
senescence, DNA repair and apoptosis [89]. The Bcl-2 pro-apoptotic effector proteins, 
Bax and Bak, are both known transcriptional targets whose expression is induced upon 
activation of p53 [88]. In contrast, the expression of Bcl-2 is found to be negatively 
influenced [88]. Furthermore, expression of the BH3-only activator proteins, PUMA 
and phorbol-12-myristate-13-acetate-induced protein 1 (Noxa) have been found to be 
induced following p53 activation in response to DNA damage [88]. 
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2.1.5.2 – Post-Transcriptional Regulation  
Post-transcriptional regulation of gene expression falls under the control of a class of 
short non-coding RNAs, 18 to 24 nucleotides in length, termed miRNAs [90-92]. 
Mature single-stranded miRNA molecules regulate protein synthesis by base-pairing 
with imperfect complementarity to sequences in the 3’-untranslated region (3’-UTR) of 
target mRNA [90-92]. Indeed, the interactions between miRNA and mRNA are reported 
to be predominately restricted to the 5’-proximal “seed” region (positions 2-8) of the 
miRNA [90-92]. While it is established that only 1% of genome transcripts encode 
miRNA in mammalian cells, nearly 30% of all encoded genes are regulated by miRNA 
with each mRNA being targeted by multiple sources [93, 94]. The inhibition of protein 
synthesis by miRNA is mediated either by repressing translation or by inducing 
deadenylation and subsequent degradation of mRNA targets [90, 92]. miRNAs function 
in the form of ribonucleoprotein complexes termed miRISCs (miRNA-induced 
silencing complexes), the core components of which are argonaute (AGO) proteins and 
the 182-kDa glycine-tryptophan (GW182) protein [90]. It has been experimentally 
demonstrated that GW182 represses protein synthesis when artificially connected to the 
3’-UTR of mRNA indicating that it functions as an effector molecule of translational 
repression while miRNAs mainly serve as the identifiers of mRNA targets [95, 96]. 
Meanwhile AGO proteins are reported to act as scaffolds to anchor miRNA and recruit 
the silencing effect GW182 to the target mRNA [90]. While the exact molecular 
mechanisms behind miRISC mediated translational repression have yet to be fully 
elucidated, interference of mRNA 5’-cap recognition by the eukaryotic translation 
initiation factor 4E (eIF-4E) and prevention of 80S ribosomal complex assembly are 
known to play a role [90]. GW182 also plays a crucial role in miRNA-mediated 
deadenylation and decapping associated with mRNA degradation, recruiting the CAF1 
(CCR4-associated factor 1) – CCR4 (carbon catabolite repression 4) – NOT1 (negative 
on TATA-less) deadenylase complex and the DCP1 (mRNA decapping enzyme 1) – 
DCP2 decapping complex to the target mRNA [90, 92]. The body of the mRNA is 
subsequently degraded by XRN1, a 5’-3’ exonuclease [90, 92]. 
While little is known regarding the control of mitochondrial gene expression by miRNA 
owing to the small percentage of validated targets elucidated, a number of miRNAs 
which play a crucial role in the regulation of mitochondrial function have been 
identified [97, 98]. MiR-210 has been shown to target iron-sulphur cluster assembly 
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proteins and its up-regulation decreases the activity of prototypical iron-sulphur proteins 
controlling mitochondrial respiration [97]. MiR-696 has been experimentally validated 
to target PGC-1α, with its up-regulation shown to result in significant reductions in fatty 
acid oxidation and mtDNA content [97]. Down-regulation of miR-23 was also found to 
be associated with significant increases in PGC-1α mRNA expression and protein 
content, which coincided with up-regulation in the expression of the mitochondrial 
metabolic proteins citrate synthase (CS) and cyt c [98]. Specific miRNAs have also 
been implicated in the regulation of mitochondrial mediated apoptosis. Bcl-2 is a 
validated target of miR-15, miR-16-1 and miR-181a with their up-regulation found to 
induce apoptosis via mitochondrial mediated pathways [24, 97, 99]. MiR-34a has also 
been found to target Bcl-2 following its transcriptional activation by p53 [24]. 
Conversely, miR-26a, miR-29b and miR-125b have all been demonstrated to directly 
target Bak mRNA, conferring a potent anti-apoptotic effect upon their induction [100-
102]. 
Mounting evidence suggests that many components of the miRNA machinery and the 
repression process itself may not be localized to the cytosol but occur in association 
with different cellular organelles and structures [90]. Both the components of miRISC 
and repressed mRNA are found to accumulate in processing bodies (P-bodies), 
cytoplasmic structures implicated in the storage and degradation of translationally 
repressed mRNA [90, 103]. Though P-body integrity is not essential for miRNA 
function, many of the p-body components are found to play an important role in 
miRNA-mediated repression [90, 103].  P-bodies are also enriched in proteins required 
for mRNA degradation, including CCR4-NOT1, DCP1-DCP2 and XRN1 [90]. In 
addition to P-bodies, several studies have recently demonstrated that unique miRNAs 
are enriched in mitochondria independent of total cellular abundance [104-107]. To 
date, mitochondria-associated_miRNA (mito-miRNA) have been identified in rat liver 
[105], mouse liver [104], human HeLa epithelial cells [106] and human skeletal 
muscular cells [107], with expression profiles found to be heavily dependent on 
organism and cell type [103]. For many of these mito-miRNAs in-silico analysis has 
identified potential gene targets from the mitochondrial genome indicating that they are 
involved in regulating gene expression within the organelle [105]. Indeed, it has 
recently been demonstrated that miR-181c is capable of translocating into the 
mitochondria where it was found to bind to, and translationally repress, mitochondrial 
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encoded COX subunit I (mt-COX1) mRNA [108]. However, a number of mito-miRNAs 
have also been identified which are complementary to neither the mitochondrial genome 
nor nuclear RNAs encoding mitochondrial proteins [105]. Instead these miRNAs 
exhibited predicted targets in the cytoplasm which are known to mediate cellular 
processes such as cellular proliferation, differentiation and apoptosis [105]. It has been 
hypothesized that mitochondria may serve as a storage site for these miRNAs with their 
sequestration and release acting as a mechanism for intracellular signalling [105]. While 
the mechanism behind such a mode of action remains unclear, it has been proposed that 
P-bodies, which are known to have dynamic interactions with mitochondria, could play 
a role in facilitating the trafficking of miRNAs in and out of the organelle [103].  
2.1.6 – Factors that Affect Mitochondrial Function: Aging, Exercise and Insulin 
Resistance 
It has been hypothesized that the decline in mitochondrial function associated with 
aging results from an increase in mtDNA mutations and a decrease in mtDNA 
abundance, with oxidative damage induced by ROS being the underlying cause [43]. 
The mitochondrial theory of aging hypothesizes that oxidative stress initiates a positive 
feedback cycle whereby the accumulation of damage induced by ROS over time impairs 
mitochondrial function which subsequently leads to an augmentation in the generation 
of ROS [10]. In support of the proposed role that mitochondria play in the process of 
aging, research indicates that an increase in damage to mtDNA is associated with aging 
[10], while mitochondrial antioxidant capacity is also reported to be diminished, as 
evidanced by significant reductions in CoQ levels with cellular aging [109]. Oxidative 
damage to mitochondrial and nuclear nucleic acids is significantly increased in all major 
tissues in aged organisms including mice, hamsters, rats and humans [43, 110, 111]. 
While many studies provide evidence in support of the role that declining mitochondrial 
function plays in the process of aging, research from the laboratory of Short and 
colleagues [43, 112] suggests that the decline seen in mitochondrial function may result 
from age associated lifestyle changes rather than as a direct consequence of aging.  
Schrauwen and Hesselink [113] suggest that mitochondrial dysfunction arises in under-
utilized skeletal muscle when the supply of nutrients to the mitochondrial matrix 
exceeds the organelle’s capacity to oxidize these substrates. Pathological conditions 
associated with a senescent lifestyle such as obesity and diabetes mellitus are associated 
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with elevated plasma free fatty acid (FFA) concentrations [113]. Elevated fatty acid 
concentrations, together with a diminished capacity to oxidize these substrates results in 
the accumulation of FFA and their metabolites, such as diacylglycerol (DAG) and 
ceramide, in the mitochondrial matrix of skeletal muscle and other non-adipose tissue 
including pancreatic β cells, heart and liver [113]. FFAs and their metabolites are very 
sensitive to attack from ROS, forming highly reactive lipid peroxides, which can 
negatively influence mitochondrial function, by reacting with mtDNA and proteins 
[113]. 
Conversely mitochondrial biogenesis, induced by contractile activity in skeletal muscle 
associated with regular aerobic exercise, results in a greater sensitivity of mitochondrial 
respiration to free ADP levels in the mitochondrial matrix, since smaller increments in 
concentrations of the metabolite are required to maintain the same level of oxygen 
consumption, thus improving the respiratory control over ATP production and 
increasing the efficiency of oxidative phosphorylation [7]. Biogenesis lowers the rate of 
respiration required per mitochondrion for any given workload, reducing the level of 
ROS, and subsequently attenuating the potential for ROS mediated lipid, protein or 
DNA damage [7]. 
Insulin is recognized as an important regulator of mitochondrial function [44, 114-117]. 
Intravenous insulin infusion was found to increase mitochondrial capacity for oxidative 
phosphorylation and augment the activity of oxidative enzymes in skeletal muscle [114, 
115]. In addition, insulin has been shown to increase the rate of mitochondrial protein 
synthesis and is known to induce mitochondrial biogenesis [115-117]. In contrast, 
insulin resistant states, such as type II diabetes, are associated with mitochondrial 
dysfunction [118]. Boushel et al. [118] examined rates of oxidative phosphorylation in 
the skeletal muscle of diabetic patients and while they did not establish an impairment 
of the function of isolated mitochondria, they did observe a diminished oxidative 
capacity in skeletal muscle which was attributed to a decrease in mitochondrial content 
and volume. In support of this, several studies have found a down-regulation of genes 
responsible for the induction of mitochondrial biogenesis, including PGC-1α, NRF-1, 
NRF-2 and Tfam, in insulin resistant subjects [118, 119]. Elevated plasma FFA 
concentrations have long been associated with the development of insulin resistance, 
which results from the intracellular accumulation of pro-inflammatory lipid metabolites, 
such as fatty acyl CoA and DAG, and the subsequent activation of stress sensitive 
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kinases including AP-1 and NF-κB, that antagonize insulin signalling [120-123]. The 
mechanism of interference with normal insulin signalling involves an augmented 
phosphorylation of serine and threonine residues on key elements of the insulin 
signalling pathway, including insulin receptor substrate-1 (IRS-1), which prevents the 
activation of downstream molecules such as PI3-K’s [124]. Recent studies have 
provided evidence supporting the role of oxidative stress as the cause underlying the 
induction of insulin resistance by high concentrations of FFA’s [120, 124]. St-Pierre et 
al. [125] demonstrated that the rate of mitochondrial H2O2 emission is significantly 
greater when basal respiration is supported by fatty-acid compared to carbohydrate 
based substrates, while Anderson et al. [120] found that treatment of rats, kept on a 
high-fat diet, with the antioxidant SS31 completely blocked the development of insulin 
resistance. In addition, 50µM H2O2 added to cultured 3T3-L1 adipocytes inhibited 
glucose uptake and glycogen synthesis in the presence of insulin, indicating that 
increased levels of oxidative stress can induce insulin resistance as an isolated factor 
[124].  Anderson et al. [120] concluded that the reducing potential of the respiratory 
chain provides a means for the cell to sense metabolic imbalance, with the generation of 
ROS from the mitochondria providing a means of initiating a counter-balancing 
response, by shifting the redox state of the cell and decreasing insulin sensitivity in an 
attempt to restore metabolic balance. However, Bloch-Damti and Bashan [124] point 
out that prolonged stimulation of this mechanism can lead to a chronic cellular 
desensitization of insulin and the development of pathological conditions. 
2.2 – Growth Hormone and IGF-1 
Growth hormone, which is also known as somatotropin, is a protein hormone that is 
secreted by the somatotroph cells of the anterior pituitary [3]. Hypothalamic secretion of 
growth hormone releasing hormone (GHRH), withdrawal of somatostatin, also known 
as growth hormone inhibiting hormone (GHIH), and the presence of GH releasing 
peptides, such as ghrelin, mediate its release [126]. GH exists in several different 
isoforms, the most abundant of which is a 22kDa molecule that contains 191 amino 
acids [127]. Other biologically active forms of growth hormone include a 20kDa 
isoform, a 17kDa isoform and a 5kDa isoform [127].  While some of its effects are 
mediated directly via its actions on the GHR’s of target cells, many of the noted 
anabolic and metabolic effects of GH are mediated indirectly through its activation of 
another peptide hormone, IGF-1, a 70-amino acid containing peptide that is released 
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primarily from the liver in response to stimulation by GH [2, 3, 127]. IGF-1 acts to 
stimulate cellular proliferation and differentiation in numerous cell types including, 
myoblasts, osteoblasts, adipocytes, oligodendrocytes, neurons and haemopoietic cells 
[4, 128]. It has been concluded from several studies that IGF-1 also acts in an autocrine 
or paracrine fashion, rather than solely acting at a distance via blood borne transport [2, 
3, 129]. Tissue types shown to be capable of IGF-1 production include muscle, bone 
and adipose tissue [5, 129]. Human leucocytes have also been shown to produce IGF-1 
in response to in-vitro stimulation with GH [1]. The importance of the role that IGF-1 
plays in conveying the anabolic effects of GH is evident from several studies which 
demonstrated that IGF-1 can stimulate both DNA and protein synthesis [5, 130-132]. 
GH is released from the anterior pituitary in 6 to 12 discrete pulses per day in response 
to several physiological stimuli [133]. Factors which cause an increase in GH secretion 
include exercise, stress, sleep, hypoglycaemia and amino acid uptake, with sleep and 
exercise being able to induce the strongest response [3, 133]. In contrast, 
hyperglycaemia and an increase in plasma FFA levels are capable of inducing an 
inhibition of GH release [3]. The daily GH secretion rate has been negatively correlated 
with age [134, 135]. It has been estimated that for men with a normal body mass index 
(BMI) for each decade of increasing age there is a reduction in the GH production rate 
of approximately 14% and the GH half-life of approximately 6% [134]. It is suggested 
that with increasing age there is a disruption in the pathways directing GH secretion, 
possibly as a result of a reduction in the co-ordination of the secretion of GHRH and 
somatostatin [126, 135]. 
Although circulating GH concentrations fluctuate widely due to the pulsatile nature of 
growth hormone secretion, basal plasma concentrations of 0.32 ± 0.77µg/L have been 
recorded in young adult males (21-26 years old) following overnight fasting [3, 136]. 
Sleep is known to be a principal stimulator of GH secretion with peak pulsatile GH 
secretions of 30µg/L reported [22]. Exercise is also a potent stimulus for GH release 
with the magnitude of the GH response varying according to the type intensity and 
duration of exercise [126]. Table 2.1 outlines the effects of different exercise conditions 
on peak serum GH concentrations, which vary over a range of 5.5 - 44µg/L [137-142].  
Exogenous rhGH administration has also been shown to augment circulating GH 
concentrations [138, 143, 144]. Studies conducted by Hansen et al. [143] and Lange et 
al. [144] found that an acute dose of 2.5mg rhGH elevated serum GH to concentrations 
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of approximately 15µg/L two hours following administration in physically active male 
subjects. In addition, Wallace et al. [138] recorded serum GH concentrations of 
approximately 33µg/L following 7 days of rhGH administration at a dose of 0.05mg/kg 
in endurance trained male athletes. 
Table 2.1: Effects of exercise on circulating GH concentrations in physically active 
young males. 
 
Type Subjects Intensity Duration Peak GH 
(µg/L) 
Reference 
Aerobic Ten active males 
[mean age 
= 26 ± 1.1 yrs] 
 
 
 
 
 
 
Seventeen elite 
endurance male 
athletes [mean 
age = 26.9 ± 1.5 
yrs] 
62% VO2max 
 
 
76% VO2max 
 
 
90% VO2max 
 
 
80% VO2max 
30 minutes 
 
 
30 minutes 
 
 
30 minutes 
 
 
30 minutes 
5.5 
 
 
9.5 
 
 
14 
 
 
24.3±3.6 
Pritzlaff et al. 
[137] 
 
 
 
 
 
 
 
Wallace et al. 
[138] 
Anaerobic Ten healthy males 
[mean 
age = 24.5 ± 1.1 
yrs] 
 
 
Six active male 
sprinters 
Maximum 
intensity 
sprint 
(Cycle 
Ergometer) 
 
Maximum 
intensity 
sprint 
(Treadmill) 
30 seconds 
 
 
 
 
 
30 seconds 
13.6±2.7 
 
 
 
 
 
44 
Stokes et al. 
[139] 
 
 
 
 
Nevill et al. 
[140] 
Resistance Ten strength 
trained males 
[mean age = 22 ± 2 
yrs] 
 
 
 
 
Eight strength 
trained males 
[mean 
age = 25.4 ± 4.14 
yrs] 
10RM loads 
 
 
 
10RM loads 
 
 
 
10 RM loads 
 
10 RM loads 
4 sets  
1 min rest 
 
 
4 sets  
3 min rest 
 
 
1 set 
 
3 sets  
 
26.5±2.0 
 
 
 
22.9±1.6 
 
 
 
8 
 
15 
Boroujerdi & 
Rahimi [141] 
 
 
 
 
 
 
Gotshalk et al. 
[142] 
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It has been suggested that IGF-1 may be a more useful indicator of the status of the 
GH/IGF-1 pathway, because of its low diurnal variability compared to GH [2]. Resting 
serum IGF-1 concentrations have been recorded over a range of 123-280µg/L in healthy 
male subjects between the ages of 20 years and 32 years [3, 145]. The influence of 
exercise on circulating IGF-1 concentrations has been shown to be dependent on the 
duration of exercise [3, 146].  Nguyen et al. [146] demonstrated that while serum IGF-1 
levels increased by 11.9% from basal concentrations in healthy male athletes following 
an incremental exercise test to exhaustion (mean duration 21 ± 1 mins), concentrations 
were observed to decrease by approximately 15% in the same group of athletes 
following a Nordic ski race (mean duration 3hr 12 ± 3 mins). Endurance exercise 
training has been shown to significantly affect circulating IGF-1 levels with Roelen et 
al. [147] observing a rise in serum IGF-1 concentrations from 252 ± 56µg/L pre-
training to 344 ± 61µg/L following two weeks of intense endurance exercise training. 
While exogenous administration of rhGH has not been shown to influence circulating 
IGF-1 levels in studies administering an acute dose [143, 144], continuous daily rhGH 
administration has been found to exert a significant effect [148]. Berggren et al. [148] 
demonstrated in ten healthy subjects who were administered 0.033mg/kg of rhGH for 
28 consecutive days that serum IGF-1 concentrations were augmented from 316 ± 
103µg/L at baseline to 678 ± 267µg/L post-treatment. In addition a higher dosage of 
0.067mg/kg of GH yielded post-treatment serum IGF-1 concentrations of 769 ± 
218µg/L [148]. 
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2.2.1 – Physiological Effects of Growth Hormone and IGF-1 
The growth promoting effects of GH and IGF-1 are mediated primarily via an anabolic 
effect on protein metabolism [149]. Several studies have found that there is an increase 
in lean body mass when rhGH is administered to healthy subjects [30, 150, 151]. It has 
been demonstrated that GH stimulates nitrogen retention [152] and increases protein 
synthesis at a whole body level [153, 154]. However, controversy exists over which 
tissues benefit from this protein conservation [152]. While pathological conditions of 
GH excess are associated with an increase in lean body mass, skeletal muscle 
hypertrophy is not evident and patients typically present with muscle weakness [155, 
156]. Studies carried out by Fryburg et al. [157, 158] demonstrated that short term 
infusion of rhGH increases muscle protein synthesis as indicated by an increase in the 
rate of disappearance of phenylalanine across the forearm during isotope dilution 
protocols. However, other studies [149, 154, 159] have been unable to show any effect 
of GH on muscle protein synthesis. Yarasheski et al. [154] treated healthy male subjects 
with rhGH for 12 weeks. While they found an increase in whole body protein synthesis 
as a result of rhGH administration, the rate of quadriceps muscle protein synthesis was 
found to be no greater in rhGH treated subjects compared to the control group.  
Skeletal muscle is a predominantly post-mitotic tissue, the myocytes of which are 
incapable of proliferating in response to growth factor stimulation [160]. It is the 
proliferation of satellite cells, which are small mono-nucleated cells located between the 
basal lamina and the sarcolemma of muscle fibres, that leads to overload induced, 
skeletal muscle hypertrophy [160].  IGF-1 has been shown to stimulate the proliferation 
and differentiation of satellite cells, which subsequently fuse with existing myotubes, 
resulting in an increase in the nuclear DNA content of skeletal muscle fibres and an 
enhanced capacity for muscle protein synthesis [160]. Several authors have suggested 
that skeletal muscle IGF-1 isoforms play a role in the muscle hypertrophy and tissue 
remodelling that occurs with resistance training [2, 127]. Mechanical loading induces 
production of a specific isoform of IGF-1 within skeletal muscle which is termed 
“mechano growth factor” (MGF) [160]. It is possible that local muscular production of 
IGF-1 may be increased in response to endurance and resistance exercise, but not be 
represented through changes in serum IGF-1 levels in exercise studies [2]. It has been 
reported that five days of endurance training in rats resulted in increases in MGF 
without any corresponding changes in circulating IGF-1 [161]. 
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A marked increase in resting energy expenditure (REE) is seen with GH administration 
[162]. Lean body mass is a positive determinant of REE and it has been suggesting that 
the calorigenic actions of GH are secondary to increments in lean body mass [163]. 
However a stimulation of energy expenditure has been recorded after only 5 hours of 
intravenous rhGH infusion in healthy subjects, and a significant decline in REE has 
been noted after short term (24hr) discontinuation of rhGH treatment in GH-deficient 
adults, both of which imply that GH may stimulate REE independent of changes in 
body composition [163]. 
GH is known to increase the circulation of fatty acids in the blood. The biological 
mechanisms of the lipolytic effects of GH remain to be determined but involve a 
reduced lipoprotein lipase (LPL) activity, stimulation of hormone-sensitive lipase 
(HSL) and suppression of the antilipolytic effects of insulin [164]. GH was found to 
reduce adipose tissue LPL activity by 65% and muscle LPL activity by 20%, while 
exogenous administration of rhGH has been found to significantly enhance HSL activity 
[165]. Hormone sensitive lipase regulates the breakdown of triglycerides in adipose 
tissue to yield non-esterified fatty acids (NEFAs) and glycerol [162]. It is stimulated by 
catecholamine activation of ß-adrenergic receptors on cell membranes which leads to an 
increase in intracellular cAMP levels through the increased activation of adenylate 
cyclase [133, 162]. This leads to an increased activation of protein kinase-A which 
phosphorylates HSL at a single serine residue [133, 162]. Stimulation of lipolysis is 
instrumental for the protein conserving actions of GH during fasting [149]. Inhibition of 
lipolysis during rhGH administration using acipimox, a niacin derivative that lowers 
blood lipid concentrations, increases muscle protein breakdown by 50%, neutralizing 
growth hormone’s ability to restrict protein breakdown, while restoration of high FFA 
levels decreased whole body phenylalanine degradation by 10-15% [166]. 
Increased lipid availability is suggested to be responsible for the insulin resistance 
observed with elevated GH levels [149]. GH and FFA concentrations were positively 
correlated with peripheral and hepatic insulin resistance [167], while lowering FFA 
levels pharmacologically with acipimox improves insulin sensitivity. However, it has 
been reported that GH induced insulin resistance precedes increases in circulating lipid 
intermediates suggesting that GH also induces insulin resistance in a manner 
independent of its lipolytic action [168]. 
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 2.2.2 – The Signal Transduction Pathways of Growth Hormone and IGF-1 
The underlying mechanisms of the metabolic and anabolic effects of GH have been 
studied through elucidation of its signalling pathways in target tissues [169, 170]. The 
initial step in GH signalling is dimerization of the GHR, which brings together two 
Janus kinase 2 (JAK2) molecules [149]. When brought together these molecules 
phosphorylate tyrosine residues on the cytoplasmic side of the receptor and other 
molecules adjacent to the receptor-JAK2 complex, such as STAT proteins, which 
translocate to the nucleus and activate gene transcription by binding to responsive DNA 
elements of specific genes within DNA [149]. Administration of rhGH in-vivo has been 
found to induce stimulation of STAT 1, 3 and 5 in hypophysectomised rats [171]. GH 
also activates the Ras/Raf-1/mitogen activated protein (MAP) kinase pathway which is 
involved in cell proliferation [149]. Protein kinase C also plays a role in GH signalling 
as treatment with inhibitors of protein kinase C has been shown to decrease GH 
induction [172]. GH leads to phosphorylation of IRS-1 and IRS-2, opening binding sites 
for phosphoinositide 3-kinase (PI-3 kinase), a class of enzyme that, in addition to 
having roles in cellular proliferation, differentiation and intracellular trafficking are also 
a key component in the insulin signalling pathway [149].  
Two distinct cytoplasmic regions of the GH receptor have been identified as being 
important for GH receptor mediated signal transduction, i) a proline rich region, termed 
Box I, which is located close to the trans-membrane domain and ii) the C-terminal 184 
amino acid sequence [170]. The Box I region is required for the binding of the tyrosine 
kinase JAK2 and the activation of all subsequent signal transduction proteins associated 
with this molecule [170]. The C-terminal region has been demonstrated to be involved 
in a GH induced increase in intracellular Ca2+ [170]. Ca2+ signalling has been found to 
regulate gene expression in several cases [173, 174]. In addition, studies performed by 
Billestrup et al. [170] on GH receptor transgenic mice found that GHR’s lacking the C-
terminal 184 amino acid sequence were unable to induce a transcriptional response to 
GH of the SPI 2.1 gene, which codes for a serine protease inhibitor, indicating that this 
specific amino acid sequence is required for stimulation of SPI 2.1 transcription. From 
this data it is evident that activation of the JAK2 kinase and increases in intracellular 
Ca2+ are both essential for growth hormone’s ability to stimulate transcription of certain 
genes [170]. 
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The physiological effects of IGF-1 are predominantly mediated through interaction of 
the hormone with the IGF-1 receptor (IGF-1R) [128]. IGF-1 may also mediate some of 
its effects by binding to the closely related insulin receptor (IR); however this 
interaction occurs at a much lower affinity than that of insulin with its own receptor 
[128, 175]. Both the IR and the IGF-1R are cell surface receptors that belong to a family 
of receptor tyrosine kinases [176]. The IGF-1R is expressed in almost all cell types, 
with a few notable exceptions including hepatocytes and mature B lymphocytes [4]. The 
receptor is a tetramer consisting of two extracellular α subunits and two primarily 
intracellular β subunits that are linked together by disulphide bonds [176]. The binding 
of IGF-1 to the extracellular domain of the IGF-1R activates the intracellular tyrosine 
kinase, resulting in receptor autophosphorylation which is facilitated by the binding of 
ATP to the receptor’s intracellular domain [128, 176]. Activation of the receptor causes 
the phosphorylation of tyrosine residues on several intracellular substrates, resulting in 
the activation of a number of down-stream signalling cascades. Tyrosine 
phosphorylation of IRS-1 and Shc following IGF-1R activation allows these proteins to 
phosphorylate the SH-2 domain of the growth factor receptor-bound protein-2 (Grb-2), 
which leads to the activation of the Ras /Raf-1 / MAP kinase pathway [128, 177]. IRS-1 
phosphorylation also leads to the activation of PI-3 kinase, which indirectly activates 
the serine/threonine kinase p70s6k through the activation of Akt [177].  
Valentinis and Baserga [4] have noted that IGF-1 transmits two contradictory signals to 
cells, which will induce either cellular proliferation or terminal differentiation. They 
suggest that whether a cell undergoes proliferation or differentiation in response to IGF-
1 is dependent on the cell type and the level of expression of signalling proteins, such as 
IRS-1, within the cell [4]. Coolican et al. [177] have shown that inhibition of the MAP 
kinase signalling pathway using PD098059, which is a non-competitive inhibitor of 
MEK, leads to an inhibition of IGF-1 stimulated proliferation in L6A1 myoblasts. The 
same group also found that inhibition of p70s6k activation, through administration of the 
immunosuppressant drug rapamycin, completely abolished IGF-1 stimulated 
differentiation in L6A1 myoblasts [177]. Their results indicate that the MAP kinase 
pathway plays a primary role in the proliferative response to IGF-1 while the PI-3 
kinase / p70s6k pathway is essential for IGF-1 stimulated differentiation [177]. 
However, the PI-3 kinase signalling pathway has also been implicated in the 
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proliferation of cells in response to IGF-1 and in mediating the hormone’s anti-
apoptotic effects [4, 128]. 
2.2.3 – The effects of rhGH Administration on Athletic Performance  
The use of rhGH for the purposes of enhancing athletic performance has been 
extensively reported in the literature [25, 26, 33, 37]. Exaggerated claims about the 
anabolic and metabolic effects of GH have been posted on websites promoting the use 
of rhGH as a rejuvenating agent for the elderly or as a muscle building agent for athletes 
and body builders [178]. In contrast, there is a lack of evidence published in peer 
reviewed literature that supports the performance enhancing effects of rhGH [178]. 
Only a limited number of studies have evaluated the effects of supra-physiological 
doses of rhGH, a genetically engineered peptide that is identical to the 22kDa 
endogenous growth hormone isoform in amino acid sequence and three-dimensional 
structure, on exercise capacity outcomes in healthy subjects [30]. Evidence from these 
studies does not support the existence of a performance enhancing effect of GH and has 
found that in some cases rhGH administration may have an adverse effect on exercise 
capacity [30]. Berggren et al. [148] assessed the exercise capacity of a group of young 
healthy male and female subjects who performed an incremental exercise test to 
exhaustion on a cycle ergometer following one month of receiving supra-physiological 
doses of rhGH (0.067 mg/kg/day). GH was found to have no significant effect on 
maximum oxygen consumption or power output during exercise compared with placebo 
treated controls [148]. Irving et al. [179] evaluated the effects of time after acute rhGH 
administration on metabolic and performance measures during 30 minutes of aerobic 
exercise conducted at an intensity above the subjects lactate threshold and concluded 
that GH does not alter exercise performance regardless of the timing of rhGH 
administration in relation to exercise. rhGH administration was not seen to have any 
significant effect on physiological parameters related to performance during exercise, 
including total work output, caloric expenditure, heart rate response, blood lactate 
response or the rate of perceived exertion (RPE) [179].  
Only two studies to date have evaluated the effects of rhGH administration on strength 
parameters in healthy young subjects undergoing a resistance training protocol [154, 
180]. Yarasheski et al. [154] provided subjects with either rhGH (0.04 mg/kg) or a 
placebo, 5 days a week while they underwent a 12 week resistance training program, 
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while in a study conducted by Deyssig et al. [180] all subjects performed between 8 and 
14 hours of high intensity resistance training per week for 6 months prior to self-
administering rhGH (0.03 mg/kg) nocturnally for a 6 week period. In both studies rhGH 
administration was not found to result in significant improvements in either muscle 
biceps strength or quadriceps strength as assessed by 1 repetition maximum (1RM) 
strength testing [30, 154, 180]. Deyssig et al. [180] concluded that any improvements in 
strength from baseline measurements were the result of a training effect and not due to 
rhGH treatment. Despite having induced no significant effect on strength parameters, 
GH is known to significantly increase lean body mass [30, 154, 180]. Yarasheski et al. 
[154] hypothesized that resistance training stimulates muscle protein synthesis to a rate 
above which the GH stimulus cannot further advance. 
It is argued that clinical studies examining the performance enhancing effects of GH 
have not used rhGH doses large enough to induce any significant anabolic effects [178]. 
Liu et al. [30] reported that the average daily rhGH dose administered in clinical studies 
was 0.036mg per kilogram of body weight, with treatment regimes in these studies 
ranging from acute rhGH doses to between 7 and 42 days of continuous therapy. Rennie 
[178] claims that these treatment regimens fail to match the supra-physiological doses 
which athletes and bodybuilders who abuse rhGH are purported to use. However, the 
rhGH doses used in clinical trials have been sufficient to elevate plasma IGF-1 
concentrations 3 to 6 times above normal baseline levels and to induce significant 
increases in lipolysis, water retention and the rate of lipid oxidation [148, 178]. Rennie 
[178] argues that it is unlikely that these same IGF-1 levels would be insufficient to 
have any effect on rates of protein metabolism. 
2.3 – Growth Hormone and IGF-1: Impact on Mitochondrial Function 
Early animal studies, conducted on isolated hepatic mitochondria, used manometry to 
examine the effects of GH administration on rates of oxidative phosphorylation, in the 
presence of carbohydrate and lipid substrates [181, 182]. Melhuish and Greenbaum 
[181] found that acute administration of GH (1mg), 4 hours prior to sacrifice in rats, 
increased the rate of oxidation in isolated liver mitochondria by 40% when β-
hydroxybutyrate was used as a substrate. However, the rate of oxidative 
phosphorylation when GH was administered was not found to differ significantly to that 
of control samples and a lower P/O ratio (ratio of ATP produced to oxygen consumed) 
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was recorded in GH trials, indicating that GH impacts negatively on the efficiency of 
oxidative phosphorylation [181]. Sordahl et al. [182] demonstrated that lowered P/O 
ratios from isolated mitochondria in hypophysectomized cats were restored to values 
seen in healthy mitochondria following 3 days of in-vivo GH administration. In contrast, 
in-vitro GH administration exerted no effect on the P/O ratios of isolated mitochondria, 
suggesting that GH mediates its effects on oxidative phosphorylation indirectly, 
possibly though the actions of IGF-1 [182]. In addition, the positive effect of insulin on 
the efficiency of mitochondrial function was found to be inhibited in the presence of 
GH in-vitro [182]. Several studies have hypothesized that the ability of GH to restore 
function to the mitochondria of hypophysectomized animals is mediated through its 
effects on the rate of synthesis of mitochondrial proteins [183, 184]. Maddaiah et al. 
[183] demonstrated that the incorporation of radio-labelled leucine into rat liver 
mitochondria was significantly elevated by GH administration, while a subsequent 
study from this group [184] found that a reduced content of cytochrome proteins in 
mitochondria following hypophysectomy was restored to normal levels after two weeks 
of GH treatment. A significant effect of GH on mitochondrial cytochrome content might 
explain observed decreases in the efficiency of oxidative phosphorylation following GH 
administration in healthy animals [181], as elevated cytochrome content has been 
associated with high rates of mitochondrial respiration [47]. In particular, COX is 
recognized as the location of a “slippage” between redox reactions and proton pumping 
and an increment in its concentration is associated with a decrease in the overall 
efficiency of the respiratory chain [47].  
Conversely, studies that measured oxygen consumption rates from isolated 
mitochondria following in-vivo GH administration in rats failed to establish an effect of 
GH on oxidative phosphorylation [185, 186]. DiMarco and Hoppel [185] demonstrated 
that GH had no effect on the P/O ratio of isolated liver mitochondria in the presence of 
either lipid (hexanoate) or carbohydrate (pyruvate) substrates, while Peyreigne et al. 
[186] found that 14 days of GH treatment in male Wister rats did not affect the 
respiratory states of isolated skeletal muscle mitochondria, measured in the presence or 
absence of ADP and Pi. A limitation of these studies is that the well-defined conditions 
used during in-vitro experiments, such as State 3 (optimum phosphorylating conditions) 
and State 4 (non-phosphorylating conditions) respiration never occur in-vivo, while the 
saturating concentrations of substrates used do not reflect physiological conditions [48]. 
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Perret-Vivancos et al. [187] found that in-vitro administration of GH induced an 
increase in the oxygen consumption of cultured Chinese hamster ovary (CHO) cells, 
indicating a direct effect of the hormone on mitochondrial function. Exposure of cells to 
GH concentrations of 200nM produced optimum stimulation of oxygen consumption 
which was associated with an increased oxidation of reducing equivalents as determined 
through the analysis of the intrinsic fluorescence of reduced pyridine nucleotides 
(NADH) [187]. However, the effect of GH on these variables is not evident in CHO 
cells transfected with GHR’s lacking the BOX-1 intracellular domain, which is required 
for the binding of JAK2 to the GHR and the subsequent activation of GH intracellular 
signal transduction pathways [187]. This indicates that signalling molecules down-
stream of the GHR mediate the hormone’s effects on mitochondrial oxidative capacity 
[187]. GH and its receptor are known to be internalized in cells via the clathrin coated 
pit pathway, to be degraded by lysosomes and via the caveolae pathway, which 
translocates the hormone into sub-cellular compartments [188, 189]. In analysing the 
subcellular distribution of radio-labelled human growth hormone (hGH) in female rat 
hepatocytes, Postel-Vinay et al. [190] found no radioactivity associated with 
mitochondria. In agreement a study by Mutvei et al. [191] concluded that no high 
affinity binding sites for GH were present on rat liver mitochondria. However, Perret-
Vivancos et al. [187] demonstrated, in cells where internalization of the GHR was 
impaired, that there were perturbations in the cell’s respiratory state, suggesting an 
implication of the internalization process of GH on the regulation of the hormone’s 
effects on mitochondrial function. In addition, permeabilization of the mitochondrial 
membrane has been found to abolish any effect induced by GH on either oxygen 
consumption or rates of oxidative phosphorylation suggesting that the primary effect of 
GH on the state of cellular respiration is mediated on the mitochondrial membrane 
[181].  
Few studies have examined the in-vivo effects of rhGH administration on healthy 
human tissue [192, 193]. Lange et al. [193] found that combining 12 weeks of rhGH 
administration with aerobic exercise in elderly women significantly increased the 
activity of oxidative enzymes involved in the tricarboxylic acid (TCA) cycle (CS (P < 
0.02)) and in β-oxidation pathways (L-3-hydroxyacyl-CoA dehydrogenase (HAD) (P < 
0.02)) of skeletal muscle mitochondria. In agreement, Short et al. [192] found 
significant increases in the activity of these enzymes (CS = + 16% / HAD = + 13%) in 
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skeletal muscle of healthy human subjects in response to 14 hours of intravenous rhGH 
infusion. In addition, rhGH infusion resulted in an 8-35% increment in the rate of ATP 
production in isolated skeletal muscle mitochondria [192].  
While these authors successfully demonstrated increased mitochondrial oxidative 
activity in response to GH, attempts at establishing the hormone’s effects on 
mitochondrial biogenesis have yielded inconclusive results [192, 193]. Analysis of the 
fractional synthetic rate of muscle proteins using C13-labeled leucine, found that GH had 
no effect on the rate of synthesis of muscle mitochondrial proteins [192]. However, 
these measurements only represent average rates of synthesis and do not reflect changes 
in specific proteins [192]. Although increases were seen in mRNA levels of Tfam, a 
transcription factor responsible for inducing the replication and transcription of mtDNA, 
and both individual mitochondrial encoded (COX3) and nuclear encoded (COX4) 
mitochondrial proteins, the expression of key transcription factors involved in the 
regulation of mitochondrial biogenesis, including PGC-1 α, NRF-1 and NRF-2, were 
not affected by rhGH infusion [192]. Short et al. [192] suggest that an additional 
stimulus, such as exercise, may be necessary for GH to induce a significant effect on 
mitochondrial biogenesis.  
In contrast to studies which have demonstrated a positive effect of GH on mitochondrial 
oxidative enzyme activity, micro-array analysis on the expression of genes in skeletal 
muscle of hypopituitary rats and humans treated with rhGH have found a down-
regulation of gene transcripts expressing enzymes involved in β-oxidation (3-
hydroxyacyl-CoA dehydrogenase), the TCA cycle (oxoglutarate dehydrogenase / 
succinate dehydrogenase) and the ETC (subunits of COX and ATP synthase), 
suggesting a reduction in oxidative capacity in response to GH treatment [194, 195]. 
Deficiencies in the plasma concentrations of other pituitary hormones, in light of the 
hypopituitary nature of the subjects used in these trials may have negatively impacted 
on the actions of GH. In addition, it is possible that GH induced insulin resistance might 
negate any positive effects which the hormone may induce on the expression of 
mitochondrial proteins in skeletal muscle [23, 196]. In contrast, an increase in the 
expression of mitochondrial oxidative enzymes was observed in the liver of aged rats, 
which highlights a tissue-specific effect of GH on gene expression and suggests that the 
liver may play a key role in mediating the effects of GH on energy expenditure [197]. 
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While the research of Lange et al. [193] and Short et al. [192] demonstrates an in-vivo 
effect of rhGH administration on skeletal muscle mitochondrial function, their work 
fails to establish the mechanism behind this effect. To our knowledge, studies 
examining the effects of IGF-1 on skeletal muscle mitochondrial function or rates of 
gene expression and mitochondrial protein synthesis have, to date, not been conducted 
[192]. Garcia-Roves et al. [198] demonstrated that elevated FFA concentrations also 
induce an increment in the expression of enzymes involved in β-oxidation (medium 
chain acyl-CoA dehydrogenase), the TCA cycle (CS) and the respiratory chain (cyt c), 
suggesting that GH may mediate its effects indirectly through the actions of lipolysis. In 
opposition to this hypothesis Leung and Ho [199] have demonstrated a direct effect of 
GH on rates of mitochondrial fatty acid oxidation in cultured human fibroblast cells, 
while in-vitro IGF-1 administration was found to have no effect. In addition, the 
temporal extent of changes induced by GH on mitochondrial oxidative capacity and 
gene expression persist following cessation of rhGH administration is unknown as 
studies to date have only analysed variables within a post treatment window of 24 hours 
[192, 193], while the effects of long term rhGH administration on mitochondrial 
function, to date, have not been studied [192]. 
Studies conducted on cultured human cell-lines have demonstrated anti-oxidant effects 
following rhGH and IGF-1 administration in-vitro [200, 201]. Csiszar et al. [200] found 
that rhGH, at concentrations of 3.3 and 33µg/mL and IGF-1, at concentrations of 10, 
100 and 1000µg/L, significantly reduced cellular O2− and H2O2 production, in addition 
to mitochondrial O2− production, following 24 hours of treatment in human coronary 
arterial endothelial cells (HCAECs). In agreement, Thum et al. [201] observed cellular 
ROS levels to be significantly reduced in cultures of a human endothelial cell-line 
(EAhy126 cells) at rhGH concentrations of 100 and 1000µg/L after 24 hours. Both 
studies attributed the observed effects to a GH/IGF-1 elicited improvement in 
antioxidant status, with Csiszar et al. [200] noting a significant up-regulation of the 
antioxidant enzymes manganese-superoxide dismutase (Mn-SOD), copper, zinc-
superoxide dismutase (Cu, Zn-SOD), and glutathione peroxidise 1 (GPX-1). In contrast, 
Brown-Borg et al. [202] observed that rhGH and IGF-1 significantly decreased 
antioxidant capacity in cultured murine hepatocytes after 24 hours. Catalase and GPX-1 
activity were found to be significantly suppressed in the presence of GH at 1 and 
10µg/mL and in the presence of IGF-1 at 3.8, 38 and 380µg/L [202]. Indeed, GH 
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studies conducted on animals have demonstrated that excessive concentrations of the 
hormone can impact negatively on mitochondrial function by modifying levels of 
oxidative stress [39-41, 203, 204]. Seiva et al. [39] demonstrated that high doses of 
rhGH (2mg/kg) exerted detrimental effects related to energy metabolism and oxidative 
stress in rat myocardium, while a lower dose (1mg/kg) exerted beneficial effects on 
energy production and reduced levels of oxidative damage. This was attributed to the 
capacity of the antioxidant glutathione to handle the increase in superoxide production 
following administration of the low rhGH dose, while this capacity was exceeded at the 
higher dose [39]. Studies performed on transgenic animal models exhibiting an excess 
production of GH found that these animals possessed higher rates of oxygen 
consumption and free radical production [40, 204]. In contrast to animals over-
expressing GH, Ames dwarf mice, which are characterized by a deficiency in GH 
secretion, exhibit less oxidative damage to mtDNA in liver, brain and heart tissue 
compared to wild type mice [40, 204]. Of note however, fibroblasts from Lewis dwarf 
rats, an animal model which exhibits normal pituitary function except for a selective 
genetic GH deficiency, were observed to have similar rates of cellular O2− and H2O2 
production compared to wild type controls [205]. In addition, the expression of 
important anti-oxidant enzymes, Mn-SOD, Cu, Zn-SOD and catalase were not found to 
be down-regulated in comparison with wild type rats [205]. Indeed, thirty days of GH 
replacement therapy was found to significantly increase antioxidant capacity in these 
animals through up-regulation of the expression of GPX-1 [205]. To date, how in-vivo 
rhGH administration in healthy human subjects affects the generation of ROS or the 
level of oxidative stress in mitochondria has not been evaluated. However, in patients 
with acromegaly, ATP production has been shown to be reduced by 25%, indicating 
that excessive GH concentrations can induce prolonged mitochondrial dysfunction 
[206]. 
It has been demonstrated that both GH and IGF-1 confer protection against cellular 
apoptosis, mediated via an effect on the permeability transition pore of the IMM [17, 
18]. Yamamura et al. [17] demonstrated that Ca2+ induced opening of the mtPTP, as 
assessed from identification of large amplitude swelling of mitochondria and 
measurement of levels of cyt c release, was significantly inhibited by IGF-1 pre-
treatment in rat myocardium, while Mitsunaka et al. [18] found that rhGH treatment 
prevented apoptosis following activation of plasma membrane bound Fas receptors, 
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which initiate intracellular death signalling pathways, in both CEM/L7 and IM-9 
lymphocytes. The mechanism behind these noted anti-apoptotic effects was attributed to 
GH/IGF-1 induced up-regulation and down-regulation of respective, anti-apoptotic and 
pro-apoptotic Bcl-2  family proteins, which are hypothesized to regulate mtPTP opening 
by interacting with the VDAC on the OMM [17, 18, 207]. Indeed, several studies have 
demonstrated that GH induces an up-regulation of Bcl-2 gene and protein expression in 
peripheral blood lymphocytes and monocytes in-vitro [18, 19, 208]. In addition, Bcl-xL 
mRNA levels in cultured insulin producing cells (INS-1 cells) were observed to be 
significantly up-regulated following only four hours of exposure to rhGH at 
concentrations of 500µg/L [209]. In contrast, one month of rhGH administration, at a 
dosage of 2mg/kg/day, was not found to significantly affect the expression of Bcl-2 in 
male senescence-accelerated prone mice (SAMP8 mice) [210]. The anti-apoptotic 
effects induced following rhGH administration in this study were instead attributed to a 
significant down-regulation of Bad, a pro-apoptotic signalling protein, and Bax, its 
down-stream effector [210]. Similarly, rhGH administration was not found to impact 
Bcl-2 expression in a human gastric cancer cell-line (BGC823 cells) in-vivo, following 
the inducement of carcinoma xenografts in nude mice [211]. In regard to IGF-1, the 
anti-apoptotic affects observed by Yamamura et al. [17] following systemic IGF-1 
treatment in male Sprague-Dawley rats were attributed to significantly elevated Bcl-xL 
and significantly decreased Bax protein concentrations in isolated cardiomyocyte 
mitochondria. In addition, Kang et al. [212] observed that cultured mesangial cells 
exhibited a significant decrease in the Bax/Bcl-2 protein ratio in the presence of 
100µg/L IGF-1, although individual changes in the expression of these proteins was not 
reported. Increased phosphorylation of Bad at Ser112 and Ser136 was also observed 
following IGF-1 administration in this study, leading to inactivation of the proteins pro-
apoptotic activity [212]. At present it is unknown what effect increases in cellular stress 
levels in response to long term rhGH use in subjects with a healthy GH/IGF-1 axis 
would have on the mitochondria mediated induction of cell death pathways. 
 
 
 
 
64 
 
 
 
 
 
 
 
 3. Outline of Project Studies:          Aims and Hypotheses 
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The two major aims of this research project were firstly, to investigate whether rhGH 
and IGF-1, over a range of physiological and supra-physiological concentrations, 
regulates key components of mitochondrial function and secondly, to determine the 
implications of any potential regulation in terms of its impact on cellular viability. This 
included the investigation of a novel mitochondrial associated signalling pathway as a 
potential mechanism for the regulation of mitochondrial mediated apoptotic effects by 
GH and IGF-1. The project consists of three studies, the individual aims and hypothesis 
for each of which are outlined below. 
3.1 – Outline of Study One 
The purpose of this study was to determine whether rhGH and rIGF-1 exert a direct 
effect on the function of mitochondria over a range of physiological and supra-
physiological concentrations in PBMCs from healthy male subjects. Physiological GH 
concentrations are defined as serum GH concentrations which fall within the range seen 
following the stimulation of peak endogenous GH responses in normal subjects. 
Through the measurement of serum GH concentrations following administration of an 
insulin tolerance test, Hoffman et al. [213] determined this range to be 5.3 – 42.5 µg/L 
in normal subjects. Normal physiological serum IGF-1 concentrations for healthy male 
between 20 – 35 years of age have been reported to be within the range of 137 - 
257µg/L [214]. For the purposes of this study supra-physiological concentrations of GH 
and IGF-1 are defined as any concentration which exceeds these reference ranges. The 
effects of GH were investigated over a concentration range of 0.25 - 100µg/L while the 
effects of IGF-1 were investigated over a concentration range of 100 - 600µg/L. The 
concentrations used are cited in table 3.1 below. 
GH 0.25 0.5 1 2.5 5 10 25 50 100 
IGF-1 100 200 300 400 500 600    
Table 3.1: Concentrations of GH and IGF-1 used for in-vitro analysis in Study One 
(µg/L). 
Ten healthy male subjects between the ages of 18 and 35 years were recruited to 
participate in the study. Subjects had a 30mL blood sample taken in the morning 
following an overnight fast. PBMCs were isolated from whole blood by density gradient 
centrifugation and resuspended in RPMI-1640 cell culture medium. 
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Once isolated, PBMCs were incubated for 4 hours in the presence of either rhGH or 
rIGF-1 at pre-determined concentrations as outlined in Table 3.1. All samples were 
subsequently analysed by flow cytometry for the determination of Δψm, mitochondrial 
O2− generation, mtPTP activity and cellular viability.  
3.1.1 – Outline of Variables Analysed in Study One 
 
3.1.1.1 Mitochondrial Membrane Potential (Δψm) 
The Δψm is the electrical component of the proton motive force (Δpm) that exists across 
the IMM [62]. It exhibits a negative charge inside the mitochondrial matrix which is 
normally maintained at approximately 100-120 mV [14]. The creation of this electrical 
gradient is driven by the activity of the ETC which pumps H+ from the mitochondrial 
matrix across the IMM to the inter membrane space [8]. The membrane potential in turn 
drives the flow of H+ back to the mitochondrial matrix through the enzyme protein 
complex ATP-synthase where ATP is synthesised by the phosphorylation of ADP [8]. 
As noted previously, at excessively high trans-membrane potentials, the efficiency of 
mitochondrial ATP synthesis decreases due to an increase in proton leak across the 
IMM and a decrease in the stoichiometry between electron flux and proton pumping 
along the ETC [14]. Analysis of Δψm allows for interpretation of how the functional 
status of mitochondria responds to rhGH and rIGF-1 and in conjunction with levels of 
mitochondrial O2− generation provides an insight into how these hormones affect the 
efficiency of energy production within the organelle.  
3.1.1.2 Mitochondrial Superoxide Generation 
Under normal physiological conditions it is estimated that approximately 1-3% of 
electrons carried by the ETC leak out of the pathway and transfer directly to oxygen to 
produce O2− [215]. Complex I and Complex III of the ETC are thought to be the most 
important sites of mitochondrial superoxide production [215, 216]. The O2− undergoes a 
reaction catalysed by the antioxidant enzyme Mn-SOD in the mitochondria to produce 
H2O2, which in the presence of intracellular antioxidants such as catalase and 
gluthathione is reduced to H2O [215]. However if superoxide production exceeds the 
capacity of the antioxidant enzymes, then highly reactive oxygen species (hROS), such 
as the .OH, will accumulate in the mitochondria and lead to damage of mitochondrial 
DNA, proteins and lipid membranes [10, 216]. Analysis of superoxide levels within 
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mitochondria allows for determination of whether the functional response of the 
organelle to rhGH and rIGF-1 has negative implications in terms of an increased risk of 
structural damage to key mitochondrial components [215]. 
3.1.1.3 Mitochondrial Permeability Transition Pore Activity 
As mentioned previously, the mtPTP is activated in response to a variety of 
physiological stresses, including excessive intracellular Ca2+ concentrations, depleted 
intra-mitochondrial substrate levels and an augmentation of the oxidative status of the 
cell [11, 54, 55]. In contrast, conditions of optimum cellular function associated with the 
adequate supply of ADP and Pi to the mitochondrial matrix and a low rate of ROS 
generation keep the pore in a closed conformational state [11, 54, 55].  Opening of the 
mtPTP initiates cellular apoptotic pathways via the release of cyt c and AIF [11, 54, 55]. 
Thus, analysis of the open / closed status of the mtPTP provides an indication of the rate 
of mitochondrial mediated cellular apoptosis, allowing for interpretation of how the 
mitochondrial response to rhGH and rIGF-1 affects functional conditions at a cellular 
level. 
3.1.1.4 Cellular Viability 
Cellular viability, the capacity of a cell to maintain its physiological function, is a 
defining characteristic of healthy living cells which are distinguishable from non-viable 
cells undergoing one of either two forms of cell death: apoptosis and necrosis [11, 51, 
217].  As mentioned previously, apoptosis is a programmed form of cell death 
responsible for the removal of damaged or diseased cells without incurring an 
inflammatory reaction [51]. Apoptosis is a controlled process which is dependent upon 
the availability of ATP and is mediated by the activation of extracellular and 
intracellular signalling pathways which can affect cells at an individual level [11, 51]. In 
contrast, necrosis is defined as a pathological form of cell death resulting in the 
liberation of chemical factors from the cell which lead to a localized inflammatory 
response [51, 217]. Necrosis is an uncontrolled and passive process that can affect large 
numbers of cells and whose mediation is triggered either through interference of the 
cells energy supply or as a direct result of damage to the cell membrane [51, 217]. 
Identification of the percentages of viable, apoptotic and necrotic cells within a sample 
allows for a direct interpretation of the functional consequences of rhGH and rIGF-1 
effects at a cellular level. 
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3.1.2 – Study One Aims 
The primary aims of Study One were as follows: 
1. To investigate whether rhGH and IGF-1 exert any direct effect on the efficiency 
of mitochondrial function, through the examination of relative changes in Δψm 
and mitochondrial O2− levels, following the in-vitro administration of rhGH and 
rIGF-1 in PBMCs from healthy male subjects, over a range spanning both 
physiological and supra-physiological concentrations. 
2. To investigate the implications for cellular viability imposed by such rhGH and 
IGF-1 mediated effects on the mitochondrial function of PBMCs’ at both 
physiological and supra-physiological concentrations, through the examination 
of relative changes in the level of activity of the mtPTP in addition to the direct 
assessment of changes in the percentages of viable, apoptotic and necrotic cells. 
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3.1.3 – Study One Hypotheses 
The hypotheses of Study One were as follows: 
• Neither rhGH nor rIGF-1 will exert any significant effect on Δψm values in 
samples treated at physiological concentrations compared to untreated control 
samples. In contrast, Δψm values will be significantly increased by both rhGH 
and rIGF-1 in samples treated at supra-physiological concentrations compared 
samples treated at physiological concentrations and untreated samples.  
• Both rhGH and rIGF-1 will either significantly decrease or exert no significant 
effect on mitochondrial O2− levels in samples treated at physiological 
concentrations compared to untreated control samples. In contrast, 
mitochondrial O2− levels will be significantly increased by both rhGH and rIGF-
1 in samples treated at supra-physiological concentrations compared to samples 
treated at physiological concentrations and untreated samples.  
• Neither rhGH nor rIGF-1 will exert any significant effect on the level of mtPTP 
activity in samples treated at physiological concentrations compared to untreated 
control samples. In contrast, the level of mtPTP activity will be significantly 
increased by both rhGH and rIGF-1 in samples treated at supra-physiological 
concentrations compared to samples treated at physiological concentrations and 
untreated samples.  
• Neither rhGH nor rIGF-1 will exert any significant effect on the percentages of 
cellular apoptosis and necrosis in samples treated at physiological concentrations 
compared to untreated control samples. In contrast, these percentages will be 
significantly increased by both rhGH and rIGF-1 in samples treated at supra-
physiological concentrations compared to samples treated at physiological 
concentrations and untreated samples.  
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3.2 – Outline of Study Two 
Study Two was designed for the purposes of investigating the mitochondrial effects 
exerted by physiological and supra-physiological concentrations of rhGH and rIGF-
1 under various respiratory conditions of substrate saturation in PBMCs from 
healthy male subjects. The effects of GH were investigated over a concentration 
range of 0. 5 - 50µg/L while the effects of IGF-1 were investigated over a 
concentration range of 100 - 500µg/L. The concentrations used are cited in table 3.2 
below. 
GH 0.5 5 50 
IGF-1 100 300 500 
Table 3.2: Concentrations of GH and IGF-1 used for in-vitro analysis in Study Two 
(µg/L). 
Cellular respiration is dependent upon the continuous supply of endogenous 
substrates into the mitochondrial matrix in-vivo [218]. However, in isolated 
mitochondria or permeabilized cells in-vitro, the endogenous supply of respiratory 
substrates is lost [219]. The artificial supply of specific combinations of respiratory 
substrates under these conditions allows for control of electron supply to the ETC, 
where electron entry can either be mediated exclusively through complex I or 
complex II or via the convergent supply of electrons to both complexes 
simultaneously [218, 220, 221]. The transfer of electrons to the ETC via the β-
oxidation pathway can also be controlled through the supply of specific fatty acid 
respiratory substrates [221]. 
Ten healthy male subjects between the ages of 18 and 35 years were recruited to 
participate in the study. Subjects had a 30mL blood sample taken in the morning 
following an overnight fast. PBMCs were isolated from whole blood by density 
gradient centrifugation and resuspended in RPMI-1640 cell culture medium. 
Once isolated, PBMCs were incubated for 4 hours in the presence of either rhGH or 
rIGF-1 at pre-determined concentrations as outlined in Table 3.2 for the purposes of 
establishing hormonal effects on mitochondrial function before the various 
respiratory conditions were induced. Cells were permeabilized following hormonal 
treatment and subsequently analysed for the determination of Δψm values and levels 
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of mitochondrial hROS production by flow cytometry, in the presence of substrate 
combinations which give rise to the following respiratory conditions:  
1) Complex I mediated respiration – Administration of a substrate combination of 
pyruvate and malate (Pyr/Mal) results in the activation of isocitrate dehydrogenase, 
α-ketoglutarate dehydrogenase complex and malate dehydrogenase within the TCA 
cycle, giving rise to the reduction of NAD+ to form NADH [218]. These reducing 
equivalents feed electrons into complex I of the ETC, which subsequently travel 
down a thermodynamic gradient, through the Q-cycle and complex III, to complex 
IV where they are involved in the reduction of O2 to H2O [218]. Complex II is not 
involved in mitochondrial respiration in the presence of Pyr/Mal in-vitro, as malate 
equilibrates with fumarate at concentrations above 2mM [218]. This inhibits the 
conversion of succinate to fumarate by succinate dehydrogenase, preventing the 
formation of FADH2 [218].   
2) Complex II mediated respiration – Administration of rotenone inhibits the 
transfer of electrons from iron-sulfur centres in complex I to ubiquinone [220]. 
NADH-linked dehydrogenases within the TCA cycle subsequently become inhibited 
by the redox shift from NAD+ to NADH [220]. Under conditions of rotenone 
induced complex I inhibition, administration of succinate (Succ/Rot) supplies 
electron to the ETC exclusively through complex II via the activation of succinate 
dehydrogenase leading to the reduction of FAD to form FADH2 [220]. Succinate 
administration, in the absence of rotenone inhibition, results in elevated 
mitochondrial concentrations of oxaloacetate, a potent competitive inhibitor of 
succinate dehydrogenase [220]. Reverse electron transfer from complex I to 
complex II also occurs if complex I is not inhibited, stimulating the production of 
ROS [220]. 
3) Combined Complex I and Complex II mediated respiration – The convergent 
transfer of electrons via complex I and complex II into the Q-cycle corresponds with 
the operation of the TCA cycle and mitochondrial respiration in-vivo [221]. 
Administration of a combination of pyruvate, malate and succinate (Pyr/Mal/Succ) 
allows for the complete operational function of the TCA cycle in permeabilized cells 
in-vitro [221]. The complex I substrate combination of Pyr/Mal alone does not allow 
for the transfer of electrons to complex II, owing to a substrate mediated inhibition 
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of succinate dehydrogenase [221]. The additional administration of succinate at high 
concentrations overcomes this inhibition and drives the activity of succinate 
dehydrogenase to produce FADH2, complementing the formation of NADH via the 
activity of the NADH-linked dehydrogenases [221].  
4) Fatty acid mediated respiration – Administration of octanoate, a medium chain 
FFA the oxidation of which by mitochondria is not carnitine dependent, supplies 
electrons produced during β-oxidation to the ETC via the reducing equivalent, 
electron-transferring flavoprotein (ETF) [221]. While the capacity to oxidize fatty 
acids has been found to be relatively low in isolated mitochondria, respiration rates 
have been demonstrated to improve significantly in the presence of malate [222, 
223]. Substrate oxidation under these conditions (Oct/Mal) in-vitro, give a measure 
of mitochondrial respiration owing to β-oxidation together with the oxidation of 
acetyl-CoA through the TCA cycle [221, 223]. Indeed, it has been shown that 
respiratory rates are higher under substrate conditions that support the convergent 
transfer of electrons into the Q-cycle through complex I and ETF, than with electron 
input via either complex I or complex II alone [221]. 
3.2.1 – Outline of Variables Analysed in Study Two  
3.2.1.1 Highly Reactive Oxygen Species Production 
ROS are defined as any oxygen-containing species that exhibits a higher reactivity 
than O2 [224]. The redox status of these molecules can range from relatively stable 
species such as O2− and H2O2 to what are termed hROS which include .OH and 
ONOO- [224]. While many biochemical reactions are responsible for the generation 
of O2− and H2O2 in-vivo, hROS are mainly generated by non-enzymatic processes 
involving the mediation of transition metal cations [224]. Indeed, .OH is generally 
produced through the reactions of mitochondrial produced O2− and H2O2 with 
transition metals such as iron or magnesium [224]. In addition, decomposition of 
ONOO- can also yield .OH which is reported to have a half-life in the nanosecond 
range [224]. While direct tissue damage has only been attributed to O2− and H2O2 at 
supra-physiological concentrations, oxidative stress associated with the presence of 
.OH is well established, owing to its high non-specific reactivity with a variety of 
biomolecules [224]. Whereas O2− and H2O2 are neutralized through the activity of 
catalase, peroxidases and superoxide dismutases, there are no known antioxidant 
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enzymes responsible for the removal of hROS [224]. Analysis of hROS levels 
within mitochondria allows for determination of whether the functional response of 
the organelle to rhGH and rIGF-1 under conditions of substrate saturation has 
negative consequences in terms of an increased risk of oxidative damage to key 
mitochondrial components [215]. 
3.2.1.2 Electron Transport Chain Activity 
The activity of ETC complexes, in terms of their ability to induce phosphorylation 
of ADP via the generation of an electrochemical potential across the IMM, has 
important implications for cellular function [219]. As noted previously, complex I 
and complex III of the ETC are the principal sites of ROS generation within 
mitochondria [215, 216]. In particular, the functional activity of complex I has been 
identified to play a key role in the regulation of ROS generation and in the 
determination of the efficiency of mitochondrial ATP production [64, 225]. Defects 
in respiratory chain activity, resulting in a decline in levels of cellular ATP 
production and an augmentation of the rate of ROS generation, are associated with 
an initiation of apoptotic pathways and are implicated in the age-associated decline 
of mitochondrial function [219]. Analysis of ETC activity, through the examination 
of Δψm values and hROS levels under various conditions of mitochondrial 
respiration, will provide an indication of how mitochondrial responses to rhGH and 
rIGF-1 are implemented and allow for determination of the principal source of ROS 
generation along the ETC. 
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3.2.2 – Study Two Aims 
The primary aims of Study Two were as follows: 
1. To investigate the role played by individual respiratory complexes in mediating 
the mitochondrial effects of rhGH and rIGF-1 through the examination of 
relative changes in Δψm and mitochondrial hROS levels under the respiratory 
conditions outlined in section 3.2 which to varying degrees allowed for control 
over the sites of electron entry into the respiratory chain at complexes I and II. 
2. To investigate how rhGH and rIGF-1 mediated mitochondrial responses are 
affected under conditions of substrate saturation at both physiological and 
supra-physiological concentrations. 
 
3.2.3 – Study Two Hypotheses 
The hypotheses of Study Two were as follows: 
• Both Δψm and hROS values will be significantly increased under conditions of 
respiration utilizing the activity of complex I at saturating substrate 
concentrations compared to conditions of respiration utilizing the activity of 
complex II at saturating substrate concentrations following the inhibition of 
complex I. 
• Under conditions of respiration utilizing the activity of complex I at saturating 
substrate concentrations, neither rhGH nor rIGF-1 will exert any significant 
effect on Δψm in samples treated at physiological concentrations compared to 
untreated control samples. However, hROS values under these conditions will 
either not change or be significantly decreased. In contrast, both Δψm and 
hROS values will be significantly increased by both rhGH and rIGF-1 in 
samples treated at supra-physiological concentrations compared samples 
treated at physiological concentrations and untreated samples. 
• Under conditions of respiration utilizing the activity of complex II at saturating 
substrate concentrations following the inhibition of complex I, neither rhGH 
nor rIGF-1 will exert any significant effect on Δψm or hROS values in samples 
treated at either physiological or supra-physiological concentrations compared 
to untreated control samples. 
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3.3 – Outline of Study Three 
Study Three was designed to determine the effect of the administration of recombinant 
human growth hormone for one week on the regulation of mitochondrial mediated 
apoptosis in PBMCs from healthy male subjects who undertake regular physical 
activity.  
Ten healthy male subjects between the ages of 18 and 35 years who had engaged in 
resistance training at least three times a week for a period of at least 12 months were 
recruited to participate in the study. Subjects were randomly assigned to receive either 
recombinant human growth hormone (n=5) (1mg – Genotropin, Pfizer, Australia) or a 
placebo (n=5) in the form of a solution of physiological saline (0.9%) for seven 
consecutive days. Treatment was administered subcutaneously in a double blind 
manner. The selected dosage was chosen in order to minimize the occurrence of 
adverse side effects observed in previous studies where rhGH was administered at 
higher dosages [148, 154, 180]. Such side effects include transient fluid retention, 
increased rates of sweating, carpel tunnel compression and joint edema and pain [148, 
154, 180]. 
Blood was collected from each subject 24 hours prior to treatment in addition to 1, 8, 
15 and 22 days post treatment. Subjects were instructed to fast for 12 hours prior to 
sample collection. PBMCs were isolated from whole blood by density gradient 
centrifugation. Once isolated, cytosolic and mitochondrial fractions were extracted 
from PBMCs using magnetic activated separation techniques. Total RNA and protein 
were subsequently extracted from both cytosolic and mitochondrial fractions using 
column based isolation techniques. Following synthesis of complementary DNA 
(cDNA) from total RNA, the level of gene expression for Bcl-2 and Bak in cytosolic 
fractions and miR-181a and miR-125b in both cytosolic and mitochondrial fractions 
was analysed by real-time polymerase chain reaction (RT-PCR). Protein 
concentrations of Bcl-2 and Bak in mitochondrial fractions were analysed using 
enzyme-linked immunosorbant assays.  
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3.3.1 – Outline of Variables Analysed in Study Three 
3.3.1.1 Bcl-2 and Bak Expression 
The Bcl-2 protein is an anti-apoptotic member of the Bcl-2 family whose association 
with apoptotic effector molecules on the mitochondrial outer membrane prevents 
proteolipid pore formation and the subsequent release of apoptotic proteases from the 
inter-membrane space [56]. Bak is a pro-apoptotic member of the Bcl-2 family, termed 
an effector molecule, which is localised to the mitochondrial outer membrane [59]. 
Following activation by BH-3 only proteins, homo-oligomerization of Bak leads to 
permeabilization of the mitochondrial outer membrane, an event which represents the 
irreversible execution phase of mitochondrial mediated apoptosis [59]. Analysis of the 
gene and protein expression of these apoptotic regulatory proteins allows for the 
determination of how rhGH administration affects the regulation of mitochondrial 
mediated apoptosis in PBMCs. 
3.3.1.2 Cytosolic and Mitochondrial miRNA Expression 
Both of the miRNAs investigated in Study Three were chosen as they had previously 
been demonstrated to target either Bcl-2 or Bak mRNA [99, 102, 226-228]. MiR-181a 
has been demonstrated to act as a potent inhibitor of cellular proliferation and has been 
experimentally validated to down-regulate the expression of Bcl-2 [99, 227, 229]. 
MiR-125b, which has been shown to provide protection against cellular senescence 
and apoptosis, has been experimentally validated to down-regulate the expression of 
Bak [102, 226, 228, 230]. Analysis of the effects of rhGH on the expression of these 
miRNA in both cytosolic and mitochondrial fractions allows for the investigation of 
potential pathways by which rhGH could mediate the regulation of mitochondrial 
mediated apoptotic effects.  
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3.3.2 – Study Three Aims 
The primary aims of Study Three were as follows: 
1. To investigate the potential implications of the administration of rhGH in 
healthy male subjects for cellular viability through the analysis of the hormone 
mediated effects on the expression of the apoptotic regulatory proteins, Bcl-2 
and Bak. 
2. To determine whether the protection provided by rhGH’s putative anti-
apoptotic effects remains sufficient, in the long term, to counter the 
development of pro-apoptotic stimuli that are associated with prolonged 
elevations in GH concentrations in-vivo. 
3. To examine whether both cytosolic and mitochondrial associated miRNA 
signalling could be responsible for the rhGH induced changes observed in the 
expression of Bcl-2 associated regulatory proteins.  
 
3.3.3 – Study Three Hypotheses 
The hypotheses of Study Three were as follows: 
• Bcl-2 expression will be significantly up-regulated while Bak will be 
significantly down-regulated following rhGH administration. However, the 
significance of these initial anti-apoptotic effects will become attenuated by 22 
days post-treatment. 
• The cytosolic expression of miR-181a will be significantly decreased while 
expression of cytosolic miR-125b will be significantly increased following 
rhGH administration. However, the significance of these initial anti-apoptotic 
effects will become attenuated by 22 days post-treatment. 
• The mitochondrial expression of miR-181a will be significantly increased 
while expression of mitochondrial miR-125b will be significantly decreased 
following rhGH administration. However, the significance of these initial anti-
apoptotic effects will become attenuated by 22 days post-treatment. 
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 4. Methods of Analysis 
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4.1 – Isolation Techniques 
4.1.1 – Cell Isolation: Density Gradient Centrifugation 
Density gradient centrifugation, using Ficoll-Paque PLUS, allows rapid and efficient 
isolation of mononuclear cells from human peripheral blood without altering either the 
phenotype or function of the mononuclear cell population [231]. Ficoll-Paque PLUS, a 
solution consisting of a mixture of the high molecular weight polysaccharide Ficoll with 
sodium diatrizoate, exhibits a low viscosity and has density of 1.077g/mL [231]. Anti-
coagulated blood (5mL) is diluted with an equal volume of phosphate buffered saline 
(PBS), layered over 3mL of Ficoll-Paque PLUS and centrifuged at 900*g, 18o – 20oC, 
for 30 minutes [231]. The specific viscosity, osmolarity and density of Ficoll-Paque 
PLUS allows for the differential separation of mononuclear cells during centrifugation 
from other elements found in the blood [231, 232]. Ficoll acts as an erythrocyte 
aggregant at room temperature, causing these cells to sediment through the Ficoll-Paque 
PLUS layer at an accelerated rate [232]. In addition, the osmotic pressure placed on 
granulocytes by the hypertonic Ficol-Paque PLUS increases their density above that of 
the separation medium resulting in their sedimentation at the bottom of this layer [231]. 
Lymphocytes, monocytes, and platelets all have a lower density than the separation 
medium and accumulate at the interface between the plasma and the Ficoll-Paque PLUS 
layer [231]. These cells are then recovered from the interface while platelets are 
separated from the mononuclear cells by subsequent washing in a balanced salt solution 
[231]. Sample yields are reported to range between one and two million mononuclear 
cells per mL of blood in health individuals [231]. Approximately 60% to 70% of 
isolated mononuclear cells are reported to be lymphocytes with a viability of > 95% 
[231]. Monocytes and macrophages make up the remainder of the population and are 
reported to have a viability of > 95% [231].  
4.1.2 – Mitochondrial Isolation: Magnetic Cell Sorting 
Magnetic activated cell sorting (MACS) is an isolation technique which utilizes super-
paramagnetism to separate cells through the magnetic labelling of specific cell surface 
antigens [233]. While originally developed for the purification of specific cell 
populations, the technique has been successfully applied to the isolation of cellular 
organelles including Golgi vesicles [234], endosomes [235], lysosomes [236], nuclei 
[237], and mitochondria [107, 238]. Indeed, it has been demonstrated that mitochondrial 
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isolation using the MACS approach provides a high yield of functionally intact 
mitochondria in a fast, reproducible and standardized procedure which can be 
performed with as few as 1*106 cells [233]. 
The procedure involves the labelling of mitochondria in cell lysate with anti-TOM22 
antibody conjugated microbeads [107, 233]. These monoclonal antibodies bind 
specifically to the 22-kDa translocase of outer mitochondrial membrane (TOM22) on 
the cytoplasmic surface of human mitochondria [107, 233]. Microbeads are an evenly 
distributed suspension of super-paramagnetic nanoparticles, 50nm in diameter, which 
allow for the efficient isolation of labelled mitochondria as they are passed through high 
gradient magnetic columns [107, 233]. Cellular contaminants are washed from the 
columns which are subsequently removed from the magnetic field, allowing for the 
elution of isolated mitochondrial fractions [107, 233].  
As demonstrated by Hornig et al. [233], mitochondrial isolation by MACS compares 
favourably with traditional and frequently used differential centrifugation (DC) 
protocols as well as more sophisticated density gradient ultra-centrifugation (UC) 
procedures. Flow cytometric analysis of mitochondrial fractions showed that 
mitochondria isolated using the MACS protocol were found to be significantly 
enriched, with 89% of isolated events found to be TOM22 positive, compared with 59% 
of the mitochondrial fraction prepared by DC [233]. In addition, the functional quality 
(assessed through the determination of respiratory control ratios; a measure of the 
tightness of mitochondrial respiration) and purity (defined as the absence of 
contaminants from the endoplasmic reticulum and nucleus) of mitochondrial fractions 
was shown to be significantly enhanced using MACS compared with DC [233]. In 
contrast, the UC method exhibited levels of mitochondrial enrichment (88% of events 
were TOM22 positive) which did not significantly differ from the MACS approach 
[233]. Furthermore, the quality and purity of MACS isolated mitochondria was 
comparable to mitochondria isolated using UC, a procedure which is both more time 
consuming and costly than MACS [233].  
4.1.3 – Total RNA Purification: Solid Phase Extraction 
Commercially available kits for RNA purification utilize either a conventional organic 
phase extraction, a solid phase extraction or a combination of these procedures [239]. 
Organic phase extraction is a single step technique whereby RNA is isolated from DNA 
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and other organic biomolecules following the biphasic separation of a guanidinium 
thiocyanate-phenol-chloroform solution into organic and aqueous phases under acidic 
conditions [240, 241].  Guanidinium thiocyanate is a chaotropic agent which denatures 
proteins, disrupting protein-nucleic acid interactions and inactivating nuclease enzymes 
[240, 241]. Total RNA is collected from the aqueous phase of the solution and 
recovered by alcohol precipitation [240, 241]. While organic phase extraction has been 
demonstrated to deliver high yields across all sizes of RNA [240], the process is time 
consuming and samples isolated by the method are reported to be frequently 
contaminated with proteins, genomic DNA (gDNA) and organic solvents owing to 
incomplete phase separation  during liquid-liquid extraction [240]. In contrast, solid 
phase extraction has been demonstrated to be efficient protocol which allows for the 
recovery of high quality RNA exhibiting low levels of contamination from proteins and 
other organic biomolecules without the required use of toxic organic solvents [241, 
242]. 
Solid phase extraction of nucleic acids involves the passing of a dissolved sample 
through the solid phase material of what are termed “spin-columns” under centrifugal 
force [241, 243]. Specific nucleic acids (DNA or RNA) selectively bind to the solid 
phase material under defined pH and ionic conditions [241, 243]. Solid phase extraction 
is a four step process which involves cell lysis, nucleic acid adsorption to solid phase 
material, washing and elution [241, 243]. Cells are first homogenised in a buffer 
containing detergents and high concentrations of chaotropic salts, resulting in cell lysis, 
protein denaturation and nuclease inactivation [241, 243]. A silicon-based affinity 
medium is commonly used for the adsorption of nucleic acids, which is dependent on 
the presence of chaotropic ions at high concentrations [241, 243]. Under conditions of 
high ionic strength, the hydration shells surrounding nucleic acids and the silicon-based 
medium become destabilized, resulting in the dehydration of both [241, 243]. Positively 
charged ions subsequently saturate the silicon-based molecules which allows for the 
formation of cationic salt bridges between the affinity medium and the negatively 
charged phosphate backbone of nucleic acids [241, 243]. Ionic conditions can be 
optimized to favour RNA adsorption over that of DNA [241, 243]. Although DNA 
contamination of the affinity medium does occur during RNA purification, even under 
optimized conditions, this can be removed by digestion through the application of 
DNase directly onto the solid phase medium [244]. Subsequent washing of the affinity 
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medium allows for the removal of salt, protein and other cellular contaminants [241, 
243]. Purified RNA molecules become rehydrated following the application of either 
TE buffer or distilled water to the spin-column and are finally eluted under conditions 
of low ionic strength [241, 243].    
Most commercially available spin-columns utilize silica (SiO2) based materials such as 
glass fibre or silica gel as their RNA affinity medium [241, 242]. However, silicon 
carbide (SiC) was utilised as the chromatographic medium of RNA purification in 
Study Three. It has been reported that commercially available kits, designed for the 
purification of total RNA, which utilize a silica-based separation medium selectively 
exclude RNAs that are less than 200 nucleotides in size and do not efficiently recover 
the miRNA fraction [245]. Indeed miRNA yields have been demonstrated to be between 
3.7 – 7.9 times higher using SiC-based RNA purification over silica-based RNA 
binding columns [246]. In addition, SiC-based RNA binding columns were found to 
exhibit the highest RNA yield and the broadest RNA size distribution when compared 
to phenol-based RNA purification, silica-based RNA binding column extractions and 
combined phenol / silica-based column approaches [239]. 
4.2 – Flow Cytometry 
Flow Cytometry is a technology that utilizes light scattering and fluorescence emission 
to quantitatively analyse the properties of individual particles, such as cells, as they flow 
in a fluid stream through a beam of light [247]. A flow cytometer consists of several 
systems which work in unison in order to provide a quantitative measurement of cellular 
parameters [247, 248]. The fluidics system uses hydrodynamic focusing to transport a 
single stream of particles through a laser beam for interrogation [247]. The biological 
sample is injected into a stream of sheath fluid in the flow chamber, where differences 
in the density and velocity of the two fluids allows them to form a two-layer stable flow 
(laminar flow) that does not interact [247]. The sheath fluid flows at a greater velocity 
than the sample fluid, restricting it to the centre of the flow chamber. The optical system 
consists of a laser and a series of focusing lenses which generate light signals when they 
interact with particles in the flow stream, and a series of dichroic mirrors and bandpass 
filters which direct specific wavelengths of light to the appropriate photo-detector for 
signal processing [247, 248]. Light emitted from sample particles in the flow stream 
generates a small current when it comes into contact with a photo-detector, the 
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amplitude of which is proportional to the total number of light photons received by the 
detector [247]. The electrical current is amplified by a series of linear and logarithmic 
amplifiers and is subsequently converted to a voltage pulse, which is assigned a digital 
value by the Analog-to-Digital Converter (ADC). The ADC converts a pulse ranging 
from 0-1000 mV to a digital number representing 0-1000mV channels, with each 
voltage pulse generated expressing data from a single particle [247]. Finally, computer 
software is used to store the data, display results graphically and generate statistics [247, 
248]. 
4.2.1 – Measurement Parameters 
4.2.1.1 Light Scatter 
Sample particles deflect laser light as they pass through the beam, scattering light in 
all directions. Light scattered in a forward direction is measured approximately 20o 
offset from the axis of the laser beam and is collected in the forward scatter channel 
(FSC) by a type of photo-detector called a photodiode [247]. Forward scatter light is 
proportional to a particle’s surface area and equates to a particle’s size [247]. Side 
scatter light, which is measured perpendicular to the axis of the laser beam, is 
collected in the side scatter channel (SSC) by a photomultiplier tube (PMT) detector 
[247]. Side scatter light reflects cellular granularity or the internal complexity of 
sample particles [247]. 
4.2.1.2 Fluorescence 
Light is a form of electromagnetic energy that travels in waves [249]. The energy 
content of a light beam is directly proportional to its wave frequency and inversely 
proportional to wavelength, which also determines the colour of light [249]. A 
fluorescent compound is capable of absorbing light energy within a specific wavelength 
range that is characteristic of that compound, leading to excitation of the electrons 
within that compound which raises them to a high energy unstable state [247]. The 
compound subsequently undergoes conformational changes and returns to a more stable 
state by releasing some of the absorbed energy as heat [247]. Fluorescence refers to the 
subsequent release of the remaining energy as light which is emitted at a longer 
wavelength to the light source which originally excited the compound [249]. The 
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difference in wavelength between the excitation light source (E excitation) and the 
fluorescent light source (E emission) is called Stokes shift [249]. 
A flow cytometer uses lasers to focus light consisting of a single wavelength on the 
individual particles of a sample [247-249]. In order to analyse specific cellular 
parameters, fluorescent probes called fluorochromes that are maximally excited within 
the specific wavelength utilized by a flow cytometer are used to target specific cellular 
antigens or intracellular molecules. This allows for the biological and biochemical 
properties of the target molecule to be quantified by the subsequent emission of 
fluorescent light, as the amount of fluorescent signal detected is proportional to the 
number of fluorochrome molecules on the particle [247, 249]. Fluorescent probes have a 
wide range of applications including, quantifying distinct cellular populations, cell 
surface receptors or intracellular organelles, measuring enzyme activity and quantifying 
cellular ion concentrations [247]. Flow cytometers use separate fluorescence (FL-) 
channels to detect the specific wavelength of light emitted from fluorochromes [247]. A 
list of the flurorochromes used in this thesis and their respective excitation and emission 
wavelengths are presented in table 4.1 below. 
 
Table 4.1: Summary of the excitation / emission wavelengths of the fluorochromes 
utilized and the associated parameters analysed in Studies One and Two. 
 
 
 
Fluorochrome Assay Parameter Excitation Peak 
Emission 
Peak 
JC-1  (Monomer) 
JC-1 (Aggregate) 
Mitochondrial Membrane Potential 
 
514nm 
514nm 
529nm 
590nm 
DilC1(5) Mitochondrial Membrane Potential 638nm 658nm 
MitoSOX Red Mitochondrial Superoxide Production 510nm 580nm 
Annexin V-Cy5 Apoptotic Cells 625nm 670nm 
Sytox Green Dead Cells 504nm 523nm 
Calcein Mitochondrial Permeability Transition Pore Activity 495nm 515nm 
HFP Highly Reactive Oxygen Species 490nm 515nm 
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4.2.2 – Data Analysis 
Measurements made on each photo-detector of a flow cytometer provide data on a 
single parameter or variable [247]. Computer software allows this data to be graphed 
and analysed statistically [247, 248]. Single parameters can be displayed on a histogram 
with the parameters signal value in channel numbers displayed on the x-axis and the 
number of events recorded represented on the y-axis [247]. Two measurement 
parameters can be displayed on a dot plot, with one parameter represented on the x-axis 
and the other on the y-axis [247]. Contour plots and density plots also provide a two 
parameter display, while using contour lines and colour changes respectively to provide 
a three dimensional representation of the event count [247]. Statistics generated can 
provide the arithmetic mean, the geometric mean, or the median channel values for any 
given parameter, which allow for interpretation of the central tendency of the data 
[250]. 
During data collection the conversion of a light scatter or fluorescent signal into a 
digital value can be processed by either linear or logarithmic amplification of the 
electrical current produced by a photo-detector [247]. Linear data is reported on a 1024 
channel scale in proportion to the intensity of collected light and displayed graphically 
on axes with linear values [251]. Logarithmic amplified data is reported on a 1024 
channel scale with the digital channel number proportional to the log of the original 
light intensity [251]. Linear amplification displays data over a limited range of 
intensities (1-1024) and subsequently is used for analysis of parameters in which a 
narrow range of signal intensity is expected, such as forward scatter and side scatter 
light [251]. Logarithmic amplification is normally used to display data of fluorescent 
parameters as it compresses strong signals which range up to hundreds or thousands of 
times the intensity the intensity of weak signals, thus allowing such data to be displayed 
graphically [247, 251]. Flow cytometry software allows for analysis of the relative 
intensities of logarithmically amplified signals by converting the channel values to a 
number that corresponds to the fluorescent intensity of the original light signal [252]. 
These values are displayed graphically on a four log decade scale (100 – 104) and 
correspond to linear values in the range of 1 – 10,000 [252]. 
A frequent goal of flow cytometric analysis is to classify cells as positive or negative for 
a given marker or to determine the precise ratio of positive to negative cells [253]. In 
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order to accurately distinguish between positive and negative data sets, the use of 
negative control samples is required [253]. Commonly used control samples in flow 
cytometry include negative isotype controls that provide non-specific staining for an 
antibody of a particular isotype conjugated to a particular fluorochrome and biological 
comparison controls, which provide relevant comparison conditions to determine the 
degree of positivity or negativity for a particular marker [253]. For example, assays 
examining the functional activity of a given cellular parameter by stimulating the 
activity of that parameter may use an unstimulated sample as a means of distinguishing 
between positive and negative events [253]. The use of histogram markers on single 
parameter graphs and quadrant markers on dual parameter graphs can identify positive 
and negative data sets, the percentages of which are analysed statistically [247]. 
Computer software allows for subsets of collected data to be analysed in isolation 
through the use of a “gate” [247]. The purpose of creating gates is to identify cells of 
interest while excluding data from unwanted cells [247].  A gate creates numerical or 
graphical boundaries based on the parameters displayed on the graph which is being 
analysed [247]. These boundaries define the characteristics of particles to be included in 
further analysis [247]. The most common application of gating is the targeting of 
specific cell populations when analysing blood samples [247]. Graphing forward scatter 
and side scatter parameters on a dot plot allows for visualization of specific cellular 
populations, such as granulocytes, monocytes and lymphocytes due to differences in the 
physical properties of these cells, which makes it possible to create boundaries around 
the population of interest [247]. 
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4.2.3 – Analysis of Variables 
4.2.3.1 Mitochondrial Membrane Potential (Δψm) 
In Study One, Δψm was analysed on a FACS Calibur flow cytometer using the 
MitoProbeTM JC-1 Assay Kit (Life Technologies, Australia). JC-1 (5,5',6,6'tetrachloro-
1,1',3,3'-tetraethylbenzimidazol-carbocyanine iodide) is a lipophilic cationic dye that 
exhibits potential dependent accumulation in the mitochondrial matrix [254, 255]. The 
fluorescence emission of JC-1 changes depending on Δψ, due to the reversible 
formation of JC-1 aggregates upon membrane polarization [256]. When concentrations 
of the dye in the mitochondria are low, the dye exists in its monomeric form, emitting 
light at an emission maximum of 530nm (green) when excited at 488nm [254]. When 
concentrations of the dye in the mitochondria are high, the dye aggregates to form J-
complexes which emit light at an emission maximum of 590nm (orange) when excited 
at 488nm [254]. Aggregate formation begins at potential values corresponding to 
approx 80 – 100 mV and reaches a maximum at approx 200 mV, as illustrated in 
figure 4.1 [256]. Measurements provided by JC-1 are qualitative, based on the ratio of 
fluorescence emission at 590nm and 530nm, and quantitative, based on the absolute 
values of both green and red fluorescence emission [256]. The orange / green 
fluorescence intensity ratio gives an indication of Δψm that is independent of factors 
such as mitochondrial volume, shape or density, allowing comparative measurements 
of membrane potential and determination of the percentage of mitochondria within a 
population that respond to an applied stimulus [254, 257, 258]. 
In Study Two, Δψm was analysed by flow cytometry using the Δψm indicator, 
1,1′,3,3,3′,3′-hexamethylindodicarbo - cyanine iodide (DilC1(5)) (Life Technologies, 
Australia). DilC1(5) is a cationic dye that, at concentrations below 100nM, 
accumulates primarily in mitochondria with active membrane potentials [259]. It emits 
a peak fluorescence emission of 658nm when excited at 633nm [259]. 
Negative control samples were treated with the mitochondrial uncoupler carbonyl 
cyanide 3- chlorophenylhydrazone (CCCP), a protonophore that carries H+ ions across 
lipid membranes, to confirm that the JC-1 and DilC1(5) responses were sensitive to 
Δψm [255]. Positive control samples were treated with oligomycin, an antibiotic that 
inhibits oxidative phosphorylation by binding to ATP synthase and which has 
previously been utilised as a positive control for Δψm in isolated organelles [258]. By 
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blocking the flow of protons into the mitochondrial matrix through the F0 subunit of 
ATP synthase, oligomycin maximizes the proton gradient as it has no direct effect on 
electron transport [258]. Figure 4.1 illustrates the effects exerted by CCCP and 
oligomycin on JC-1 fluorescence.  
 
 
 
Figure 4.1: Flow cytometric analysis of mitochondrial membrane potential. A) Cellular 
and mitochondrial loading of JC-1, image adapted from Cossarizza [260]. B) Dot plot 
displaying green vs. orange mean channel fluorescence values for JC-1 from gated 
lymphocytes in the presence of CCCP. C)  Dot plot displaying green vs. orange mean 
channel fluorescence values for JC-1 from gated lymphocytes in the presence of 
oligomycin. D) Dot plot displaying green vs. orange mean channel fluorescence values 
for JC-1 from gated lymphocytes in untreated cells. 
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4.2.3.2 Mitochondrial Superoxide Generation and Cellular Viability 
In Study One, mitochondrial superoxide production was analyzed by flow cytometry 
using MitoSOXTM Red Mitochondrial Superoxide Indicator (Invitrogen, Australia). 
MitoSOX Red is a derivative of the flourochrome hydroethidine (HE) that contains a 
positive charge on its phosphonium group, allowing it to accumulate in mitochondria 
as a function of Δψm [261]. When the probe is oxidized, it leads to the fluorescent 
product 2-hydroxy-ethidium, which stains the DNA of mitochondria and emits light 
with a peak emission of 567nm when excited at 488nm [261]. MitoSOX Red is readily 
oxidized by O2− but exhibits a limited response to other ROS and oxidation of the 
probe is prevented by superoxide dismutase [261]. The use of MitoSOX Red by flow 
cytometry has been validated for the selective detection of mitochondrial superoxide 
production in a wide range of cell types [262-264].  
The advantage of this method of analysis over other cell based techniques is that it 
provides quantitative measurements of mitochondrial superoxide generation in live 
cells without compromising cellular function [261, 262]. During data analysis it is 
necessary to exclude fluorescent values from dead cells as dissipation of the Δψm 
during cell death causes release of the fluorophore from the mitochondria and leads to 
staining of nuclear DNA, resulting in large increments in fluorescence emissions 
which do not accurately indicate superoxide levels [261]. Annexin V and Sytox Green 
are fluorometric markers of apoptotic and dead cells respectively [261]. Annexin V is 
a 35–36 kDa phospholipid binding protein that has a high affinity for 
phosphatidylserine, a phospholipid that is externalised to the surface of plasma 
membranes in cells undergoing apoptosis [265]. When conjugated to the cyanine dye, 
Cy5, the probe emits light at a peak value of 660nm when excited at 633nm [266]. 
Sytox Green binds to the DNA of dead cells and emits fluorescence at an emission 
peak of 523nm when excited at 488nm, as it can only enter cells that have lost their 
plasma membrane integrity, as illustrated in figure 4.2 [261]. 
Antimycin A, which inhibits mitochondrial respiration and augments mitochondrial 
superoxide production by inhibiting electron transfer at complex III of the ETC, was 
used as a positive control in order to confirm the sensitivity of MitoSOX Red for the 
detection of mitochondrial superoxide generation [261]. Figure 4.2 illustrates the 
effects exerted by antimycin A on MitoSOX Red fluorescence. Negative control 
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samples were treated with superoxide dismutase-polyethylene glycol (SOD-PEG), an 
antioxidant protein and superoxide scavenger conjugated to the polyether compound 
polyethylene glycol which prolongs the circulatory half-life of the native enzyme and 
enhances its ability to diffuse across plasma membranes [261]. 
 
Figure 4.2: Flow cytometric analysis of mitochondrial superoxide production A) 
Depiction of how AnnexinV-Cy5 and Sytox Green label apoptotic and dead cells 
respectively, image adapted from Imgenex [267]. B) Dot plot displaying mean channel 
fluorescence values for Sytox Green vs. AnnexinV-Cy5 from gated lymphocytes in 
untreated cells. C) Dot plot displaying mean channel fluorescence values for Sytox 
Green vs. AnnexinV-Cy5 from gated lymphocytes in the presence of antimycin A. D) 
Histogram displaying mean channel fluorescence values for MitoSOX Red from gated 
live cell population. E) Histogram displaying mean channel fluorescence values for 
MitoSOX Red from gated live cell population in the presence of antimycin A. 
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4.2.3.3 Mitochondrial Permeability Transition Pore Activity 
In Study One, mtPTP activity was assessed by flow cytometry using the MitoProbeTM 
Transition Pore Assay Kit (Life Technologies, Australia)), which allows for direct 
examination of mtPTP opening through monitoring of the mitochondrial fluorescence 
of calcein, a fluorescent dye that emits light at a peak intensity of 517nm when excited 
at 488nm [268]. Although the probe itself is cell impermeant, calcein can be loaded 
into cells and accumulate in cytosolic compartments, including mitochondria, by using 
its acetoxymethyl ester form (calcein-AM) [268]. Once the acetoxymethyl ester is 
cleaved by intracellur esterases the dye present in the mitochondria becomes trapped 
[268]. In order to detect changes in mitochondrial calcein fluorescence in intact cells, 
the fluorescent signal is quenched by the addition of cobalt chloride (CoCl2) in both 
cytosolic and nuclear compartments [268]. Petronilli et al. [268] used confocal 
microscopy to confirm the localization of calcein fluorescence to mitochondrial 
compartments in MH1C1 cells. Opening of the mtPTP results in a spontaneous 
decrease in the mitochondrial fluorescence of calcein which is mediated by either the 
entry of CoCl2 into the mitochondrial matrix or the mitochondrial release of calcein, as 
illustrates in figure 4.3 [268]. 
Ionomycin, a Ca2+ ionophore that allows excess Ca2+ to enter mitochondria, was used 
as a positive control as mitochondrial Ca2+ overload is known to induce mtPTP 
activation [269]. Nicolli et al. [269] confirmed that the decrease observed in the 
mitochondrial fluorescence of calcein in the presence of Ca2+ ionophores is induced by 
mtPTP opening because the response is significantly reduced by cyclosporine A 
(CsA), a polypeptide that is known to prevent mitochondrial transition pore formation 
by binding to Cyp D. In addition, cyclosporine H (CsH), an analog of CsA that does 
not inhibit mtPTP activation was found to have no effect on mitochondrial calcein 
fluorescent emissions [269]. Figure 4.3 illustrates the effects exerted by ionomycin 
and CsA on calcein fluorescence. 
Early research into the activity of the mtPTP in-vivo provided indirect measurements 
based on events that are secondary to the induction of mtPTP opening, such as 
mitochondrial depolarization and mitochondrial matrix swelling [268, 270-272]. Such 
events are subject to a variety of influences and may not accurately reflect mtPTP 
activity [268]. Flow cytometric analysis using the calcein – CoCl2 method allows for 
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direct measurement of mtPTP opening in living cells [268]. A limitation of this 
technique is that Co2+ can adversely affect cellular respiration by inhibiting 
mitochondrial Ca2+ uptake, however Petronilli et al. [268] note that most of the Co2+ 
present in cells is bound to calcein in the cytosol and that calcein fluorescent emissions 
respond normally to mtPTP agonists and antagonists. 
 
Figure 4.3: Flow cytometric analysis of mitochondrial permeability transition pore 
activation. A) Cellular and mitochondrial loading followed by cytosolic quenching of 
calcein, image adapted from Salisbury [273]. B) Histogram displaying mean channel 
fluorescence values for calcein from gated lymphocytes following cobalt chloride 
quenching in the presence of ionomycin. C)  Histogram displaying mean channel 
fluorescence values for calcein from gated lymphocytes following cobalt chloride 
quenching in untreated cells. D) Histogram displaying mean channel fluorescence 
values for calcein from gated lymphocytes following cobalt chloride quenching in the 
presence of CsA. 
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4.2.3.4 Highly Reactive Oxygen Species Production 
In Study Two, hROS production was analysed by flow cytometer using the ROS 
indicator, 3’-p-hydroxyphenyl fluorescein (HPF) (Life Technologies, Australia). HPF is 
a hROS indicator with a high specificity for .OH and the ONOO– [274-276]. It emits a 
peak fluorescence emission of 515nm when excited at 488nm [274]. HPF offers greater 
specificity and a higher resistance to light induced oxidation than commonly used ROS 
indicators such as dichlorofluorescin (DCF) [274, 275]. Positive control samples were 
treated with H2O2 in the presence of ammonium iron II sulphate in order to induce .OH 
production via the Fenton reaction. Figure 4.4 illustrates the effects exerted by H2O2 and 
ammonium iron II sulphate on HPF fluorescence. 
 
Figure 4.4: Flow cytometric analysis of highly reactive oxygen species production. A) 
Histogram displaying mean channel fluorescence values for HPF from gated 
lymphocytes in untreated cells. B) Histogram displaying mean channel fluorescence 
values for HPF from gated lymphocytes in the presence of H2O2 and ammonium iron II 
sulphate. 
 
4.3 – Real-time RT-PCR 
The processes of reverse transcription (RT) and polymerase chain reaction (PCR) (RT-
PCR) provide a powerful combination which is applicable to the detection and 
quantification of both mRNA and miRNA [277, 278]. However, PCR efficiency 
becomes compromised as amplification product, which are termed amplicons, 
accumulate owing to a depletion of reaction components and the re-association of the 
amplified target strands with each other, which inhibits primer annealing [279]. As a 
result, the exponential rate at which template is generated following each cycle of the 
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PCR reaction eventually declines, making the end point quantitation of amplicons 
following conventional PCR unreliable [279]. Real-time PCR uses fluorescent reporter 
molecules to measure the products generated during each cycle of the PCR reaction, 
combining nucleic acid amplification and amplicon detection into one homogenous 
assay [280]. Identification of amplification products by fluorescence detection in real-
time is highly accurate compared with classical end point detection [280]. In addition, a 
wide dynamic quantification range allows for the analysis of samples that differ in their 
target abundance by orders of magnitude (> 107 – fold) [281]. Thus, real-time RT-PCR 
represents the standard for the detection and quantification of gene expression levels, in 
particular for the detection of RNA from limited amounts of sample and for the 
elucidation of small changes in RNA expression levels [277].  
4.3.1 – Assay Parameters 
4.3.1.1 Reverse Transcription 
The production of a single-strand cDNA copy from isolated RNA represents the first 
phase of the RT-PCR process [280, 281]. Oligonucleotide primers anneal to the RNA 
template, permitting its elongation through the RNA-dependent DNA polymerase 
activity of the retroviral enzyme, reverse transcriptase [280]. The choice of primers 
used to initiate cDNA synthesis can be either target gene-specific or non-specific 
[280]. Target gene-specific primers allow RT reactions to take place at elevated 
temperatures which increases specificity and decreases the background noise 
associated with unwanted transcripts [280]. However, the use of gene-specific primers 
necessitates that a separate RT reaction be carried out for each gene of interest which 
can result in high inter-assay variability [280]. In contrast, the use of non-specific 
primers results in the synthesis of a cDNA “pool” from which separate target specific 
PCR reactions can be assayed [280]. Non-specific primers include random hexamers, 
which contain all possible nucleotide combinations of a 6-base oligonucleotide 
allowing for binding at multiple origins along every RNA template and poly-T 
oligonucleotides (Oligo-dT), which consist solely of 16-25 deoxythymidine residues 
allowing for annealment to polyadenylated 3’ (poly-A) tails found on most mRNAs 
[280]. In addition, mature miRNAs can be reversed transcribed into cDNA through the 
use of oligo-dT primers following their polyadenylation through the activity of poly 
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(A) polymerase [282]. RT reactions primed by random hexamers and oligo-dT primers 
maximize the number of genes that can be assayed from small RNA yields [280]. 
4.3.1.2 Polymerase Chain Reaction 
PCR is the amplification of a specific target sequence through repeated cycles of 
temperature manipulation which facilitates enzymatic replication of the target 
amplicon [277, 278]. The process utilizes the ability of the thermostable enzyme 
Thermus aquaticus (Taq) DNA polymerase to synthesize DNA strands which are 
complementary to the template available [278]. However, DNA polymerase can only 
add free nucleotides to a pre-existing 3’-OH group, necessitating that oligonucleotide 
primers which exhibit unique complementarity to the target amplicon be base paired to 
the template sequences [283]. Each cycle of the reaction consists of a three step 
process which is initiated through heating the reaction to 94oC resulting in the 
denaturation of all ds-DNA present [284]. The reaction is subsequently cooled to the 
specific annealing temperature (in the range of 40 – 60oC) of the two primers present, 
allowing them to hybridize to their complementary sequences on opposite strands of 
the target amplicon [284]. The cycle is completed by heating the reaction to 72oC to 
allow for elongation of the template strands by DNA polymerase [284]. 
As a PCR progresses, the reaction goes through three distinct phases of product 
amplification; the exponential phase, the linear phase and the plateau phase [285]. 
During exponential amplification there exists a high degree of efficiency surrounding 
amplicon production where the amount of DNA synthesized is theoretically doubled 
following each successive cycle [285]. This is followed by the linear phase of 
amplification where the efficiency of the reaction slows down owing to a decrease in 
the critical concentrations of one or more reaction components [285]. As a result 
increases in amplified product are observed on an arithmetic rather than logarithmic 
scale [285]. As reaction components become increasingly limited, the rate of target 
amplification increases until the PCR reaches its plateau phase where there is little or 
no increase in PCR product [285]. The amount of amplified target is directly 
proportional to its original concentration in the starting template only during the 
exponential phase of PCR amplification [285].   
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4.3.1.3 Amplicon Detection 
Real-time RT-PCR measures the progress of amplification through the monitoring of 
changes in fluorescence within the PCR reaction [279]. This is achieved through the 
addition of non-sequence specific fluorescent intercalating double stranded DNA 
(dsDNA) binding agents, such as SYBR Green, to the reaction mix [279]. SYBR 
Green, which has an excitation maxima of 497nm and an emission maxima of 520nm, 
exhibits an extremely low intrinsic fluorescence [286]. However, its fluorescence 
quantum yield is increased by up to 1000 fold when intercalated into dsDNA [286]. 
Thus, the intensity of the fluorescent signal is dependent on the quantity of dsDNA 
present in the reaction [286]. The level of fluorescence is measured at the end of the 
elongation phase of each PCR cycle, when the quantity of dsDNA reaches its 
maximum level [286].  
A limitation to the use of SYBR Green is that the dye binds to all dsDNA formed 
during the PCR reaction and is therefore not specific to the target amplicon, allowing 
for the presence of non-specific PCR products and “primer-dimers” to generate 
artefact within the fluorescent signal [277, 287]. Melt curve analysis is therefore used 
to monitor the specificity of the reaction [277, 287]. At the end of the PCR run, 
fluorescence is constantly measured as the temperature of the reaction is gradually 
raised at a constant rate from a low temperature where all amplified products are stable 
to a point at which all dsDNA present has become fully dissociated [287]. Melt curves, 
as shown in figure 4.5, are subsequently generated through plotting the negative first 
derivative of the change in fluorescence as a function of temperature (-dF/dT) against 
temperature [277, 287]. The identification of characteristic peaks at the melting 
temperature (Tm) of the amplicon (which corresponds to the point at which 50% of 
target DNA is denatured) will distinguish it from amplification artefacts that melt at 
lower temperatures and exhibit broader peaks [277, 287]. 
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Figure 4.5: Melt curve displaying the negative first derivative of the change in 
fluorescence as a function of temperature (-dF/dT) against temperature (oC) 
 
4.3.2 – Data Analysis 
4.3.2.1 Cycle Threshold 
Amplification plots, as shown in figure 4.6, are generated using the fluorescence 
emission data collected during the PCR protocol [278]. A baseline reading is recorded 
during the initial PCR cycles in which a fluorescent signal is being accumulated but is 
beneath the detection capabilities of the instrument [278]. Quantification in real-time 
RT-PCR is achieved through the measurement of the number of cycles required for the 
fluorescent signal to cross a threshold level [278]. This arbitrary threshold must be set 
at a value at least three standard deviations above the baseline noise level and occur in 
the exponential phase of target amplification in order to produce accurate and 
reproducible data [278]. The cycle number at which a fluorescent signal is detected 
above this chosen threshold value is defined as the “cycle threshold” (Ct) [278]. The 
Ct of a sample is inversely proportional to the concentration of target sequence in the 
starting template [278]. Thus, the more target copies present at the beginning of a 
reaction, the fewer cycles of amplification that are required to generate the number of 
amplicons which can be detected  reliably [278].   
98 
 
 
Figure 4.6: RT-PCR amplification plot displaying fluorescence emissions against cycle 
threshold. 
 
4.3.2.2 Relative Quantification 
Relative quantification uses the comparative threshold method (2-ΔΔCt method) to 
determine approximate changes in the steady state expression of a gene across 
multiple samples relative to the expression of an internal control RNA [278]. The 
method compares the Ct values from target RNAs to those from one or more 
endogenous reference or ‘housekeeping’ genes with the results expressed as ratios of 
the target specific signal to that of the endogenous reference [278].  Mathematical 
equations are used to calculate the expression of ‘experimental’ target samples in 
relation to a reference ‘control’ sample such as a non-treated or placebo treated sample 
[278]. The amount of target RNA in an experimental sample, normalized to an 
endogenous housekeeping gene and relative to the normalized control sample is thus 
given by equation 4.1: 
2-ΔΔCt, 
 where ΔΔCt = ΔCt (experimental sample) – ΔCt (control sample), and ΔCt = Ct 
(target gene) – Ct (reference gene) [278]. 
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4.3.2.3 Data Normalization 
The accuracy of calculated expression results in real-time RT-PCR experiments are 
significantly affected by minor differences in the quantity and quality of template RNA 
or variation in the efficiency of cDNA synthesis and PCR amplification [279]. It is 
therefore essential to apply a normalization strategy to control for the significant error 
introduced by these parameters [279]. The reliability of any relative real-time RT-PCR 
experiment can be improved through the use of a housekeeping gene which serves as an 
endogenous references control in the assay to correct for sample to sample variation in 
RT-PCR efficiency and errors in sample quantification [279].  
The most commonly used housekeeping genes include β-actin – a cytoskeletal protein, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) – a glycolytic enzyme and 18s or 
28s – ribosomal RNAs [278, 279]. All of these genes are necessary for basic cell 
survival and should theoretically be expressed at a constant level among different cell 
types at all stages of development [278, 279]. Their expression level should also remain 
relatively constant under different experimental conditions [278, 279]. However, no 
single gene is capable of meeting the criteria required of a universal reference gene as 
all are regulated in some capacity and none are constitutively expressed under all 
conditions in all cell types [281]. Therefore, the expression stability of selected 
housekeeping genes must be experimentally validated for the cell population under 
investigation as the reliability of the expression data depends on the choice of the most 
relevant housekeeping gene for the cells of interest [281].     
Furthermore, it is imperative that the amplification efficiencies of target and reference 
samples are similar as even small differences directly affect the accuracy of any 
calculated expression result [279]. A difference in amplification efficiency of 3% 
between target and reference gene amplicons is reported to generate error in the 
calculated expression ratio of 47% when target amplification efficiency exceeds 
reference amplification efficiency and 209% when reference amplification efficiency 
exceeds target amplification efficiency after 25 cycles of the PCR run [279]. It is 
therefore essential that selected primers are validated to achieve a directly comparable 
level of efficiency for the target and housekeeping gene amplicons under investigation 
[279].   
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 5. Study One:  The Effect of Recombinant Human Growth Hormone and Insulin-like Growth Factor-1 on the Mitochondrial Function and Viability of Peripheral Blood Mononuclear Cells In-Vitro 
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5.1 – Abstract 
This study proposes that the benefits induced by both hormones at a cellular level are 
countered at supra-physiological concentrations due to an augmentation in the 
production of mitochondrial-derived free radicals with a subsequent increase in 
oxidative damage compromising mitochondrial function. In order to test this hypothesis, 
PBMCs were incubated for 4 hours with either rhGH (Range = 0.25 – 100µg/L) or IGF-
1 (Range = 100 – 600µg/L) and subsequently analysed by flow cytometry for the 
determination of cellular viability, Δψm, mitochondrial superoxide (O2−) generation and 
mtPTP activity. Levels of mitochondrial superoxide generation were found to be 
significantly reduced compared to control samples (lymphocytes – 21.5±1.6AU / 
monocytes – 230.2±9.8AU) following rhGH treatment at concentrations of 5µg/L 
(13.5±1.3AU, P≤0.05) and 10µg/L (12.3±1.5AU, P≤0.05) in lymphocytes and at 
concentrations of 10µg/L (153.4±11.4AU, P≤0.05) in monocytes, while no significant 
effect was found at higher concentrations or following treatment with IGF-1. In 
addition, treatment with either hormone was not found to have any significant effect on 
Δψm, mtPTP activity or percentages of cellular viability. Results indicate that at 
physiological concentrations, rhGH elicits a protective cellular effect through the 
reduction of oxidative free radicals within mitochondria. This effect was diminished at 
supra-physiological concentrations but not to a level that would elicit disruption of 
mitochondrial function.  
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5.2 – Introduction 
Both GH and its mediator IGF-1 induce specific anabolic effects via stimulation of 
cellular proliferation and differentiation in numerous cell types, including myoblasts, 
osteoblasts, adipocytes, oligodendrocytes, neurons and haemapoeitic cells [2, 4, 128]. 
They also exhibit a broad range of regulatory actions on cellular metabolism including a 
stimulation of lipolysis and lipid oxidation, an increased resistance to the actions of 
insulin and an enhanced level of energy expenditure [23, 128]. When present at normal 
physiological concentrations (0.32±0.72μg/L – Resting; 5 - 44μg/L – Following 
stimulation by exercise), the actions of GH are regarded as beneficial [136, 137, 140]. 
Growth hormone deficient adults exhibit impairments in maximum oxygen 
consumption, ventilatory threshold, cardiac output, lean body mass and lipid 
metabolism which are all improved by replacement therapy with rhGH [21].  
Reported improvements in exercise capacity and muscle strength in growth hormone 
deficient (GHD) patients following rhGH administration piqued the interest of sporting 
professionals looking to obtain a performance enhancing effect. The use of rhGH for the 
purposes of enhancing athletic performance has been extensively reported in the 
literature with doping regimes estimated to range from 3.3 to 8.3 mg per day (10-
25IU/day), 3 to 4 days per week [38]. These supra-physiological concentrations are far 
in excess of the 0.3 to 0.6 mg per day (1-2 IU/day) usually prescribed to adult GHD 
patients [38]. However, evidence in the peer reviewed literature fails to support claims 
that supra-physiological GH concentrations exert performance enhancing benefits, with 
many studies finding no significant improvement in either muscle strength or endurance 
capacity following administration of rhGH to healthy subjects [178-180]. In addition, 
acromegaly, a pathological condition characterized by excessive GH secretion, is 
associated with impairments of strength, aerobic capacity and cardiac performance [21]. 
Indeed, patients with acromegaly, if left untreated, have an increased mortality 
associated with cardiovascular disease, pulmonary complications and cancer which 
suggests that the administration of rhGH to healthy individuals at high doses could have 
negative health implications [22].  
Growth, protein synthesis and many of the components of fuel metabolism require the 
utilization of cellular energy, obtained through the dephosphorylation of ATP which is 
primarily generated via oxidative phosphorylation in the mitochondria. In a recent 
103 
 
publication, Kadenbach et al. [14] postulated a possible mechanism for the direct 
hormonal regulation of oxidative phosphorylation. Under resting conditions, when 
cellular ATP requirements are low, oxidative phosphorylation is known to be under the 
regulation of a high intra-mitochondrial ATP/ADP ratio, where allosteric inhibition of 
COX by ATP functions to keep Δψm low [14]. Bender and Kadenbach [20] found that 
through a calcium dependent dephosphorylation of serine and threonine residues on 
subunit 1 of COX, allosteric inhibition of the enzyme by ATP was no longer present, 
allowing for higher Δψm values (≥140mV) under conditions of increased ATP 
utilization. Although specific effecter molecules and signalling pathways for this 
mechanism have not yet been elucidated, Kadenbach et al. [14] suggest that any 
stimulation of cells by hormones, cytokines or neurotransmitters resulting in modified 
gene expression must lead to the parallel activation of signalling pathways targeted to 
mitochondria in order to modulate oxidative phosphorylation to cell specific energy 
requirements. In addition, at Δψm above 140mV, the production of ROS is reported to 
increase exponentially with increasing Δψm [14]. Consequential oxidative damage to 
lipids, proteins and mitochondrial DNA can have detrimental effects for the cell, 
ranging from uncontrolled cellular proliferation to accelerated cell death [10]. Indeed, 
oxidative stress is reported to be one of the key activators of the mtPTP, whose opening 
initiates mitochondrial apoptotic pathways via the release of cyt c and AIF from the 
mitochondrial inter-membrane space [54]. 
Few studies to date have examined the effect of rhGH administration on mitochondrial 
function in healthy human subjects. Lange et al. [193] and Short et al. [192] found 
significant increases in the activity of mitochondrial oxidative enzymes in skeletal 
muscle, in response to rhGH administration, in healthy human subjects. In addition, 
Short et al. [192] found that 14 hours of intravenous rhGH infusion resulted in an 8-
35% increment in the rate of ATP production of isolated skeletal muscle mitochondria. 
To our knowledge, limited research has been conducted into examining the effects of 
IGF-1 administration on mitochondrial function in tissue from healthy human subjects. 
While research investigating the direct effects of GH and IGF-1 on mitochondrial 
function in human tissue is sparse, studies conducted on animals have shown that 
excessive concentrations of GH can impact negatively on mitochondrial function by 
modifying levels of oxidative stress [39, 40, 203]. Sieva et al. [39] demonstrated that 
high doses of rhGH (2 mg/kg) exerted detrimental effects related to energy metabolism 
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and oxidative stress in rat myocardium, while a lower dose (1 mg/kg) exerted beneficial 
effects on energy production and reduced levels of oxidative damage. In addition, 
studies conducted on transgenic animal models exhibiting an excess production of GH 
found that these animals possessed higher rates of oxygen consumption and free radical 
production [40, 203].  
The purpose of this study was to determine whether GH and IGF-1 exert direct effects 
on the activity of mitochondria over a range of physiological and supra-physiological 
concentrations in PBMCs of healthy human subjects. Determination of the functional 
integrity of mitochondria was interpreted through examination of Δψm, mitochondrial 
generation of O2−, and the active state of the mtPTP. This occurs in response to 
physiological stresses including a depletion of intra-mitochondrial substrate levels and 
any augmentation of the oxidative status of the cell [54]. In addition, the effect of 
treatment on percentages of viable, apoptotic and dead cells was also determined.  
We propose that both GH and IGF-1 induce an up-regulation of oxidative 
phosphorylation in order to meet the energy demands associated with their anabolic 
effects and that this increment in the rate of ATP production is mediated at the expense 
of the efficiency of electron transport along the respiratory chain, which at supra-
physiological concentrations leads to an augmented production of ROS. This could have 
negative implications for optimum cellular function in terms of increased oxidative 
damage to key mitochondrial components and mitochondria mediated activation of 
cellular apoptotic pathways. 
5.3 – Methods 
5.3.1 – Subjects 
Ten healthy male subjects (mean ± SEM: age =23±1yrs, height = 1.78±.02m, body mass 
= 77.1±1.9kg, BMI = 24.39±.71kg/m2) were recruited to participate in the study which 
was ethically approved by the Bond University Human Research Ethics Committee. All 
subjects had the nature of the study and the associated risks involved explained to them 
prior to providing written informed consent. Exclusion criteria included smoking, the 
use of therapeutic, recreational or performance enhancing drugs, including anabolic 
steroids and rhGH up to twelve months prior to participation in the study, the presence 
of diabetes, cardiovascular disease or the use of prescription medication. 
105 
 
5.3.2 – Reagents Used 
Hanks balanced salt solution (HBSS), RPMI Medium 1640, CCCP, JC-1, calcein 
acetoxymethylester (calcein AM), cobalt (II) chloride (CoCl2), ionomycin, mito-
hydroethidine (MitoSOX Red) and SYTOX Green were purchased from Invitrogen 
(Carlsbad, CA, USA). Oligomycin, CsA, antimycin-A and SOD-PEG were purchased 
from Sigma Aldrich (St Louis, MO, USA). Ficoll-paque PLUS was obtained from GE 
Healthcare (Rydalmere, NSW, Australia). Annexin V-Cy5, annexin V binding buffer 
and recombinant insulin-like growth factor-1 (rIGF-1) were purchased from Biocore 
(Sydney, NSW, Australia). Finally, rhGH was purchased from Pfizer (Sydney, NSW, 
Australia). 
5.3.3 – Blood Sample Collection and PBMC Isolation  
Subjects arrived for sample collection in a post prandial state, in the morning following 
an overnight fast having not taken part in any form of physical activity in the prior 24 
hours. Following insertion of a catheter into the antecubital vein, 30mL of blood was 
drawn into 6mL lithium heparinised vacutainers (BD, CA, USA). Collected blood was 
diluted in equal volume HBSS and subsequently layered over Ficoll-paque (PLUS) at a 
ratio of 2:1. All samples were centrifuged at 450*g for 30 mins for the separation of 
PBMCs from whole blood. Isolated cells were washed in HBSS and their concentration 
was determined using a Countess automated cell counter (Invitrogen, Carlsbad, CA, 
USA). Finally, cells were resuspended in RPMI 1640 cell culture medium at a 
concentration of 1*106-cells/mL. 
5.3.4 – rhGH and rIGF-1 Treatment 
Once isolated, cells were divided into aliquots which were either left untreated or 
administered with rhGH (concentration range = 0.25 – 100µg/L) or rIGF-1 
(concentration range = 100 – 600µg/L). All samples were subsequently incubated for 4 
hours at 37oC in the presence of 5%CO2. 
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5.3.5 – Analysis of Mitochondrial Membrane Potential 
Mitochondrial membrane potential was analysed by flow cytometry using the 
ratiometric lipophilic cation, JC-1. The dye, which exists in monomeric form at low 
Δψm and fluoresces at an emission maximum of 530nm, begins to form aggregates in 
the mitochondrial matrix at potential values corresponding to approximately 80-100mV, 
reaching a maximum at approximately 200mV [288]. These aggregates, termed J 
complexes, have an emission maximum of 590nm. The ratio of the fluorescence 
emission, between the aggregated and monomeric forms of the dye, provides an 
indication of Δψm that is independent of the size, shape or volume of mitochondria in 
the cell [288]. 
Following treatment with rhGH and rIGF-1, 1mL aliquots from each treatment 
condition were washed and resuspended in 1mL PBS. Positive and negative control 
samples are incubated at 37oC in 5% CO2 for 5 minutes in the presence of 5μM of the 
ATP synthase inhibitor, oligomycin and 50μM of the mitochondrial uncoupler, CCCP 
respectively. All samples were subsequently incubated at 37oC in 5% CO2 for 20 
minutes in the presence of JC-1 at a concentration of 2μM. Following incubation, all 
samples were washed and resuspended in 500μL PBS, prior to analysis by flow 
cytometry. 
5.3.6 – Analysis of Mitochondrial Permeability Transition Pore Activity 
Following treatment, 1mL aliquots from each treatment condition were washed and 
resuspended in 1mL HBSS containing Ca2+ at a concentration of 1.26mM. Positive 
control samples were treated with 500nM ionomycin, a Ca2+ ionophore which induces 
opening of the mtPTP by overloading the mitochondrial matrix. Negative control 
samples were treated with 1μM cyclosporin A, which prevents opening of the mtPTP by 
binding to its matrix component, Cyp-D. Control samples were incubated at 37oC in 5% 
CO2 for 5 minutes. 
All samples are subsequently loaded with 10nM calein AM, which becomes trapped 
within cellular conpartments, including mitochondria, following de-esterification of its 
acetoxymethyl group [268]. The unbound form of the dye emits fluorescence at a peak 
emission of 517nm. All samples are subsequently treated with 400μM CoCl2 which 
serves to quench the fluorescent signal from calcein in both cytosolic and nuclear 
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compartments of the cell. Opening of the mtPTP allows entry of CoCl2 into the 
mitochondrial matrix resulting in a decrease in the mitochondrial fluorescence of 
calcein [268]. All samples were subsequently incubated in the dark at 37oC in 5% CO2 
for 15 minutes. Following incubation samples were washed in 2mL HBSS/ Ca2+ and 
resuspended in 500μL PBS prior to analysis by flow cytometry. 
5.3.7 – Analysis of Mitochondrial Superoxide Generation and Cellular Viability 
Following treatment, 1mL aliquots from each treatment condition were washed and 
resuspended in 1mL PBS. Negative control samples were incubated at 37oC in 5% CO2 
for 1 hour in the presence of the superoxide scavenger SOD-PEG at a concentration of 
200IU/mL. All samples were subsequently incubated at 37oC in 5% CO2 for 30 minutes 
in the presence of 5μM MitoSOX Red. Oxidation of the probe by O2− produces the 
fluorescent compound L-hydroxy-ethidium, which stains mitochondrial DNA and emits 
fluorescence at a peak emission of 567nm [261]. Positive control samples were 
incubated for a further 30 minutes in the presence of 100μM of the cytochrome c 
oxidoreductase inhibitor, antimycin A.  
Following incubation, all samples are washed and resuspended in 100μL of annexin V 
binding buffer. For the determination of cellular viability all samples were incubated in 
the dark at room temperature for 15 minutes with 5μL of annexin V-Cy5, which binds 
with high affinity to phosphatidylserine, a phospholipid externalized to the surface of 
the plasma membranes of the apoptotic cells and 1μM SYTOX Green, a DNA stain 
which acts as an indicator of necrosis as it is impermeable to intact plasma membranes 
[261]. Annexin V-Cy5 emits fluorescent light at a wavelength of 660nm while SYTOX 
Green emits fluorescent light at a peak emission of 523nm. All samples were 
resuspended in 400μL annexin V binding buffer prior to analysis by flow cytometry. 
5.3.8 – Analysis by Flow Cytometry 
All samples were analysed using a FACS Calibur flow cytometer (BD, Australia). For 
the analysis of Δψm, samples were excited at a wavelength of 488nm with fluorescent 
emissions detected in channels using bandpass filters of 515-545nm and 564-606nm. 
For the analysis of mtPTP activity, cells were excited with a wavelength of 488nm 
while fluorescent emissions were detected in a channel using a 515-545nm bandpass 
filter. For the analysis of mitochondrial superoxide production and the determination of 
cellular viability samples were excited by both 488nm and 633nm wavelengths with 
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emitted light being detected in channels using bandpass filters of 515-545nm, 564-
606nm and ≥670nm. For all samples analysed a total of 10,000 events were collected 
while lymphocyte and monocyte populations were gated and analysed separately. All 
data collected was analysed using Cellquest Pro software (BD, Australia). 
5.3.9 – Statistical Analysis 
All data is reported as mean ± SEM. A one-way analysis of variance (ANOVA) was 
used to determine whether significant differences existed within treatment groups for 
each of the analysed variables, while Dunnett’s T3 multiple comparisons were used for 
post hoc analysis between treatment conditions (SPSS Inc, PAWS Statistics Version 18, 
USA). Statistical significance was determined at an alpha level of 0.05. 
 
5.4 – Results 
5.4.1 – Mitochondrial Membrane Potential 
Ratios of the mean channel fluorescence between J-Complexes (Orange) and the 
monomeric form of JC-1 (Green) for all treatment conditions are presented in Figure 
5.1. Treatment with CCCP significantly reduced ratios compared to untreated samples 
in lymphocyte (mean difference ± SEM, 95% confidence intervals, p-values:                           
-3.45±0.26, -4.73 – -2.17, P≤0.05) and monocyte (-3.11±0.30, -4.57 – -1.66, P≤0.05) 
populations. The ratio was significantly increased following treatment with oligomycin 
compared to untreated samples in lymphocyte populations (0.75±0.30, -0.58 – 2.08, 
P≤0.05). However, no significant difference was observed following treatment with 
oligomycin in monocytes (-0.69±0.32, -2.15 – 0.78, P=0.91). In addition, no significant 
differences were found between untreated and rhGH or rIGF-1 treated samples at any 
concentration administered. 
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Figure 5.1: Mitochondrial Membrane Potential A) JC-1 Orange/Green ratio (mean ± 
SEM) from PBMCs for negative and positive controls compared to untreated samples. 
(* P<0.05 compared to CCCP, ** P<0.05 compared to untreated). B) JC-1 
Orange/Green ratio from PBMCs for GH treated samples compared to untreated 
samples. C) JC-1 Orange/Green ratio (mean ± SEM) from PBMCs for IGF-1 treated 
samples compared to untreated samples. 
Controls
Re
d 
/ G
re
en
 R
at
io
CC
CP
Un
tre
ate
d
Oli
go
my
cin
CC
CP
Un
tre
ate
d
Oli
go
my
cin
0
1
2
3
4
5
Lymphocytes
Monocytes
A)
*
*
*
*
**
Growth Hormone
Re
d 
/ G
re
en
 R
at
io
Un
tre
ate
d g/Lµ
0.2
5
g/Lµ
0.5
g/Lµ1
g/Lµ
2.5
g/Lµ5
g/Lµ
10
g/Lµ
25
g/Lµ
50
g/Lµ
10
0
0
1
2
3
4
5
Lymphocytes
Monocytes
B)
IGF-1
Re
d 
/ G
re
en
 R
at
io
Un
tre
ate
d g/Lµ
10
0
g/Lµ
20
0
g/Lµ
30
0
g/Lµ
40
0
g/Lµ
50
0
g/Lµ
60
0
0
1
2
3
4
5
Lymphocytes
Monocytes
C)
110 
 
5.4.2 – Mitochondrial Permeability Transition Pore Activity 
Mean channel fluorescence values, presented in arbitrary units (AU), from intra-
mitochondrial calcein for all treatment conditions are presented in Figure 5.2. Treatment 
with ionomycin resulted in a significant reduction in the mean channel fluorescence 
compared to untreated samples for both lymphocyte (mean difference ± SEM, 95% 
confidence intervals, p-values: -48.97±4.17AU, -60.98 – -36.96AU, P≤0.05) and 
monocyte (-270.78±22.90AU, -338.12 – -203.46AU, P≤0.05) populations. Values for 
mean channel fluorescence were significantly increased following treatment with 
cyclosporin A compared to untreated samples in both lymphocyte (20.03±7.50AU, 0.10 
– 39.96AU, P≤0.05) and monocyte (106.08±39.22AU, 0.94 – 211.22AU, P≤0.05) 
populations. Values for mean channel fluorescence were not significantly different 
between untreated and rhGH or rIGF-1 treated samples for any concentration 
administered. 
Figure 5.3 shows the percentage change in fluorescence values compared to negative 
control samples for all treatment conditions, which provides an indication of the 
percentage of mitochondria within a sample exhibiting activation of mtPTP. Untreated 
samples showed significant decreases in fluorescence values compared to negative 
controls for both lymphocyte (-18±2%, -25 – -11%, P≤0.05) and monocyte (-24±4%, -
34 – -13%, P≤0.05) populations. In addition, the percentage decrease in fluorescence 
values from negative controls was significantly higher following treatment with 
ionomycin compared to untreated samples in both lymphocytes (-96±1%, -98 – -94%, 
P≤0.05) and monocytes (-95±1%, -97 – -92%, P≤0.05). Finally, there was found to be 
no significant differences between untreated and rhGH or rIGF-1 samples at any 
treatment concentration in either cell population. 
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Figure 5.2: Mitochondrial Permeability Transition Pore Activity A) Calcein mean 
channel fluorescence (mean ± SEM) from PBMCs for negative and positive controls 
compared to untreated samples. (* P<0.05 compared to Ionomycin, ** P<0.05 
compared to untreated). B) Calcein mean channel fluorescence (mean ± SEM) from 
PBMCs for GH treated samples compared to untreated samples. C) Calcein mean 
channel fluorescence (mean ± SEM) from PBMCs for IGF-1 treated samples 
compared to untreated samples. 
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Figure 5.3: Mitochondrial Permeability Transition Pore Activity A) Percent of PBMCs  
(mean ± SEM) exhibiting active mtPTPs for negative and positive controls compared to 
untreated samples. (* P<0.05 compared to Cyclosporin A, ** P<0.05 compared to 
untreated). B) Percent of PBMCs (mean ± SEM) exhibiting active mtPTPs for GH 
treated samples compared to untreated samples. C) Percent of PBMCs (mean ± SEM) 
exhibiting active mtPTPs for IGF-1 treated samples compared to untreated samples. 
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5.4.3 – Mitochondrial Superoxide Generation 
MitoSOX Red mean channel fluorescence values (AU) are shown in Figure 5.4 for all 
treatment conditions. Fluorescence values were significantly increased following 
treatment with antimycin A compared to untreated samples in both lymphocyte (mean 
difference ± SEM, 95% confidence intervals, p-values: 48.80±4.88AU, 35.24 – 
62.37AU, P≤0.05) and monocyte (220.48±33.71AU, 126.72 – 314.24AU, P≤0.05) sub-
populations. Treatment with SOD-PEG resulted in no significant effect in mean channel 
fluorescence. 
Fluorescence values were significantly reduced compared to untreated samples at rhGH 
concentrations of 5µg/L (-7.95±2.07AU, -15.81 – -0.10AU, P≤0.05) and 10µg/L (-
9.14±2.20AU, -17.44 – -0.84AU, P≤0.05) in lymphocytes, in addition to at the 
concentration of 10µg/L (-76.76±16.29AU, -140.05 – -13.47AU, P≤0.05) in monocytes. 
No significant differences were observed following rhGH treatment at any other 
concentration in either cell population. Finally, rIGF-1 did not exert any significant 
effect on mean channel fluorescence compared to untreated samples in either 
lymphocyte or monocyte populations. 
5.4.4 – Cellular Viability 
The percentages of viable cells from analysed samples are presented in Figure 5.5 for all 
treatment conditions. Cell viability significantly decreased following treatment with 
antimycin A compared to untreated cells in both lymphocytes (mean difference ± SEM, 
95% confidence intervals, p-values: -6±1%, -9 – -2%, P≤0.05) and monocytes (-8±2%, -
13 – -4%, P≤0.05). In contrast, the percentage of cellular apoptosis, (Figure 5.6), was 
significantly increased by antimycin A treatment compared to untreated samples in both 
lymphocytes (4±1%, 1 – 7%, P≤0.05) and monocytes (8±2%, 3 – 12%, P≤0.05). In 
addition, the percentage of dead cells, (Figure 5.7), was also found to be significantly 
increased in lymphocytes treated with antimycin A compared to unstimulated cells 
(2±1%, 1 – 3%, P≤0.05). However, antimycin A was not found to significantly affect 
the percentage of dead cells in the monocyte sub-population. Following treatment with 
SOD-PEG no significant differences were found in percentages of viable, apoptotic or 
dead cells compared to untreated cells. Finally, there were found to be no significant 
differences between unstimulated and rhGH or rIGF-1 treated samples in the 
percentages of live, apoptotic and dead cells for any concentration administered.  
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Figure 5.4: Mitochondrial Superoxide Production A) MitoSOX Red mean channel 
fluorescence (mean ± SEM) from PBMCs for negative and positive controls compared 
to untreated samples. (* P<0.05 compared to SOD-PEG, ** P<0.05 compared to 
untreated). B) MitoSOX Red mean channel fluorescence (mean ± SEM) from PBMCs 
for GH treated samples compared to untreated samples. (* P<0.05 compared to 
untreated). C) MitoSOX Red mean channel fluorescence (mean ± SEM) from PBMCs 
for IGF-1 treated samples compared to untreated samples. 
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Figure 5.5: Cellular Viability A) Percentage of viable PBMCs (mean ± SEM) for 
negative and positive controls compared to untreated samples. (* P<0.05 compared to 
SOD-PEG, ** P<0.05 compared to untreated). B) Percentage of viable PBMCs (mean ± 
SEM) for GH treated samples compared to untreated samples. C) Percentage of viable 
PBMCs (mean ± SEM) for IGF-1 treated samples compared to untreated samples. 
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Figure 5.6: Cellular Viability A) Percentage of apoptotic PBMCs (mean ± SEM) for 
negative and positive controls compared to untreated samples. (* P<0.05 compared to 
SOD-PEG, ** P<0.05 compared to untreated). B) Percentage of apoptotic PBMCs 
(mean ± SEM) for GH treated samples compared to untreated samples. C) Percentage 
of apoptotic PBMCs (mean ± SEM) for IGF-1 treated samples compared to untreated 
samples. 
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Figure 5.7: Cellular Viability A) Percentage of dead PBMCs (mean ± SEM) for 
negative and positive controls compared to untreated samples. (* P<0.05 compared to 
SOD-PEG, ** P<0.05 compared to untreated). B) Percentage of dead PBMCs (mean ± 
SEM) for GH treated samples compared to untreated samples. C) Percentage of dead 
PBMCs (mean ± SEM) for IGF-1 treated samples compared to untreated samples. 
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5.5 – Discussion 
The principal finding of this study was that rhGH, when present at concentrations of 5 
and 10µg/L, significantly reduced the generation of O2− in the mitochondrial matrix of 
PBMCs’ (Figure 5.4). However rhGH, at concentrations of 25µg/L and above, and 
rIGF-1 at any treatment concentration exerted no significant effect on mitochondrial 
superoxide levels. In contrast, Csiszar et al. [200] found that mitochondrial superoxide 
levels were significantly decreased in cultured HCAECs following 24 hours incubation 
in the presence of IGF-1 (10-1000µg/L) and supra-physiological concentrations of 
rhGH (0.001 – 0.01 IU/mL – approximately 0.33 – 3.33μg/mL). These changes were 
largely attributed to the elicitation of significant concentration-dependent increases in 
the expression of the antioxidant enzymes Mn-SOD, Cu, Zn-SOD, and GPX-1 by GH 
and IGF-1 [200]. Sanz et al. [41] observed both a significant increase in oxidative 
damage to mitochondrial DNA and a decrease in the rate of mitochondrial H2O2 
generation in the liver cells of Wistar rats that were treated with rhGH for two weeks. 
Their results suggest that an initial pro-oxidative effect induced by the treatment is later 
countered by an increase in antioxidant protection [41]. Although the expression of 
antioxidant genes was not investigated in the present study, it is unlikely that GH or 
IGF-1 exerted any significant effect on the concentration of antioxidant enzymes 
following only 4 hours of incubation. 
In the only study published to date examining the effect of in-vitro GH administration 
on ROS production following only 4 hours of treatment, Thum et al. [201] observed 
significant decreases in intracellular ROS production in human endothelial cells which 
were attributed to an improved regulation of cellular metabolic and antioxidant status. 
In contrast to the findings from the present study, these effects were only seen at rhGH 
concentrations of 1,000µg/L, with concentrations of 10 and 100µg/L inducing no 
significant effect [201]. However, such discrepancies could be attributed to the use of 
dichlorodihydrofluorescin diacetate (H2DCFDA), a non-specific indicator of ROS 
production, in the study by Thum et al. [201], in order to determine changes in 
oxidative status at a cellular level. This may not have been sensitive enough to detect 
the comparatively small changes in mitochondrial located O2− which were found in the 
present study, at lower GH concentrations using a specific indicator of O2− which was 
directly targeted at mitochondria (MitoSOX Red). In addition, while effects observed 
using rhGH concentrations of 1,000µg/L may indicate that such high concentrations are 
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necessary in order to induce the antioxidant effects of the hormone within this time 
frame, doubt is raised as to whether this indicates a direct effect via mitochondrial 
regulation due to the failure of Thum et al. [201] to distinguish between mitochondrial 
and cytosolic free radical production. Indeed, it is known that endothelial cells can 
produce large amounts of O2− in their cytosol through activation of NADPH oxidase, a 
mechanism which has been demonstrated to be inhibited by IGF-1 over expression in-
vivo [289-291]. 
To date no studies have investigated the effects of GH or IGF-1 on the generation of 
ROS in human tissue in-vivo, while research conducted on animal models examining 
the impact of the GH/IGF-1 axis on levels of oxidative stress have produced conflicting 
results. In agreement with their findings on the in-vitro effects of rhGH and IGF-1 on 
cultured HCAECs, Csiszar et al. [200] observed elevated levels of mitochondrial 
superoxide together with a reduction in the expression of antioxidant enzymes in 
endothelial cells from the aortas of hypopituitary Ames dwarf mice, who exhibit low 
levels of circulating GH and IGF-1, compared to wild type control mice.  In contrast, 
Brown-Berg et al. [40] found a reduction in levels of H2O2 in mitochondria from the 
liver of Ames dwarf mice, in addition to a 47% decrease in levels of protein oxidation, 
compared to wild type mice. Csiszar et al. [200] suggest that such discrepancies may be 
attributed to differences between plasma and tissue concentrations of IGF-1. While they 
found that circulating levels of IGF-1 play a central role in regulating oxidative stress in 
the vasculature, they hypothesized that autocrine/paracrine pathways of IGF-1 
expression exhibit a greater control over antioxidant defence in other tissues [200]. This 
may account for the differences observed in the effects of rhGH and rIGF-1 on 
mitochondrial superoxide generation in the present study. It must be noted that in 
addition to GH and IGF-1, Ames dwarf mice also exhibit deficiencies in other pituitary 
derived hormones, including prolactin and thyroid stimulating hormone, which could 
have impacted on the results obtained in these studies [292]. In fibroblasts from Lewis 
dwarf rats, an animal model which exhibits a specific deficiency of GH secretion, 
Unguari et al. [292] observed similar rates of cellular O2− and H2O2 production 
compared with control rats, however subsequent treatment with GH was found to 
significantly increase antioxidant capacities in these animals. 
Although in the present study no significant changes were observed in the rate of 
mitochondrial superoxide production with supra-physiological concentrations of GH in-
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vitro, how such concentrations, when administered in-vivo, will affect oxidative status is 
currently unresolved. Seiva et al. [39] demonstrated that while administration of 1mg/kg 
per day of rhGH for 2 weeks in Wistar rats significantly lowered levels of lipid 
peroxidation in cardiac tissue, a doubling of the treatment concentration resulted in 
detrimental increases in oxidative damage. They concluded that any beneficial effect on 
cellular antioxidant capacity exerted by the hormone was overcome by greater pro-
oxidant effects at high doses [39]. GH is known to increase the rate of lipolysis leading 
to elevated plasma concentrations of FFA’s, while administration of rhGH in-vivo has 
been shown to induce insulin resistance [21, 23]. Such effects themselves are associated 
with increased levels of oxidative stress [45, 293]. A significant reduction in the 
expression of genes involved in oxidative phosphorylation was found by Sparks et al. 
[293] in subjects fed an isoenergetic, high-fat diet for 3 days, while the mitochondrial 
oxidative capacity of type 2 diabetic patients was reported by Hawley and Lessard [45] 
to be 40% lower than that of healthy volunteers. As a result, several authors [45, 113] 
have hypothesized that a subsequent excess supply of reducing equivalents to the 
respiratory chain cannot be dissipated by oxidative phosphorylation leading to an 
increase in the mitochondrial proton motive force and an augmentation in the 
production of ROS. In support of this, Sanz et al. [41] found that while two weeks of 
rhGH treatment in ad libitum fed Wistar rats increased oxidative damage to 
mitochondrial DNA in hepatocytes, the same treatment in caloric restricted animals 
induced no significant effect. However, the limitations in translating the results from 
animal models to human subjects must be noted here as animal studies do not always 
accurately predict human outcomes [294]. 
Although no significant differences were found in Δψm values following rhGH 
administration at any concentration (Figure 5.1), it is possible that the method of 
analysis utilized in the present study was not sensitive to transient changes in Δψm 
which may significantly impact rates of O2− generation. In support of this assumption, 
Jaburek et al. [49] notes that even a slight increase in proton backflow into the 
mitochondrial matrix may substantially suppress mitochondrial ROS formation. Thus, 
the possibility cannot be excluded that the decrease in mitochondrial superoxide levels 
seen with rhGH treatment at physiological concentrations results from an attenuation of 
the mitochondrial proton motive force and an increase in the efficiency of oxidative 
phosphorylation. 
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Kadenbach et al. [14] suggest that any extracellular signalling molecule which induces 
anabolic effects via intracellular signal transduction pathways must also modulate 
oxidative phosphorylation via the activation of signalling pathways directed at 
mitochondria. The maximum rate of activity of ATP synthase occurs at Δψm of 
approximately 120mV but this potential declines as the flow of protons back into the 
mitochondrial matrix through its F0 subunit increases [20]. Thus in order to allow for 
augmentation of the rate of ATP production, the resting Δψm must be increased. Recent 
work conducted by Kadenbach et al. [14] has led to the hypothesis that when specific 
amino acid residues on COX are de-phosphorylated, the ability of ATP to allosterically 
inhibit the enzyme is switched off resulting in an augmentation of the rate of activity of 
the respiratory enzymes and a subsequent increase in Δψm. COX, the terminal enzyme  
complex of the respiratory chain, is also the most exergonic of the respiratory chain 
enzymes (∆G°’ = -100kJ/mol) and is considered to be the principal regulatory site of 
oxidative phosphorylation [14]. Through polargraphic analysis of the activity of COX, 
Kadenbach and Bender [20] demonstrated that de-phosphorylation of the isolated 
enzyme with protein phosphatase 1 switched off allosteric ATP inhibition, while cAMP 
dependant activation of protein kinase A switched on the allosteric inhibition of activity 
at high intra-mitochondrial ATP concentrations. Incubation of isolated mitochondria 
from bovine liver with Ca2+ was also found to switch off the ATP inhibition of COX, 
suggesting that intra-mitochondrial Ca2+ concentrations play a key role in up-regulating 
the activity of respiratory enzymes in response to extracellular signals [20]. However 
this did not result from a direct interaction with the enzyme as inhibition of protein 
phosphatise activity was found to abolish any effect induced by Ca2+ on COX activity in 
isolated mitochondria [295].   
Billestrup et al. [170] demonstrated that GH induced increases in intracellular free Ca2+ 
concentrations in CHO cells via activation of voltage dependent L-type Ca2+ channels in 
the plasma membrane, although high doses of rhGH were needed before significant 
differences were observed, with a minimally effective dose of 50µg/L and a maximum 
response observed at 500µg/L. However, Perret-Vivancos et al. [187] found that CHO 
cells expressing GH receptors which lacked the 184 amino acids of their c-terminal, the 
domain known to be responsible for inducing the hormones effects on intracellular free 
Ca2+ oscillations, had the same stimulatory effect on mitochondrial oxygen consumption 
as cells expressing full length receptors. Their findings indicate that GH induces a direct 
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effect on mitochondrial function independent of signal transduction induced changes in 
cellular Ca2+ concentrations [187]. Indeed several studies have noted the targeting of 
GH and its receptor to mitochondria with both Ardail et al. [296] and Perret-Vivancos et 
al. [187] observing the presence of GH in the mitochondrial inter-membrane space and 
bound to the mitochondrial membranes using electron microscopy and confocal 
microscopy, respectively. Additionally Perret-Vivancos et al. [187] demonstrated that 
disruption of GH internalization via a caveolar-dependent pathway abolished any 
stimulatory effect induced by the hormone on rates of cellular oxygen consumption. 
Conversely, Ardail et al. [296] found a dose dependent decrease in the activity of the 
oxidative enzymes succinate dehydrogenase and COX when GH was targeted directly at 
isolated mitochondria, with the greatest level of inhibition observed at 100nM. The 
authors hypothesized that while internalization of the hormone is necessary for 
stimulation of oxidative phosphorylation due to a synergistic interaction with GHR 
mediated signal transduction pathways, at high concentrations hormone translocation to 
the mitochondria also acts as a negative regulatory mechanism, attenuating the rise in 
Δψm and the generation of ROS [296]. 
In relation to observations from the present study, it is possible that at physiological 
concentrations GH induced an up-regulation of the rate of ATP synthesis which was 
sufficient to counter any associated augmentation of the activity of oxidative enzymes, 
resulting in the observed decrease in mitochondrial superoxide levels. At supra-
physiological concentrations, where administration of the hormone no longer induced 
significant decreases in mitochondrial superoxide generation, it is possible that as the 
rate of ATP synthesis became rate-limiting the up-regulation of the rate of oxygen 
consumption elevated the Δψm, while inhibition of the activity of respiratory chain 
enzymes due to internalization of the hormone may have prevented any significant rise 
in superoxide levels in comparison to untreated samples. 
In addition to GH, IGF-1 has also been found to initiate signal transduction pathways 
targeting mitochondria. Bijur and Jope [12] observed, following stimulation with IGF-1 
in human neuroblastoma and embryonic kidney cells, the translocation of 
phorphorylated Akt to the mitochondria where it was found to phosphorylate the β 
subunit of ATP synthase. However, at the concentrations administered in the present 
study, IGF-1 was found to induce no significant effect on either Δψm or the rate of 
mitochondrial superoxide production. 
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Neither GH nor IGF-1, at any treatment concentration, was found to have a significant 
effect on mtPTP (Figure 5.2) or the percentage of cellular apoptosis (Figure 5.6), which 
is not surprising given that both hormones failed to induce an increase in the level of 
mitochondrial oxidative stress, even at supra-physiological concentrations. Indeed both 
hormones have been shown to act as “survival agents”, preventing the onset of 
apoptosis in specific cell types [17, 18, 212, 297]. Both Mitsunaka et al. [18] who 
initiated intracellular death signalling pathways via activation of plasma membrane 
bound Fas receptors in IM-9 lymphocytes and Han et al. [297] who induced hypoxic – 
ischemic injury in neonatal rat brain neurons attributed the ability of GH to prevent 
apoptosis to an inhibition of caspase-dependent cell death pathways. In addition, 
Mitsunaka et al. [18] found that GH treatment up-regulated the expression of the anti-
apoptotic protein Bcl-2, whose interaction with the VDAC on the OMM is hypothesized 
to opening of the mtPTP and the subsequent activation of intracellular caspases via the 
release of AIF and cyt c from the mitochondrial inter-membrane space. 
Studies from the laboratories of Yamamura et al. [17] and Kang et al. [212] have also 
found that pre-treatment with IGF-1 inhibits mitochondrial mediated apoptosis via the 
release of cyt c following the induction of ischemia-reperfusion injury in rat 
myocardium and the administration of high glucose concentrations (25mM) in human 
mesangial cells respectively. Both studies attributed the anti-apoptotic effects of IGF-1 
to signal transduction mediated regulation of the expression and activity of the Bcl-2 
family of proteins, a large number of which reside on the OMM. While the anti-
apoptotic regulators of the family, Bcl-xL and Bcl-2 – in their homo-dimeric form, act 
to prevent mtPTP mediated release of cytotoxic proteins, the pro-apoptotic promoter 
Bad, acts to neutralize this function by forming heterodimers with Bcl-xL and Bcl-2 
[212]. Yamamura et al. [17] found that a 1mg dose of IGF-1 administered in-vivo to 
male Sprague-Dawley rats resulted in an up-regulation in the expression of Bcl-xL 
while the expression of the pro-apoptotic effector protein, Bax was found to be 
attenuated in cardiomyocytes. Furthermore, Kang et al. [212] demonstrated that a 
decrease in the concentration of Bax, relative to that of Bcl-2, in addition to the 
inactivation of Bad via the phosphorylation of serine residues is dependent on the IGF-1 
mediated activation of both Akt and ERK  signalling pathways. 
However it must be pointed out that IGF-1 induced changes in the expression of Bcl-2 
proteins are not immediate with Wang et al. [298] noting that a minimum of 3 hours 
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incubation was necessary before any changes are observed in rat cardiomyocytes. 
Despite this Lai et al. [299] observed that doxorubicin induced mitochondrial 
membrane depolarization in rat cardiomyocytes was reversed following only one hour 
incubation in IGF-1. These findings indicate that IGF-1 is capable of directly 
modulating Δψm, favouring an increase in the efficiency of electron transport, although 
the mechanisms underlying this modulation currently remain unresolved. 
In summary, it was found that rhGH concentrations of 5 and 10 µg/L significantly 
reduced the generation of mitochondrial-derived ROS while higher doses of the 
hormone or the administration of IGF-1 at any concentration failed to induce a 
significant effect. These concentrations fall within the range observed following the 
stimulation of peak endogenous GH responses (5.3 – 42.5 µg/L), indicating that GH 
elicits beneficial responses in mitochondrial function at physiological concentrations 
[213]. That this protection was not found to be present at higher concentrations could 
have negative implications for the cell under these conditions in-vivo, as any additional 
source of free radical production is likely to induce oxidative damage. Hormonally 
induced changes to Δψm and the rate of ATP synthesis likely play a role in mediating 
the effects of rhGH on levels of oxidative stress and their subsequent ability to inhibit 
cellular apoptosis, although no significant effect was observed for either hormone on 
Δψm in PBMCs. While evidence exists that both GH and IGF-1 signalling pathways are 
directed towards mitochondria, the mechanisms underlying their effects on 
mitochondrial function require further investigation. 
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 6. Study Two:  The Effect of in-vitro administration of Recombinant Human Growth Hormone and Insulin-like Growth Factor-1 on Mitochondrial Vitality and Highly Reactive Oxygen Species Production under differing Respiratory Conditions in Peripheral Blood Mononuclear Cells. 
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6.1 – Abstract 
Growth hormone (GH), but not insulin-like growth factor-1 IGF-1, has been 
demonstrated to decrease the rate of mitochondrial-derived reactive oxygen species 
production (mtROS) in-vitro. However at supra-physiological concentrations in-vivo 
these hormones are associated with the induction of high levels of oxidative stress. The 
purpose of this study was to investigate the mitochondrial effects exerted by 
physiological and supra-physiological concentrations of rhGH and rIGF-1 under various 
respiratory conditions of substrate saturation in PBMCs from healthy male subjects. 
PBMCs were treated with either rhGH at concentrations of 0.5, 5 and 50µg/L or IGF-1 
at concentrations of 100, 300 and 500µg/L for 4 hours for the purposes of establishing 
the hormonal effects on mitochondrial function under various respiratory conditions at 
saturating substrate concentrations. Mitochondrial membrane potential (Δψm) and the 
level of mitochondrial hROS production were analysed by flow cytometry in digitonin 
permeabilized cells, in the presence of the following respiratory substrates 1) pyruvate / 
malate 2) succinate / rotenone 3) pyruvate / malate / succinate and 4) octanoate / malate. 
Neither rhGH nor rIGF-1 exerted any significant effect on Δψm as indicated by DilC1(5) 
mean channel fluorescence values in either lymphocyte (P=0.97) or monocyte (P=0.78) 
sub-populations at any concentration administered. Similarly, neither rhGH nor rIGF-1 
exerted any significant effect on hROS levels as indicated by HPF mean channel 
fluorescence values in either lymphocyte (P=0.90) or monocyte (P=0.85) sub-
populations at any concentration administered. That neither hormone was capable of 
attenuating levels of oxidative stress mediated via either complex I linked respiration or 
lipid-derived respiration could have serious health implications for rhGH administration 
in healthy subjects which is frequently associated with significant increases in the 
availability of FFA’s as oxidisable substrates.  
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6.2 – Introduction 
In light of the risk of cellular oxidative damage associated with mitochondrial O2− 
production [300, 301], attempts at identifying the sites of electron leak from the ETC 
responsible for free radical generation have received much attention in the literature 
[302-304]. While it has been widely reported that O2− is produced by the NADH 
dehydrogenase (Complex I) and CoQ: Cytochrome c-oxidoreductase (Complex III), 
controversy exists over both the specific electron transferring components within these 
complexes that leak electrons and the site at which the highest rates of O2− are generated 
[125, 302]. While some studies, conducted using specific respiratory substrates and 
complex inhibitors have reported complex III to be the principal source of O2− and H2O2 
production [304-306], others have identified complex I to be the main contributor [303, 
307, 308]. Indeed, the relative rates of free radical production attributed to the different 
complexes may be tissue-specific with Barja [309] observing the generation of ROS 
from complex I of both heart and brain mitochondria while complex III was only found 
to be capable of generating ROS from mitochondria isolated from the heart.  
The binding of ubiquinol (QH2) to the Qo site of complex III is believed to be the 
principal O2− generating source of that complex with disruption of electron flow giving 
rise to increased steady-state concentrations of the semiquinone (.Q-) radical at that site 
[300, 301, 304]. Structurally, the Qo site of complex III is orientated towards the inter-
membrane space and O2− produced at this site has been found to be predominantly 
released into the cytosol, although evidence exists that some O2− produced here may 
also be released into the mitochondrial matrix [125, 301, 310]. Inhibition of complex I 
near its ubiquinone binding site by rotenone has been shown in many studies, to 
increase electron leak to ROS in the presence of complex I respiratory substrates, 
identifying this complex as a major source of O2− production [303, 307, 308]. Complex 
I contains several redox centres, including 8 or 9 iron-sulfur clusters and flavin 
mononucleatide (FMN), in addition to the ubiquinone binding site itself, which are all 
located proximal to the point of inhibition by rotenone [304, 307]. While each of these 
components have been examined as a potential O2− producing centre, at present the 
identification of specific sites of electron leak from complex I remains unresolved. 
Despite this it is known that the production of O2− by complex I is released on the 
matrix side of the IMM [300, 301, 310].  
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In addition to complexes I and III of the ETC, ETF and electron transfer flavoprotein 
quinine oxidoreductase (ETF-QO) are two enzymes involved in the transfer of electrons 
from reduced carriers formed during β-oxidation in the mitochondrial matrix to the 
ubiquinone pool on the IMM, which may produce O2− [125, 300]. St-Pierre et al. [125] 
found significant increases in the rate of H2O2 production in the mitochondrial matrix 
from rat skeletal muscle and heart mitochondria in the presence of palmitoyl carnitine 
with no added respiratory inhibitors. The authors identified ETF and ETF-QO as 
potential sources of O2− generation as they are known to exist in partially reduced states 
during lipid metabolism. 
A decline in the systemic release of GH and its subsequent stimulation of IGF-1 is a 
well-known effect of aging in both humans and experimental animals [200, 311]. 
Indeed, it has been demonstrated that circulating concentrations of these hormones plays 
an important role in modifying intracellular levels of oxidative stress [200, 205, 292, 
312]. Evans et al. [312] observed elevated levels of lipid peroxides in blood samples 
from GHD patients compared to healthy controls which decreased significantly 
following administration of a low dose GH therapy of 0.03IU/kg/day for 3 months. 
Csiszar et al. [200] found that, in-vitro, incubation of HCAECs for 24 hours in the 
presence of IGF-1 (10 – 1000µg/L) and GH (0.001 – 0.01 IU/mL) significantly reduced 
the mitochondrial production of O2− as well as O2− and H2O2 at a cellular level. The 
authors also found significant increases in the expression of the antioxidant enzymes 
Mn-SOD, Cu, Zn-SOD and GPX-1, which likely account for the observed hormonal 
effect on ROS production. In addition, several authors have also noted that GH is 
capable of translocating to the mitochondria [187, 296]. Ardail et al. [296] observed that 
the activity of the ETC enzymes succinate dehydrogenase (Complex II) and COX 
(Complex IV) were decreased in isolated mitochondria in the presence of high 
concentrations of GH (100nM) indicating that the hormone can attenuate mitochondrial 
O2− generation via direct modulation of the Δψm. 
However, despite the documented antioxidant effects of these hormones in recent 
studies, at supra-physiological concentrations in-vivo, GH is associated with adverse 
effects which hold negative implications for normal physiological function [21, 23]. 
Patients with acromegaly, a pathological disorder associated with a hyper-secretion of 
GH from a pituitary adenoma, suffer from neurological, cardiovascular, respiratory and 
metabolic complications which lead to increased mortality if GH and IGF-1 
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concentrations are not reduced to normal levels [22]. In addition, the prevalence of 
diabetes in acromegalic patients is reported to range between 20 to 46%, while the 
inducement of supra-physiological GH concentrations in healthy subjects has been 
shown in many studies to lead to the development of insulin resistance [21-23]. 
Increased levels of oxidative stress has been demonstrated to induce insulin resistance 
directly while it is also widely cited as a causative factor in the development of diabetes 
[23, 124], suggesting that any observed oxidative defence afforded by either GH or 
IGF-1 in some studies is negated at supra-physiological concentrations in-vivo. Studies 
on animals lend support to this hypothesis, with Seiva et al. [39] observing significant 
increases in oxidative stress, as demonstrated from levels of lipid peroxidation, 
following two weeks of high dose GH treatment (2mg/kg/day) in male Wistar rats. In 
contrast, the same authors observed reduced levels of oxidative stress and significant 
enhancements in the expression of antioxidant enzymes following administration of the 
same treatment at a lower dosage (1mg/kg/day). In addition, transgenic mice 
manipulated to over-express GH have been found to have increased levels of oxidative 
damage to liver proteins and a suppressed antioxidant capacity compared to wild type 
mice [40].  
While current studies examining the effect of GH and IGF-1 on cellular oxidative status 
have analysed levels of O2− and H2O2 production [200, 205, 292], to date no study has 
looked at how these hormones affect levels of highly reactive oxygen intermediates 
such as .OH and ONOO- which are produced when electron leak evades cellular 
antioxidant defences and are directly responsible for oxidative damage to cellular 
components. In addition, it is not known how physiological concentrations of these 
hormones influence the rate of free radical production from the principal sites of 
electron leak along the ETC or whether these rates differ at supra-physiological 
concentrations. In light of this, the present study aimed to 1) examine mitochondrial 
levels of hROS and 2) identify the principal complexes involved in ROS production 
from the ETC in PBMCs following incubation in the presence of either rhGH or IGF-1 
at both physiological and supra-physiological concentrations. This was achieved 
through flow cytometric analysis of hROS (.OH and ONOO-) levels and Δψm in 
digitonin permeabilized cells following treatment with saturating concentrations of 
various respiratory substrate combinations and the use of specific ETC complex 
inhibitors which allowed for control over the sites of electron entry into the ETC at 
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complexes I and II, in addition to the entry of electrons from reduced carriers involved 
in β oxidation at the level of ubiqunol.  
6.3 – Methods 
6.3.1 – Subjects 
Ten healthy male subjects (mean ± SD: age =23±4yrs, height = 1.78±.06m, body mass 
= 77.1±6.2kg, BMI = 24.39±2.25kg/m2) were recruited to participate in the study which 
was ethically approved by the Bond University Human Research Ethics Committee. All 
subjects had the nature of the study and the associated risks involved explained to them 
prior to providing written informed consent. Exclusion criteria included smoking, the 
use of therapeutic, recreational or performance enhancing drugs, including anabolic 
steroids and rhGH up to twelve months prior to participation in the study, the presence 
of diabetes, cardiovascular disease or the use of prescription medication. 
6.3.2 – Reagents Used 
HBSS, RPMI Medium 1640, CCCP, DilC1(5), HPF, and sodium pyruvate were 
purchased from Invitrogen (Carlsbad, CA, USA). L-malic acid (malate – pH adjusted to 
7.4), sodium succinate, sodium octanoate, ammonium iron (II) sulphate , H2O2, 
rotenone, digitonin, sucrose, potassium phosphate monobasic (KH2PO4), magnesium 
chloride (MgCl2), potassium morpholinopropane sulphonate (MOPS), ADP, 
ethylenediaminetetraactic acid (EDTA) and bovine serum albumin (BSA) were 
purchased from Sigma Aldrich (St Louis, MO, USA). Phosphate buffered saline was 
purchased from Kinetic (Burpengary, QLD, Australia). Ficoll-paque PLUS was 
obtained from GE Healthcare (Rydalmere, NSW, Australia). Recombinant insulin-like 
growth factor-1 was purchased from Biocore (Sydney, NSW, Australia). Finally, rhGH 
was purchased from Pfizer (Sydney, NSW, Australia). 
6.3.3 – Blood Sample Collection and PBMC Isolation 
Subjects arrived for sample collection in a post prandial state, in the morning following 
an overnight fast having not taken part in any form of physical activity in the prior 24 
hours. Following insertion of a catheter into the antecubital vein, 24mL of blood was 
drawn into 6mL lithium heparinised vacutainers (BD, CA, USA). Collected blood was 
diluted in an equal volume PBS and subsequently layered over Ficoll-paque PLUS at a 
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ratio of 2:1. All samples were centrifuged at 450*g for 30 mins for the separation of 
PBMCs from whole blood. Isolated cells were washed in HBSS and their concentration 
was determined using a Countess automated cell counter (Invitrogen, Carlsbad, CA, 
USA). Finally, cells were resuspended in RPMI 1640 cell culture medium at a 
concentration of 1*106-cells/mL. 
6.3.4 – rhGH and rIGF-1 Treatment 
Once isolated, cells were divided into aliquots which remained untreated or 
administered with rhGH at concentrations of 0.5, 5 and 50µg/L or rIGF-1 at 
concentrations of 100, 300 and 500µg/L. All samples were subsequently incubated for 4 
hours at 37oC in the presence of 5%CO2. 
6.3.5 – Treatment with Respiratory Substrates and Inhibitors 
Following hormonal treatment, cells had their plasma membranes permeabilized for the 
analysis of Δψm and hROS generation under differing respiratory conditions in a 
method adapted from the work of Pham et al. [219]. Briefly, sample aliquots were 
treated with digitonin at a concentration of 5μg/mL for 5 mins, washed in PBS and 
resuspended in a respiratory buffer (0.25M sucrose, 2mM KH2PO4, 5mM MgCl2, 1mM 
ETA, 0.1% BSA, 1mM ADP and 20mM MOPS – pH adjusted to 7.4). Samples were 
subsequently treated with either pyruvate (5mM) and malate (5mM) for the initiation of 
complex I mediated respiration (Pyr/Mal), succinate (10mM) and the complex I 
inhibitor, rotenone (20μM) to initiate respiration at complex II (Suc/Rot), pyruvate 
(2.5mM), malate (2.5mM) and succinate (5mM) to mediate the reduction of electron 
carriers at complexes I and II (Pyr/Mal/Suc) or octanoate (10mM) and malate (2mM) to 
mediate the transfer of electrons to reducing equivalents via β oxidation (Oct/Mal).   
6.3.6 – Analysis of Mitochondrial Membrane Potential 
Mitochondrial ∆Ψ was analysed by flow cytometry using the lipophilic cationic dye, 
DilC1(5). The dye accumulations in the mitochondria as a function of membrane 
potential at concentrations below 100nM and fluoresces at an emission maximum of 
658nm when excited at 633nm [313]. Control samples were incubated at 37oC in 5% 
CO2 for 5 minutes in the presence of 50μM of the mitochondrial uncoupler, CCCP in 
order to dissipate Δψm. Aliquots from each treatment condition (1mL) were 
subsequently incubated at 37oC in 5% CO2 for 15 minutes in the presence of DilC1(5) at 
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a concentration of 10nM. Following incubation, all samples were washed and 
resuspended in 500μL PBS, prior to immediate analysis by flow cytometry. 
6.3.7 – Analysis of Highly Reactive Oxygen Species Generation 
The generation of hROS was analysed by flow cytometry using the fluorescein 
derivative, HPF. HPF is a highly selective ROS indicator, only emitting a fluorescent 
signal upon reacting with either .OH or ONOO- [274]. The probe fluoresces at an 
emission maximum of 515nm when excited at 488nm. Control samples are incubated at 
37oC in 5% CO2 for 5 minutes in the presence of 100μM ammonium iron (II) sulphate 
and 1mM H2O2 to induce .OH generation via the Fenton reaction. 1mL aliquots from 
each treatment condition were subsequently incubated at 37oC in 5% CO2 for 15 
minutes in the presence of HPF at a concentration of 10μM. Following incubation, all 
samples were washed and resuspended in 500μL PBS, prior to immediate analysis by 
flow cytometry. 
6.3.8 – Analysis by Flow Cytometry 
All samples were analysed using a FACS Calibur flow cytometer (BD, Australia). For 
the analysis of Δψm, samples were excited at a wavelength of 633nm with fluorescent 
emissions detected in channels using a bandpass filter with a range of ≥670nm. For the 
analysis of hROS production samples were excited at a wavelength of 488nm with 
fluorescent emissions detected in channels using a bandpass filter with a range of 515-
545nm. For all samples analysed, a total of 10,000 events were collected while 
lymphocyte and monocyte populations were gated and analysed separately. All data 
collected was analysed using Cellquest Pro software (BD, Australia). 
6.3.9 – Statistical Analysis 
All data is reported as mean ± SEM. A factorial multivariate analysis of variance 
(MANOVA) was used to determine whether significant interactions existed between 
respiratory conditions and hormonal treatments for each of the analysed variables, while 
Bonferroni’s multiple comparisons were used for post hoc analysis between individual 
treatment conditions (SPSS Inc, PAWS Statistics Version 18, USA). Statistical 
significance was determined at an alpha level of 0.05. 
 
133 
 
6.4 – Results 
6.4.1 – Mitochondrial Membrane Potential 
Treatment with CCCP significantly reduced DilC1(5) mean channel fluorescence (AU) 
from samples in the presence of Pyr/Mal (mean difference ± SEM, 95% confidence 
intervals, p-values: -129.69±8.65AU, -149.22 – -110.17AU,  P≤0.05), Succ/Rot (-
181.89±19.03AU, -224.66 – -139.12AU, P≤0.05), Pyr/Mal/Succ (-130.45±20.17AU, -
175.95 – -84.95AU, P≤0.05) and Oct/Mal (-162.84±18.75AU, -205.17 – -120.50AU, 
P≤0.05) compared to untreated samples under the same respiratory conditions  in the 
lymphocyte sub-population (Figure 6.1 A). Fluorescence values from Succ/Rot treated 
samples were significantly increased compared to all other respiratory conditions 
analysed (P≤0.05), while Oct/Mal treated samples were significantly increased 
compared to Pyr/Mal (65.21±9.00AU, 41.27 – 89.14AU, P≤0.05) and Pyr/Mal/Succ 
(66.99±9.00AU, 43.05 – 90.93AU, P≤0.05) treated samples. In addition, no significant 
difference was observed between Pyr/Mal and Pyr/Mal/Succ treated samples (P=1.00).  
In the monocyte sub-population treatment with CCCP also significantly reduced 
DilC1(5) mean channel fluorescence from samples in the presence of Pyr/Mal (-
854.44±67.44AU, -1006.96 – -701.92AU, P≤0.05), Succ/Rot (-924.91±55.88AU, -
1055.58 – -794.24AU, P≤0.05), Pyr/Mal/Succ (-956.69±49.41AU, -1068.34 – -
845.04AU, P≤0.05) and Oct/Mal (-930.30±60.47AU, -1066.97 – -793.63AU, P≤0.05) 
compared to untreated samples under the same respiratory conditions (Figure 6.1 B). 
Fluorescence values from Succ/Rot treated samples were significantly increased 
compared to Pyr/Mal (146.40±28.54AU, 70.50 – 222.30AU, P≤0.05) and Pyr/Mal/Succ 
(122.73±28.54AU, 46.83 – 198.62AU, P≤0.05) treated samples but was not 
significantly different compared to Oct/Mal treated samples (P=0.73). Oct/Mal treated 
samples displayed significant increases in fluorescence compared to Pyr/Mal 
(102.03±28.54AU, 26.13 – 177.93AU, P≤0.05) and Pyr/Mal/Succ (78.36±28.54AU, 
2.46 – 154.26AU, P≤0.05) treated samples. In addition, no significant difference was 
observed between Pyr/Mal and Pyr/Mal/Succ treated samples (P=1.00).  
 
 
 
134 
 
Neither GH (Figure 6.2) nor IGF-1 (Figure 6.3) exerted any significant effect on Δψm as 
indicated by DilC1(5) mean channel fluorescence values in either lymphocyte (P=0.97) 
or monocyte (P=0.75) sub-populations at any concentration administered. Finally no 
significant interaction effect between hormonal treatment and respiratory substrate 
condition was observed in either lymphocyte (P=0.99) or monocyte (P=0.99) sub-
populations. 
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Figure 6.1: Mitochondrial Membrane Potential A) DilC1(5) Mean Channel 
Fluorescence (mean ± SEM) from lymphocytes for negative control samples treated 
with CCCP compared to untreated samples under different substrate conditions.(# 
P<0.05 compared to untreated, * P<0.05 compared to Succ/Rot, ** P<0.05 compared to 
Oct/Mal, *** P<0.05 compared to Pyr/Mal, **** P<0.05 compared to Pyr/Mal/Succ). 
B) DilC1(5) Mean Channel Fluorescence (mean ± SEM) from monocytes for negative 
control samples treated with CCCP compared to untreated samples under different 
substrate conditions. (# P<0.05 compared to untreated, * P<0.05 compared to Succ/Rot, 
** P<0.05 compared to Oct/Mal, *** P<0.05 compared to Pyr/Mal, **** P<0.05 
compared to Pyr/Mal/Succ). 
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Figure 6.2: Mitochondrial Membrane Potential A) DilC1(5) Mean Channel 
Fluorescence (mean ± SEM) from lymphocytes for growth hormone treated samples 
compared to untreated samples under different substrate conditions. B) DilC1(5) Mean 
Channel Fluorescence (mean ± SEM) from monocytes for growth hormone treated 
samples compared to untreated samples under different substrate conditions. 
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Figure 6.3: Mitochondrial Membrane Potential A) DilC1(5) Mean Channel 
Fluorescence (mean ± SEM) from lymphocytes for IGF-1 treated samples compared to 
untreated samples under different substrate conditions. B) DilC1(5) Mean Channel 
Fluorescence (mean ± SEM) from monocytes for IGF-1 treated samples compared to 
untreated samples under different substrate conditions. 
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6.4.2 – Highly Reactive Oxygen Species Production 
Treatment with H2O2 and ammonium iron (II) sulphate significantly increased HPF 
mean channel fluorescence (AU) from samples in the presence of Pyr/Mal (mean 
difference ± SEM, 95% confidence intervals, p-values: 102.40±21.15AU, 55.25 – 
149.54AU, P≤0.05), Succ/Rot (27.29±2.17AU, 22.47 – 32.11AU, P≤0.05), 
Pyr/Mal/Succ (106.36±11.51AU, 80.68 – 132.04AU, P≤0.05) and Oct/Mal 
(45.85±5.51AU, 33.42 – 58.29AU, P≤0.05) compared to untreated samples under the 
same respiratory conditions in the lymphocyte sub-population (Figure 6.4 A). 
Fluorescence values from Pyr/Mal treated samples were significantly increased 
compared to all other respiratory conditions analysed (P≤0.05), while Pyr/Mal/Succ 
treated samples were significantly increased compared to Succ/Rot (35.68±1.03AU, 
32.93 – 38.42AU, P≤0.05) and Oct/Mal (25.29±1.03AU, 22.54 – 28.03AU, P≤0.05) 
treated samples. In addition, fluorescence values from Oct/Mal treated samples were 
significantly increased compared to Succ/Rot samples (10.39±1.03AU, 7.64 – 13.14AU, 
P≤0.05). 
In the monocyte sub-population treatment with H2O2 and ammonium iron (II) sulphate 
also significantly increased HPF mean channel fluorescence (AU) from samples in the 
presence of Pyr/Mal (1578.36±237.45AU, 1042.18 – 2114.55AU, P≤0.05), Succ/Rot 
(2308.22±245.80AU, 1752.24 – 2864.21AU, P≤0.05), Pyr/Mal/Succ 
(2306.77±279.60AU, 1675.39 – 2938.15AU, P≤0.05) and Oct/Mal (2458±137.21AU, 
2148.31 – 2768.98AU, P≤0.05) compared to untreated samples under the same 
respiratory conditions (Figure 6.4 B). Fluorescence values from Pyr/Mal treated 
samples were significantly increased compared to all other respiratory conditions 
analysed (P≤0.05), while Pyr/Mal/Succ treated samples were significantly increased 
compared to Succ/Rot (243.25±6.33AU, 226.43 – 260.08AU, P≤0.05) and Oct/Mal 
(207.29±6.33AU, 190.47 – 224.11AU, P≤0.05) treated samples. In addition, 
fluorescence values from Oct/Mal treated samples were significantly increased 
compared to Succ/Rot samples (35.97±6.33AU, 19.15 – 52.79AU, P≤0.05). 
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Neither GH (Figure 6.5) nor IGF-1 (Figure 6.6) exerted any significant effect on hROS 
levels as indicated by HPF mean channel fluorescence values in either lymphocyte 
(P=0.90) or monocyte (P=0.85) sub-populations at any concentration administered. 
Finally no significant interaction effect between hormonal treatment and respiratory 
substrate condition was observed in either lymphocyte (P=0.99) or monocyte (P=0.39) 
sub-populations. 
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Figure 6.4: Highly Reactive Oxygen Species Production A) HPF Mean Channel 
Fluorescence (mean ± SEM) from lymphocytes for positive control samples treated with 
H2O2 and ammonium iron (II) sulphate compared to untreated samples under different 
substrate conditions. (# P<0.05 compared to untreated, * P<0.05 compared to Pyr/Mal, 
** P<0.05 compared to Pyr/Mal/Succ, *** P<0.05 compared to Oct/Mal, **** P<0.05 
compared to Succ/Rot). B) HPF Mean Channel Fluorescence (mean ± SEM) from 
monocytes for positive control samples treated with H2O2 and ammonium iron (II) 
sulphate compared to untreated samples under different substrate conditions. (# P<0.05 
compared to untreated, * P<0.05 compared to Pyr/Mal, ** P<0.05 compared to 
Pyr/Mal/Succ, *** P<0.05 compared to Oct/Mal, **** P<0.05 compared to Succ/Rot). 
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Figure 6.5: Highly Reactive Oxygen Species Production A) HPF Mean Channel 
Fluorescence (mean ± SEM) from lymphocytes for growth hormone treated samples 
compared to untreated samples under different substrate conditions. B) HPF Mean 
Channel Fluorescence (mean ± SEM) from monocytes for growth hormone treated 
samples compared to untreated samples under different substrate conditions. 
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Figure 6.6: Highly Reactive Oxygen Species Production A) HPF Mean Channel 
Fluorescence (mean ± SEM) from lymphocytes for IGF-1 treated samples compared to 
untreated samples under different substrate conditions. B) HPF Mean Channel 
Fluorescence (mean ± SEM) from monocytes for IGF-1 treated samples compared to 
untreated samples under different substrate conditions. 
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6.5 – Discussion 
In agreement with studies which have evaluated the rate of ROS production in isolated 
mitochondria, the level of mitochondrial hROS production was found to be significantly 
increased under conditions supporting NADH-linked respiration in comparison to all 
other respiratory conditions analysed, indicating that electron leak at the site of complex 
I is an important contributor to the level of ROS production within the mitochondrial 
matrix [309, 314, 315]. In addition, Δψm was observed to be significantly decreased 
under conditions of complex I linked respiration. While elevated Δψm is known to be 
associated with increased rates of mitochondrial ROS production, at sufficiently high 
concentrations mitochondrial derived ROS have been demonstrated to cause the 
dissipation of Δψm prior to the initiation of cellular apoptosis in several studies [219, 
316, 317]. Hence, it is likely the saturating concentrations of NADH-linked substrates 
utilized in the present study induced levels of oxidative stress that were detrimental to 
cellular viability. 
 
In contrast, under conditions of complex II linked respiration, hROS levels were 
significantly decreased in comparison to other respiratory conditions, indicating that 
complexes II – IV of the ETC, and in particular complex III, do not significantly 
contribute to electron leak on the matrix side of the IMM. Whether cytosolic levels of 
hROS were affected by electron leak initiated at complex III could not be determined in 
the present study due to the probable diffusion of such molecules out of the cell 
following surface membrane permeabilization. Finally, mitochondrial hROS production 
was significantly increased in the presence of the eight carbon saturated FFA octanoate 
in comparison to complex II linked respiration, indicating that reducing equivalents 
derived from β-oxidation play a role in the generation of mtROS. It must be noted that 
the β-oxidation generates equal amount of NADH, which passes electrons to complex I, 
and FADH2 whose electrons are transferred to ubiquinones in the inter-membrane space 
via ETF and ETF – QOR [125]. Thus, the principal site of electron leak under 
conditions of fatty acid oxidation remains to be determined. 
 
The principal finding of this study was that neither GH nor IGF-1 exerted any 
significant effect on the rate of production of the highly reactive free radicals .OH and 
ONOO-, under the respiratory conditions analysed, at any administered concentration. 
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While this is the first study to look at the effects of GH/IGF-1 on the production of these 
molecules, other studies have found that these hormones exhibit significant effects in-
vitro on the generation of the reactive intermediates, O2− and H2O2, whose creation 
precedes that of hROS [200, 201, 318]. Csiszar et al. [200] found that both 
mitochondria specific and cellular levels of O2− were significantly reduced in HCAECs 
following treatment at both physiological and supra-physiological concentrations of GH 
(0.33 - 33μg/mL) and IGF-1 (10 – 1,000µg/L). Thum et al. [201] also demonstrated 
significant decreases in intracellular ROS levels, determined using the non-specific 
ROS probe H2DCFDA, in cultured human endothelial cells 24 hours post treatment with 
GH at concentrations of 100 and 1,000µg/L. In contrast, Gustafsson et al. [318] found 
that no significant change in intracellular ROS levels was induced by the presence of 
10nM (76.5µg/L) IGF-1 in cultured human neuroblastoma cells under standard substrate 
conditions found in N2 culture medium. However IGF-1 was effective in preventing the 
rise of hyperglycaemic-induced ROS production in these cells at glucose concentrations 
in the range of 30 – 60mM. While Csiszar et al. [200] related the antioxidant effects of 
GH/IGF-1 directly to the up-regulated expression of the antioxidant enzymes Mn-SOD, 
Cu, Zn-SOD and GPX-1, Gustafsson et al. [318] found significant increases in 
uncoupling protein 3 (UCP3) expression following IGF-1 treatment and attributed the 
hormone’s antioxidant effects directly to a decrease in the rate of electron loss from the 
respiratory chain as a result of an uncoupling of oxidative phosphorylation under 
saturating substrate conditions. 
 
It is possible that significant reductions in mitochondrial O2− and H2O2 were induced by 
rhGH and IGF-1 under certain respiratory conditions in the present study and that the 
differences in the levels of these intermediates between untreated and hormone treated 
cells did not manifest as significant changes in HPF fluorescence due to the antioxidant 
capacity of untreated cells to prevent a rise in .OH and ONOO- production. However, 
significant elevations in HPF fluorescence were observed under conditions of electron 
flow through complex I, precluding the possibility of reduced levels of O2− and H2O2 as 
a result of rhGH or IGF-1 administration under these respiratory conditions. In addition, 
the antioxidant effects of GH and IGF-1 recorded in most previous in-vitro studies were 
observed following treatment times in the range of 24 – 72 hours [200, 201, 318], while 
samples were only incubated in the presence of rhGH and IGF-1 for four hours in the 
present study. Thus, it is possible that the expression of the reported antioxidant effects 
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of these hormones is time dependant and that four hours is insufficient for the 
manifestation of significant effects. 
 
Despite this, in Study One of the present thesis it was found that rhGH treatment in 
human lymphocytes in-vitro at physiological concentrations of 5 and 10µg/L 
significantly decreased levels of mitochondrial derived O2− following only four hours of 
incubation, while treatment at higher concentrations up to 100µg/L exhibited no 
significant effect. It has been hypothesized by Kadenbach et al. [14] that cellular 
activity stimulated by any hormone, cytokine or neurotransmitter must be associated 
with a parallel modulation of the rate of electron transfer along ETC complexes in order 
to compensate for the loss of Δψm due to increased ATP synthase (Complex V) activity 
as a result of the elevated energy requirements imposed on the cell by the signalling 
molecule. Relating this hypothesis to results from the Study One suggest that GH was 
exerting its effects on the rate of mitochondrial ROS generation via direct regulation of 
the organelle at the level of electron transfer within the ETC. Furthermore, while an 
efficient coupling of oxidative phosphorylation at rhGH concentrations of 5 and 10µg/L 
may explain the significant reductions in mitochondrial O2− observed in that study at 
these concentrations, a decrease in this efficiency may have occurred at higher 
concentrations as the production of ATP became rate limiting [14]. In the present study 
neither rhGH nor IGF-1 exerted a significant effect on Δψm under the respiratory 
conditions analysed at any administrated concentration. The finding that neither 
hormone induced a change in the rate of hROS production is possibly due to the effect 
exerted on Δψm by saturating concentrations of respiratory substrates. In addition, 
saturating concentrations of ADP were also utilized in the study in order to initiate state 
3 (phosphorylating) respiration following cell permeabilization, which doesn’t 
accurately reflect endogenous respiration in-vivo where cells cycle between state 3 and 
state 4 (non-phosphorylating) respiration [319]. Thus, any subtle effects induced by GH 
or IGF-1 on the efficiency of oxidative phosphorylation may have been negated under 
the respiratory conditions analysed. 
 
In the liver tissue of Wistar rats, following two weeks of GH treatment, Sanz et al. [35] 
found significant increases in the levels of oxidative damage to mitochondrial DNA 
despite observed decreases in the rate of H2O2 generation, indicating that initial pro-
oxidative effects preceded any changes in antioxidant capacity induced by the hormone. 
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Together with the finding by Gustafsson et al. [318] that IGF-1 only influenced the rate 
of ROS production in human neuroblastoma cells in-vitro following the addition of a 
stimulus to induce oxidative stress, this suggests that the changes induced by GH/IGF-1 
on cellular antioxidant capacity are not mediated via a direct up-regulation of the 
expression of antioxidant enzymes. Indeed, it has been suggested that the influence 
exerted by the GH/IGF-1 axis on cellular oxidative capacity is mediated via the 
mechanism of mitochondrial hormesis [205]. A concept which has recently garnered 
much attention in the literature [320], mitochondrial hormesis refers to an adaptive 
response to small sub-lethal increases in mitochondrial derived ROS concentrations, 
which subsequently act as signalling molecules, leading to an up-regulation of 
antioxidant enzymes and increased resistance to oxidative stress. Ungvari et al. [205] 
have demonstrated that the activity of Nrf2, a transcription factor that regulates the 
expression of a subset of genes that contribute to antioxidant defences in response to 
oxidative stress, is significantly decreased in GH deficient Lewis Dwarf rats and that 
this activity is normalised following repletion of physiological GH concentrations, 
lending support to the hypothetical involvement of GH in the induction of this 
regulatory feedback pathway. In addition, Lewis Dwarf rats also exhibited a significant 
down-regulation of the deacetylase enzyme, silent information regulator 2 / Sirtuin1 
(SIRT1) which is also reversed following treatment to attain GH repletion [205]. The 
presence of oxidative insult has been found to significantly increase the expression of 
SIRT1, which is known to act via a deacetylation of the forkhead box O (FoxO) 
transcription factor to exert changes in the expression of numerous proteins that regulate 
mitochondrial metabolism and antioxidant capacity, among which is an up-regulation of 
the antioxidant enzymes, Mn-SOD and GPX-1 [205, 321, 322]. It is likely that 
modulation of oxidative phosphorylation by the GH/IGF-1 axis is not the only factor 
affecting the efficiency of electron transfer in-vivo. Other factors which induce 
oxidative stress by up-regulating the rate of mitochondrial ROS production likely 
contribute to an interactive effect on mitochondrial respiration which is necessary for 
the production of mtROS at concentrations that will maximize their effect as 
intracellular messengers to induce an antioxidant response. Hence, a pre-existing pro-
oxidative status within the cell may be necessary for GH/IGF-1 to induce any 
significant changes in antioxidant capacity, possibly explaining the absence of any 
significant effect on mtROS levels, following pre-treatment with GH and IGF-1 in-vitro 
in the present study. 
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In animal studies, cellular oxidative responses to GH and IGF-1 administration have 
varied depending on the cell type analysed, indicating that any antioxidant effects of the 
GH/IGF-1 pathway are tissue specific [41, 200, 202]. In contrast to the findings of 
Csiszar et al. [200] who showed that in-vitro GH and IGF-1 treatment in 
cardiomyocytes isolated from wild type mice significantly up-regulated the expression 
of Mn-SOD, Cu, Zn-SOD and GPX-1, Brown-Berg et al. [202] observed significant 
decreases in the expression of Mn-SOD, GPX-1 and catalase following similar 
treatment in murine hepatocytes. In addition, Sanz et al. [41] observed significant 
increases in oxidative damage to liver tissue isolated from Wistar rats following two 
weeks of GH treatment, while oxidative damage was significantly decreased in isolated 
cardiac tissue from the same animals. Discrepancies in the GH / IGF-1 effect between 
tissue types could be attributed to the expression of cell specific isoforms of GH and 
IGF-1 regulated locally at a tissue level [200]. Indeed, several tissue types have been 
shown to be capable of locally producing both GH and IGF-1, including sub-
populations of human mononuclear leukocytes [323-326]. Thus, the autocrine / 
paracrine activation of GH / IGF-1 pathways may be more relevant to the hormonal 
effect on the rate of mtROS production in these cell types, than local concentrations of 
the systemic isoforms secreted from the anterior pituitary and the liver, respectively 
[200]. In support of this, Vinciguerra et al. [327] showed that the “local muscle 
specific” IGF-1 isoform (mIGF-1) in murine cardiomyocytes elicited a protective effect 
in response to paraquat induced oxidative stress, while increasing concentrations of the 
systemic IGF-1 isoform itself elicited a pro-oxidative response. The mIGF-1 isoform 
comprises a class 1 signal peptide sequence on its N-terminal which is 48 amino acids 
in length and a C-terminal “Ea extension” peptide sequence containing 35 amino acids, 
which the mature systemic IGF-1 isoform does not possess [327-329]. Both isoforms 
are known to trigger phosphorylation of the IGF-1R [327]. However, the systemic 
isoform is found to typically activate PI3K/Akt and MAPK dependent pathways, while 
mIGF-1 has been shown to instead activate 3-phosphoinositide-dependent kinase 
(PDK1) and serum- and glucocorticoid-inducible kinase-1 (SGK1) signalling molecules 
in cardiomyocytes, demonstrating differences in the isoforms respective signalling 
mechanisms downstream of surface receptor activation [327]. Hence, the activation of 
autocrine / paracrine pathways by locally produced isoforms may be required for 
significant effects on antioxidant capacity to be exhibited in the cell populations 
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analysed in the present study. However, the limitations in translating the results from 
animal models to human subjects must be noted here as animal studies do not always 
accurately predict human outcomes [294]. 
In conclusion, the present study has demonstrated that neither GH nor IGF-1 pre-
treatment was capable of attenuating the high rates of mitochondrial hROS production 
induced by complex I linked respiration under saturating substrate conditions. In 
addition, the oxidation of lipid-derived substrates was found to contribute to 
mitochondrial hROS levels, irrespective of the absence or presence of either hormone. 
While rates of mitochondrial ROS production under conditions of lipid-derived 
respiration did not compare to the high values observed under conditions of complex I 
linked respiration, St-Pierre et al. [125] demonstrated significant elevations in O2− 
levels in isolated mitochondria from rat skeletal muscle and cardiac tissue when 
respiring on palmitoyl carnitine, a derivative of the 16-carbon long chain FFA 
palmitate, which they attributed to a prolonged reduction of ETF and ETF-QOR, in 
addition to an increase in complex I mediated electron leak. Indeed, elevated 
concentrations of long chain FFA’s in-vivo, in excess of the mitochondrial capacity to 
oxidize them, are known to become trapped in the mitochondrial matrix, elevating the 
redox state of the organelle and giving rise to the formation of highly reactive lipid 
peroxides [45, 113]. Thus, long chain FFA’s which require active transportation across 
the IMM may be more prone to inducing ROS production than medium chain FFA’s 
such as octanoate, which can enter and leave the mitochondrial matrix freely [330]. 
These observations have implications for the administration of GH in-vivo, which has 
been demonstrated to induce two to three fold elevations in serum FFA concentrations 
in healthy subjects [21, 144, 331]. In addition, Jurand and Oliver [332] have reported 
that the percentage of the serum FFA, palmitate is significantly higher in acromegalic 
patients than in healthy controls. Oxidative stress has been shown to be significantly 
reduced by IGF-1 administration in intact cells exposed to high ambient glucose 
concentrations in-vitro, likely owing to the insulin antagonizing effects of the hormone 
acting to inhibit the over-supply of substrates to the mitochondria [212, 318]. In 
contrast, both GH and IGF-1 are known to promote lipid derived oxidation in-vivo [21]. 
Whether either hormone would have the same impact on attenuating levels of 
mitochondrial ROS induced by the presence of saturating FFA concentrations in intact 
cells is unknown. In the future, studies analysing the effects of GH and IGF-1 on 
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mitochondrial oxidative status in-vitro, should also be carried out in the presence of 
FFA at concentrations that mimic the cellular environment in-vivo, in order to account 
for any interaction that occurs between the hormonal and substrate impact on 
mitochondrial metabolism. 
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 7. Study Three:  The effect of one week’s administration of recombinant human growth hormone on the regulation of mitochondrial apoptosis in peripheral blood mononuclear cells in-
vivo. An expression study of mitochondrial and cytosolic derived miRNA, mRNA and protein. 
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7.1 – Abstract 
While the anti-apoptotic effects of administration of rhGH are well documented in-vitro, 
the temporal extent of these effects in-vivo following the cessation of rhGH 
administration is currently unknown. In the present study, healthy resistance trained 
male subjects, aged 25.4±1.22 years, were subcutaneously injected with either rhGH 
(1mg) or saline (0.9%) for seven consecutive days (Days 1-7) in a blinded fashion. 
Blood sampling was undertaken before rhGH administration and over a period of three 
weeks (Days 8, 15, 22 & 29) following the final injection of rhGH. PBMCs were 
isolated for the determination of miRNA, mRNA and protein expression levels in both 
placebos and cases. The purpose of this study was to determine whether PBMCs, post 
rhGH administration, would show any significant effects on the regulation of Bcl-2 
family members. Respective anti and pro-apoptotic, Bcl-2 and Bak genes and proteins 
were measured, over a period of three weeks following the final rhGH injection. 
Additionally, post-transcriptional regulation of gene expression by miRNAs associated 
with apoptotic genes was assessed in two cellular compartments, the cytosol and the 
mitochondria. The latter mitochondrial presence of miRNA, the functions of which have 
yet to be elucidated, has only recently been reported in the literature, raising 
consequently important questions as to whether these mitochondrial associated miRNAs 
(mito-miRNAs) act as intracellular signals in cellular apoptosis. Special attention was 
drawn on the expression levels of miR-181a and miR-125b, known as translational 
inhibitors of Bcl-2 and Bak respectively. These miRNA molecules were analysed in 
both cytosolic and mitochondrial fractions following rhGH administration. Results 
showed that rhGH had no effects on the mRNA and protein expression of Bcl-2. 
However, post rhGH administration showed a significant effect on Bak which exhibited 
decreased protein concentrations compared to baseline and following correction with 
placebos. This effect was observed up to 8 days following the last rhGH treatment. 
Cytosolic miRNA expression was not found to be significantly affected by rhGH. 
However, measurement of the expression of miR-125b in mitochondrial fractions 
showed a significant down-regulation 8 days post rhGH administration. In conclusion, 
these findings suggest that rhGH induces short term anti-apoptotic effects which may be 
partially mediated through a novel pathway not yet reported that alters the concentration 
of mitochondrially associated miRNA’s.  
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7.2 – Introduction 
Apoptosis or “programmed cell death” is a physiologically favourable form of cell death 
which in addition to maintaining homeostatic control over cell populations, functions to 
remove damaged or diseased cells without incurring an inflammatory reaction [51, 333, 
334]. Mitochondrial mediated apoptotic signals are also initiated by extracellular 
stimulation which serves to propagate the caspase response, demonstrating the key and 
central roles of mitochondrial organelles in apoptosis [335 – 337]. Dysfunctional 
regulation of these apoptotic pathways is implicated in the development of pathological 
conditions such as cancer, diabetes, ischemia-reperfusion, autoimmune disorders, 
neurodegenerative diseases and acute organ failure [11, 333, 336, 338].  
Interestingly, in-vitro rhGH administration has been well documented to induce anti-
apoptotic effects following stimulation of both the intrinsically and extrinsically 
mediated apoptotic pathways. Anti-apoptotic effects were reported and demonstrated in 
various cell lines including peripheral blood lymphocytes, monocytes and pancreatic β 
cells [208, 209, 339]. In addition, IGF-1, whose secretion from diverse tissues including 
the liver is regulated by GH in-vivo [4, 128], shows well characterised survival effects 
both for doxorubicin challenged cardiomyocytes [17, 298] and for neuroblastoma cells 
under hyperosmotic stress [340]. Additional survival effects mediated by IGF-1 are 
demonstrated in serum starved granulocytes [341], PC12 cells [342] and for renal 
mesangial cells exposed to high glucose concentrations [212].  
Despite these noted anti-apoptotic effects, supra-physiological in-vivo concentrations of 
GH, arising from either disease states or rhGH administration in healthy individuals, 
have been shown to cause hyperglycemia, hypertriglyceridemia and in some cases to 
lead to the development of new onset diabetes [23, 343]. Under such pathological 
conditions, cells are exposed to oxidative stress and damage which may predispose 
them to prematurely undergo apoptosis [124]. A recent case study by Geraci et al. [343] 
has presented findings from a 33 year old male bodybuilder with extreme 
hyperglycaemic and hypertriglycederimic blood concentrations, three weeks after 
completing an androgenic anabolic steroids program that included the intramuscular 
injection of supra-physiologic concentrations of bovine growth hormone. Sustained 
hyperglycemia has previously been reported to induce cardiomyocyte apoptosis in 
diabetes and animal models [344]. In light of the development of these pro-apoptotic 
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conditions, even following the cessation of growth hormone abuse, the temporal extent 
of the anti-apoptotic effects of GH could have important implications for cellular 
survival.  
In both extrinsic and intrinsic pathways, the release of cyt c from the inter-membrane 
space is widely regarded as the rate-limiting step towards initiation of the execution 
phase of apoptosis, the phase at which the cell is committed to programmed death [51, 
55]. While debate is ongoing as to whether cyt c release is instigated by 
permeabilization across the IMM and OMM via mtPTP activation or simply by OMM 
permeabilization, there is a general consensus that the release of cyt c is regulated by the 
Bcl-2 family of proteins [59, 333]. To date, twenty five Bcl-2 family proteins have been 
identified, which exhibit either a pro-apoptotic or anti-apoptotic function [51]. It has 
been extensively demonstrated that the concentration ratio of the anti-apoptotic OMM 
based Bcl-2 proteins, Bcl-2 and Bcl-xL, and pro-apoptotic Bax and Bak proteins is an 
important determinant as to whether a cell undergoes apoptosis in response to either 
intrinsic or extrinsic stimuli [345-349]. 
Both Bcl-2 and Bcl-xL have been demonstrated to inhibit a wide array of apoptotic 
agents.  Up-regulation of Bcl-2 gene expression in neural cells has been reported to 
result in decreased levels of intracellular ROS production, in addition to increased 
resistance to both mitochondrial dysfunction and cell death induced by oxidative stress 
[51, 350, 351]. The prevention of apoptosis upon death-receptor activation by GH 
administration in PBMCs in-vitro has been previously associated with increased Bcl-2 
expression [19, 208, 339]. In addition, GH induced an up-regulation of Bcl-xL 
expression that prevented apoptosis in pancreatic β cells targeted by the pro-
inflammatory cytokines, interleukin-1β, interferon-γ and tumour necrosis factor-α [209]. 
Increased expression of Bcl-xL was also observed in IGF-1 treated rats which conferred 
myocardial protection against ischemia-reperfusion injury [17].  
Conformational changes induced upon Bax in the cytosol by pro-apoptotic activator 
Bcl-2 proteins such as tBID, Bim and PUMA lead to translocation of the protein to the 
OMM. Subsequent homo-oligomerization activation of Bax in the OMM has been 
shown to be associated with mitochondrial membrane permeabilization and cyt c release 
[57-59]. Interestingly, synthesis of Bax is found to be significantly decreased in the 
presence of GH [210, 352]. In addition, IGF-1 treatment in rats was found to decrease 
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the cellular concentration of Bax in cardiomyocytes and to attenuate, in the presence of 
doxorubicin, the induction of Bax into the OMM [298]. Over expression of Bak has 
been widely documented to accelerate the process of apoptosis in both murine and 
human cultured cell lines [353, 354]. In a manner similar to Bax, homo-oligomerization 
of Bak is found to induce cyt c release from the mitochondrial inter-membrane space 
[57-59]. In contrast to cytosolic located Bax, Bak is perennially located within the 
OMM [57-59], explaining possibly why in single Bax-/- knockout mouse embryonic 
fibroblasts (MEFs), Bak-dependent cells are found to exhibit significantly higher rates 
of apoptosis compared to Bax-dependent cells in Bak-/- MEFs [59]. Surprisingly, the 
effects of bath GH and IGF-1 administration on the level of Bak gene and protein 
expression have, to date, not been investigated.   
The respective down- and up-regulation of these pro and anti-apoptotic proteins 
contributes significantly to the survival effects induced by GH and IGF-1. Interestingly, 
these hormones have also been shown to induce changes in miRNA - molecules in 
target cells and tissues involved in regulating protein expression [355, 356]. Mature 
miRNA’s are non-coding short single stranded RNA, sequences of approximately 18 – 
22 nucleotides in length, known to regulate gene expression post-transcriptionally [93, 
357, 358]. Through complementary binding, commonly to the 3’UTR of target mRNA 
molecules, miRNAs are able to induce mRNA degradation. Meanwhile complementary 
binding of only the 2 – 8 nucleotides of the “5’ seed region” of miRNA to its target 
mRNA is enough to induce down-regulation of gene translation, which reduces the rate 
of protein synthesis [93, 102]. It has also been shown that miRNA is capable of 
inducing translational up-regulation of target mRNA under specific conditions, such as 
cell cycle arrest [359]. To date nearly 1,000 miRNAs have been identified, while a 
single miRNA has the potential to bind hundreds of mRNA targets [93, 357, 358]. 
Indeed it is estimated that up to 30% of the gene transcriptome could be regulated by 
miRNAs [93]. Consequently, the identification and validation of miRNA/mRNA 
interactions is an ongoing and fundamental area of miRNA research [226]. Bcl-2 and 
Bak genes have been experimentally validated as targets for translational down-
regulation by miRNAs miR-181a [99, 227, 360] and miR-125b [102, 226, 228] 
respectively. In addition to their apoptotic roles, miR-181a has been demonstrated to act 
as a potent inhibitor of cellular proliferation, while miR-125b has been shown to 
adversely affect cellular senescence and apoptosis [229, 230]. Interestingly, whether or 
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not GH of IGF-1 induces changes in the expression of these specific miRNAs has not 
been reported to date in the literature. 
While miRNA have predominantly been shown to exert their post-transcriptional 
influence in the cytosol, recently several studies have demonstrated the localisation of 
miRNA in isolated mitochondria [104-107, 361]. Interestingly, the level of expression 
of mito-miRNA has been shown to be independent of the total cellular miRNA 
expression profile [104, 105]. Surprisingly, Kren et al. [105] have demonstrated that the 
mito-miRNA pool isolated from rat liver-derived mitochondria was not predicted to 
regulate any nuclear derived mRNA transcripts coding for mitochondrial located 
proteins. While the significance of these findings has yet to be elucidated, it has been 
speculated that mitochondria may serve as a miRNA reservoir [105]. Furthermore, the 
trafficking of these short nucleotide sequences between the mitochondrial compartment 
and the cytosol is thought to be under the regulation of cytosol located mRNA-
processing bodies (P-bodies) [361]. It has been suggested that the storage and 
subsequent release of selective miRNA from mitochondria may act as a mechanism of 
intracellular signalling, exerting control over cellular processes such as apoptosis, 
proliferation and differentiation [104, 105]. Indeed, the predicted gene-targets of some 
miRNA identified to be localized to mitochondria are consistent with those found to be 
down-regulated at the onset of cell death [105]. Furthermore, disruption of 
mitochondrial function has been reported to precede translational inhibition taking part 
in the apoptotic process [105]. Considering the known anti-apoptotic effects exhibited 
by rhGH administration, it is possible such anti-apoptotic roles might be mediated in 
part by mito-miRNA.  
The purpose of this study is to determine the effects on the regulation and expression of 
pro- and anti-apoptotic Bcl-2 family proteins in PBMCs following the cessation of a 
seven day programme of rhGH administration in healthy trained male subjects for a 
period of three weeks. Evaluation of Bcl-2 and Bak expression was determined for 
mRNA levels and proteins from mitochondrial fractions. In addition, cytosolic 
expression of miR-181a and miR-125b was determined to identify possible effects on 
Bcl-2 and Bak mRNA and protein expressions. As both miR-181a and miR-125b have 
previously been found to be significantly expressed in isolated mitochondria from 
human skeletal primary muscular cells [107], the present study therefore aimed at 
determining whether these two miRNAs were present in mitochondria isolated from the 
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subjects PBMCs. Correlation analysis of possible rhGH induced expression of mito-
miRNAs and Bcl-2 and BAK protein/mRNA levels was undertaken. We hypothesized 
that GH’s anti-apoptotic role might be mediated through the activation of an 
intracellular signalling cascade implicating mito-miRNA recruitment.  
Of note, the conservative rhGH concentration injected in this study was chosen in order 
to prevent the development of any adverse effects. Extreme doses of up to 25IU (8.3mg) 
rhGH per day are reportedly taken in its use as a performance enhancing drug [38]. 
However, our laboratory has previously demonstrated that at this low concentration, 
rhGH injection did significantly affect the GH/IGF-1 axis in healthy male subjects 
[362]. Ramos et al. [362], found that 1mg rhGH administration in healthy male subjects 
was sufficient to result in a significant increase in serum IGF-1 concentrations 24 hours 
post-treatment compared to baseline measurements (P<0.05), while no significant 
difference was seen in placebo treated control subjects. Additionally, in these same 
subjects, the expression of over 3,000 genes in PBMCs were observed to be 
significantly affected by the rhGH treatment protocol used for up to three weeks 
following the cessation of treatment (unpublished data). 
 
7.3 – Methods 
7.3.1 – Subjects 
Ten healthy resistance trained male subjects (mean ± SEM: age = 25.40±1.22 yrs, 
height = 1.80±0.16 m, body mass = 78.92±1.52 kg, BMI = 24.32±0.53 kg/m2) were 
recruited to participate in the study which was approved by the Bond University Human 
Research Ethics Committee. All subjects had both the nature of the study and the 
associated risks involved explained to them prior to providing written informed consent. 
Resistance trained was defined as the undertaking of a resistance exercise program, 3-5 
days per week for a period of at least 12 months. Exclusion criteria included smoking, 
the use of therapeutic, recreational or performance enhancing drugs, including anabolic 
steroids and rhGH, up to 12 months prior to participation in the study, the use of 
prescription medication, the presence of diabetes, cardiovascular disease, acromegaly or 
any diagnosed condition which would contra-indicate either participation in resistance 
exercise or the administration of rhGH.  
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7.3.2 – Reagents Used 
MACS Mitochondrial Isolation kits were purchased from Miltenyi Biotec (Auburn, CA, 
USA). RNase-free DNase I and Total RNA/Protein purification kits were purchased 
from Norgen Biotek (Thorold, ON, Canada). Miscript II RT kits, SYBR Green PCR kits 
and Hs-RNU6-2, Hs-MiR-24, Hs-MiR-92, Hs-MiR-125b and Hs-MiR-181a primer 
assays were purchased from Qiagen (Donchaster, VIC, Australia). Custom primers for 
Bcl-2, Bak, GAPDH, Hyperparathyroidism 1 (HRPT1) and 18s, as shown in Table 7.1, 
were synthesised by Geneworks (Thebarton, SA, Australia). iQ SYBR Green supermix 
was purchased from Biorad (Hercules, CA, USA). Ribonuclease A and protease 
inhibitor cocktail were purchased from Sigma Aldrich (St. Louis, MO, USA), while 
RNasin PLUS RNase inhibitor was purchased from Promega (Madison, WI, USA). 
Human Bcl-2 platinum ELISA kits and human Bak ELISA kits were purchased from 
eBiosciences (San Diego, CA, USA) and USCN (Wuhen, China) respectively. Pierce 
BCA protein assay kit was purchased from Thermo Scientific (Rockford, IL, USA). 
RNase/DNase free water and PBS (pH 7.4) were purchased from Invitrogen (Carlsbad, 
CA, USA). Ficoll paque PLUS was obtained from GE Healthcare (Rydalmere, NSW, 
Australia). Finally, Genotropin was purchased from Pfizer (Sydney, NSW, Australia). 
 
 
Table 7.1: Primer sequences used for each mRNA gene product and the corresponding 
size of the PCR amplicon generated. 
 
 
Gene Unigene ID Forward Sequence (5’ – 3’) Reverse Sequence (5’ – 3’) 
Amplicon 
Length (bp) 
18s 100008588 TTCGAGGCCCTGTAATTGGA GCAGCAACTTTAATATACGCTATTGG 123 
GAPDH 2597 CTCTGCTCCTCCTGTTCGAC ACCAAATCCGTTGACTCCGAC 108 
HRPT1 3278 GCTGAGGATTTGGAAAGGGTG CAGAGGGCTACAATGTGATGG 112 
Bcl-2 596 CATCCAGTACCTTAAGCCCTG CTCAGACAGAGCCAGTATTGG 83 
Bak 578  GAGATGGTCACCTTACCTCTG GCAACATGGTCTGGAACTCTG 117 
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7.3.3 – Experimental Design 
Subjects were randomly assigned to either a treatment group (rhGH; n=5) who received 
1mg of Genotropin, a recombinant human growth hormone which exhibits a complete 
sequence homology to the 22kDa hGH isoform, or a placebo group (P; n=5) who were 
administered with a saline solution (0.9% sodium chloride) for a period of seven 
consecutive days. Daily injections were administered subcutaneously in a double blind 
manner. Prior to each injection all participants received a standardized meal (protein 
shake) followed by a 15 minute rest period. Blood samples were collected from each 
subject 24 hours prior to treatment administration as well as 1, 8, 15 and 22 days post-
treatment. 
7.3.4 – Blood Sample Collection and PBMC Isolation 
Subjects arrived for sample collection in a post-prandial state. Blood samples were 
taken from subjects resting in a supine position, prior to insertion of a catheter into the 
antecubital vein with 20mL of blood was drawn into 10mL EDTA vacutainers (BD, 
CA, USA). Collected EDTA blood was diluted in an equal volume PBS (pH = 7.4) and 
layered over Ficoll-paque PLUS at a ratio of 2:1. Samples were subsequently 
centrifuged at 450*g for 30 minutes to achieve separation of PBMCs from whole blood. 
 
7.3.5 – Mitochondrial Isolation and Cytosolic RNA Decontamination 
Mitochondria were isolated from PBMCs using a magnetic antibody cell sorting 
method. PBMCs were resuspended in 100µL cell lysis buffer in the presence of 1µL of 
protease inhibitor and homogenised 10 times by passage through a 27 gauge needle. 
The mitochondria in the cell lysate were subsequently magnetically labelled with 
microbead conjugated anti-TOM22 antibodies. The antibody labelled cell lysate was 
then loaded into a column placed in a magnetic field separator. Of note, flow through 
cell lysate was kept for later RNA extraction and magnetically labelled mitochondria 
bound to the column were washed as per manufacturer instruction. Mitochondria were 
finally eluted following the removal of the column from the magnetic field. Isolated 
mitochondria were further pelleted by centrifugation at 13,000*g for 2 minutes at 4oC 
and resuspended in 200µL RNase A solution (Ribonuclease A concentration: 10µg/mL) 
at 37oC for one hour to remove any possible residual cytosolic RNA molecules residing 
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outside intact mitochondria. Post RNase incubation, mitochondria were pelleted a 
second time by centrifugation at 13,000*g for 2 minutes at 4oC and resuspended in 
100µL mitochondrial storage buffer. RNase activity was stopped by the addition of 5µL 
RNasin PLUS. 
7.3.6 – Total RNA and Protein Extraction from Cytosolic and Mitochondrial Lysates 
Stored isolated mitochondria were pelleted by centrifugation at 13,000*g for 2 minutes 
at 4oC, resuspended in 350µL lysis solution containing high concentrations of 
chaotropic denaturant, for rapid inactivation of RNases and proteases, and vortexed 
vigorously to produce a mitochondrial lysate. Meanwhile the collected cell lysate was 
treated with 2µL RNasin Plus and 1µL protease inhibitor cocktail to protect the 
cytosolic RNA fraction from degradation. Both cytosolic and mitochondrial lysates 
were subsequently mixed with isopropanoyl at a ratio of 2.33:1. Total RNA purification 
of cytosolic and mitochondrial lysates was performed by spin column chromatography 
using a proprietary silicon carbide (SiC) resin (Norgen Biotek Corporation) which binds 
nucleic acids in a manner dependent on ionic concentrations. Thus all sizes of RNA 
from large mRNA down to miRNA and small interfering RNA (siRNA) were separated 
from sample proteins which were removed in the column flowthrough. The flowthrough 
from mitochondrial lysate was retained and stored at -80oC for later analysis of 
mitochondrial proteins. Samples were subsequently treated with RNase free-DNase I for 
15 minutes for the removal of all traces of residual DNA from columns prior to column 
washing and elution of purified RNA as per manufacturer’s instructions. Finally, total 
cytosolic and mitochondrial RNA was quantified on a spectrophotometer (Nanodrop 
1000, Thermo Scientific). 
7.3.7 – cDNA Synthesis from Cytosolic and Mitochondrial RNA 
Reverse transcription of total RNA into cDNA was performed using the miScript II RT 
kit from Qiagen. Mitochondrial and cytosolic RNA were transcribed separately with 
12µL of purified RNA (20ng/µl) being used in each 20µL reaction volume as per 
manufacturer’s instructions. The supplied reverse transcriptase mix contained optimised 
concentrations of both poly (A) polymerase and reverse transcriptase which allowed for 
polyadenylation and reverse transcription to be performed in parallel for each sample. 
The miScript HiFlex Buffer was used for cDNA synthesis which was used as a template 
for real-time PCR (RT-PCR) gene expression analysis and quantitation of both miRNA 
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and mRNA. Mature miRNAs were polyadenylated by poly (A) polymerase and reverse 
transcribed into cDNA using modified common oligo-dT primers as these primer 
sequences hold a 3’ degenerate “anchor” and a universal tag sequence on the 5’ end 
which allowed for amplification of mature miRNA by RT-PCR. All non miRNA RNA 
types were converted into cDNA using usual oligo-dT and random primers. These 
samples were reverse transcribed at 37oC for 60 minutes prior to being heated at 95oC 
for 5 minutes for inactivation of miScript reverse transcriptase mix. 
7.3.8 – Real-time Polymerase Chain Reaction (RT-PCR) Analysis 
RT-PCR assays were performed using a Corbett Rotor-gene 6000 (Qiagen). For relative 
quantification of mRNA gene expression, 5µL of lysate-derived cDNA was mixed with 
6µL Rnase-free water, 12µL iQ SYBR Green supermix (Biorad) and various sets of 
gene specific primers (forward and reverse: 1µL each at a concentration of 5µM) in a 
25µL reaction volume. The forward and reverse sequences of the primers used for each 
gene product are listed in Table 1. GAPDH was used as an endogenous reference gene 
for normalisation of target mRNA expression. Comparative PCR efficiency between 
reference and experimental primers was confirmed by running standard curves for each 
amplicon using the same sample. The change in cycle threshold between reference and 
experimental genes was plotted against the input amount of cDNA on a log scale, with a 
slope of ≤ 0.1 on the resulting semi-log regression line indicating comparable efficiency 
[363]. RT-PCR reactions were conducted at 94oC for 12 minutes, followed by 40 cycles 
at 94oC for 30 seconds, 59oC for 30 seconds and 72oC for 30 seconds. 
For relative quantification of miRNA expression, both lysate and mitochondrially 
derived cDNA were mixed with Quantitect SYBR Green PCR master mix and miScript 
universal reverse primer (Qiagen) in combination with target-specific miScript forward 
primers in a 20µL reaction volume as per manufacturer’s instructions. The predesigned 
forward primers, purchased from Qiagen, were as follows: Hs-RNU6-2 (Cat No: 
MS00033740), Hs-MiR-24 (Cat No: MS00006552), Hs-MiR-92 (Cat No: 
MS00006594), Hs-MiR-125b (Cat No: MS00006629) and Hs-MiR-181a 
(MS00008827). Amplicon lengths of 85-87bp were expected for all mature miRNA 
PCR products. RNU6-2 served as an endogenous reference miRNA for normalisation of 
target lysate-derived miRNA expression. Concentrations of mitochondrial derived 
cDNA from five samples were normalised against sample mitochondrial protein 
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concentrations. These samples were subsequently analysed by RT-PCR as described for 
determination of the most appropriate endogenous control miRNA for normalisation of 
target mitochondrial miRNA expression. Among three possible candidates (RNU6-2 
[364], Hs-MiR-24 [365] and Hs-MiR-92 [366]), MiR-92 was found to be the most 
stably expressed. RT-PCR reactions were conducted at 95oC for 15 minutes, followed 
by 40 cycles of 94oC for 15 seconds, 55oC for 30 seconds and 70oC for 30 seconds.  
The relative expression of mRNA and miRNA were calculated using the comparative 
CT (ΔΔCT) method. The results are presented as log2 fold differences of each target 
mRNA and miRNA in all post-treatment samples relative to baseline samples. All 
reactions were performed in triplicate, while no template control reactions were run 
simultaneously with each PCR assay. Melting curve analysis was performed at the end 
of each PCR run in order to confirm the identity of each PCR amplicon and to rule out 
the production of non-specific products. Any samples exhibiting either earlier than 
expected melting temperatures (TM), indicating the formation of primer-dimers or 
multiple peaks, indicating the production of non-specific products, were excluded from 
the data set. In addition, agarose gel electrophoresis was carried out on the PCR product 
of all amplified mRNA and miRNA targets for verification of the specificity of each 
amplicon.  
7.3.9 – Determination of Bcl-2 and Bak Protein Concentrations 
Quantification of total mitochondrial protein concentration was determined using the 
Pierce bicinchoninic acid (BCA) assay (Thermo Scientific, Rockford, IL, USA). 
Samples were incubated at 37oC for 30 minutes in an alkaline medium in the presence 
of BCA and cupric sulphate. The reduction of Cu2+ ions from cupric sulphate to Cu+ 
occurs in proportion to the amount of protein present in the sample. Two molecules of 
BCA chelate each Cu+ ion formed. The product exhibits a high absorbance at 562nm, 
which was read on a Modulus microplate reader (Turner Biosystems). A standard curve, 
developed from known concentrations of BSA, was used to determine sample protein 
concentrations. Total protein concentration was subsequently normalised for all samples 
prior to analysis of Bcl-2 and Bak levels. 
Bcl-2 and Bak concentrations from mitochondrial protein samples were assessed by 
enzyme-linked immunosorbent assay, according to manufacturer’s instruction. Briefly, 
samples were incubated on antibody coated microtitre plates together with biotin-
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conjugated antibodies, both of which were specific to the analyte of interest. 
Subsequently, streptavidin-conjugated horseradish peroxidase (HRP) was added which 
binds to biotin-conjugated antibodies. Removal of unbound antibody and enzyme by 
microplate washing allows for the development of a colour change in proportion to the 
concentration of analyte present in sample wells, following the addition of 3,3’,5,5’-
tetramethylbenzidine (TMB), a substrate of HRP. The enzyme-substrate reaction was 
terminated by addition of sulphuric acid and absorbance was measured at 450nm on a 
Modulus microplate reader (Turner Biosystems, Sunnyvale, CA, USA). The optical 
density of analysed samples was used in conjunction with the development of standard 
curves for the calculation of Bcl-2 and Bak concentrations, according to manufacturers’ 
instructions. 
7.3.10 – Statistical Analysis 
All data is reported as mean ± SEM. A two-way ANOVA with repeated measures was 
used to determine whether significant differences exist between the two treatment 
groups (rhGH and placebo) for fold changes in mRNA and miRNA expression and 
mitochondrial protein concentrations. Bonferroni’s multiple comparisons were used for 
post hoc analysis to identify the location of significant differences between conditions. 
Pearson’s product moment correlational analysis was used to determine the existence of 
any significant relationships between the analysed variables (SPSS Inc, PAWS Statistics 
Version 18, USA). Statistical significance was accepted at the P<0.05 level of 
confidence.   
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7.4 – Results 
7.4.1 – Bak / Bcl-2 Protein Concentrations 
For pre-treatment measurements Bak protein concentrations from mitochondrial 
fractions in rhGH and placebo groups were not significantly different from each other 
(Figure 7.1 A). Interestingly, Bak protein concentrations were found to be significantly 
decreased in rhGH treated samples compared to placebo treated samples for 
measurements taken 1 (mean difference ± SEM, 95% confidence intervals, p-values: -
2.22±0.77µg/L, -4.01 – -0.44µg/L, P≤0.05) and 8 (-1.85±0.70ng.mL, -3.47 – -0.23µg/L, 
P≤0.05) days post-treatment. However, no significant differences were observed 
between treatment groups at 15 and 22 days post-treatment. No significant differences 
were observed in Bcl-2 protein concentrations from mitochondrial fractions between 
rhGH and placebo treated groups at any time point measured (24 hours pre-treatment; 1, 
8, 15 and 22 days post treatment) (Figure 7.1 B). 
 
7.4.2 – Bak / Bcl-2 mRNA Expression 
Seven days of administration of rhGH (1mg per day) was not found to exhibit any 
significant effect on Bak mRNA differences in expression from baseline levels for any 
measured time period (1, 8, 15 and 22 days following cessation of the treatment 
program) compared to placebo treated controls (Figure 7.2 A). Similarly, rhGH treated 
samples were not found to have any significant effect on Bcl-2 mRNA changes in 
expression from baseline levels in comparison to placebo treated samples at any time 
point analysed post treatment (Figure 7.2 B). 
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Figure 7.1: A) Protein concentrations (mean ± SEM) of Bak from PBMC mitochondrial 
extracts in rhGH treated compared to placebo treated samples. B) Protein concentrations 
(mean ± SEM) of Bcl-2 from PBMC mitochondrial extracts in rhGH treated compared 
to placebo treated samples. (* P<0.05 compared to placebo). 
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Figure 7.2: A) Changes from baseline measurements (mean ± SEM) in the expression 
of Bak mRNA levels from PBMCs in rhGH treated compared to placebo treated 
samples. B) Changes from baseline measurements (mean ± SEM) in the expression of 
Bcl-2 mRNA levels from PBMCs in rhGH treated compared to placebo treated samples. 
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7.4.3 – Cytosolic miR-125b / miR-181a miRNA Expression 
No significant differences were observed in the level of expression of miR-125b from 
cellular lysate at any time point compared to baseline measurements between rhGH and 
placebo treated groups (Figure 7.3 A). In addition, expression changes from baseline 
measurements for miR-181a from cellular lysate were not found to be significantly 
different between rhGH and placebo treated groups for any of the post-treatment time 
points (Figure 7.3 B). No significant correlation was found for the expression 
differences from baseline levels between cytosolic miR-125b and either Bak mRNA or 
protein (Table 7.2). Similarly, cytosolic miR-181a fold expression changes did not 
significantly correlate with changes in the expression of either mRNA or protein Bcl-2 
levels (Table 7.2). 
 
Table 7.2: Pearson’s correlational co-efficients of cytosolic associated miRNA fold 
changes in expression against mRNA/Protein fold changes in expression for the 
corresponding gene of interest in placebo and rhGH treated groups. 
 
 
 
 
 
 
Cytosolic_miRNA   Placebo GH 
Mir-181a     
 Bcl-2 mRNA  0.41  (P=0.08) 0.40  (P=0.09) 
 Bcl-2 Protein  -0.11 (P=0.65) -0.22 (P=0.37) 
Mir-125b     
 Bak mRNA  0.35 (P=0.14) -0.12 (P=0.64) 
 Bak Protein  0.16 (P=0.50) 0.05  (P=0.83) 
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7.4.4 – Mitochondrial miR-125b / miR-181a miRNA Expression 
The change in fold expression of miR-125b in mitochondrial fractions from baseline 
values was found to be significantly decreased in rhGH treated samples compared to 
placebo treated controls (-2.86±0.74, -4.61 – -1.11, P≤0.05) at 8 days post-treatment 
(Figure 7.4 A). However no significant differences were observed between the 
treatment groups at 1, 15 or 22 days post-treatment. No significant differences were 
observed in the level of expression of miR-181a from mitochondrial fractions at any 
time point compared to baseline measurements between rhGH and placebo treated 
groups (Figure 7.4 B). 
 
No significant correlation was found for the fold expression changes from baseline 
levels between mitochondrial associated miR-125b and either Bak mRNA or protein 
(Table 7.3). Additionally, mitochondrial associated miR-181a fold expression changes 
did not significantly correlate with changes in the expression of either mRNA or protein 
Bcl-2 levels (Table 7.3). 
 
Mitochondrial_miRNA   Placebo GH 
Mir-181a     
 Bcl-2 mRNA  -0.20  (P=0.48) 0.37  (P=0.13) 
 Bcl-2 Protein  -0.16 (P=0.57) -0.31 (P=0.21) 
Mir-125b     
 Bak mRNA  -0.08 (P=0.74) 0.37 (P=0.13) 
 Bak Protein  -0.22 (P=0.35) -0.17  (P=0.51) 
Table 7.3:  Pearson’s correlational co-efficients of mitochondrial associated miRNA 
fold changes in expression against mRNA/Protein fold changes in expression for the 
corresponding gene of interest in placebo and rhGH treated groups. 
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Figure 7.3: A) Changes from baseline measurements (mean ± SEM) in the expression 
of miR-125b miRNA levels from the cytosol of PBMCs’ in rhGH treated compared to 
placebo treated samples. B) Changes from baseline measurements (mean ± SEM) in the 
expression of miR-181a miRNA levels from the cytosol of PBMCs’ in rhGH treated 
compared to placebo treated samples. 
Cytosolic Mir-181a
Day 1 Day 8 Day 15 Day 22
-6
-4
-2
0
2
4
6
Placebo
GH
Fo
ld
 C
ha
ng
es
Cytosolic Mir-125b
Day 1 Day 8 Day 15 Day 22
-4
-2
0
2
4
Placebo
GH
Fo
ld
 C
ha
ng
es
A)
B)
169 
 
Figure 7.4: A) Changes from baseline measurements (mean ± SEM) in the expression 
of miR-125b miRNA levels from isolated PBMC mitochondria in rhGH treated 
compared to placebo treated samples. B) Changes from baseline measurements (mean ± 
SEM) in the expression of miR-181a miRNA levels from isolated PBMC mitochondria 
in rhGH treated compared to placebo treated samples. (* P<0.05 compared to placebo). 
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7.5 – Discussion 
Here we report, for the first time, significantly decreased protein concentrations of the 
pro-apoptotic Bcl-2 family member Bak in isolated PBMC mitochondria following 
rhGH administration. These decreases were observed at one and eight days post-
treatment compared to placebo treated controls. While the level of expression of Bcl-2 
plays an important role in determining whether or not a cell will undergo apoptosis, 
Zong et al. [367] demonstrated that the suppression of anti-apoptotic Bcl-2 family 
proteins was not sufficient to induce apoptosis in the absence of Bak and another pro-
apoptotic Bcl-2 family member, Bax. Indeed, considerable evidence exists to indicate 
that mitochondrial initiation of apoptosis is mediated via either a Bax or a Bak 
dependent pathway [58, 349, 367, 368]. In addition to this, the Bak protein has been 
found to be a more potent inducer of cell death than Bax and it has been demonstrated 
that over expression of the Bak gene induces high levels of apoptosis regardless of the 
level of the anti-apoptotic Bcl-2 proteins (Bcl-2 and Bcl-xL) [59, 354]. While it is well 
established that both GH and IGF-1 exert a significant down-regulation of the level of 
expression of the Bax gene [17, 210, 298, 352], to our knowledge the effect of GH on 
Bak gene expression has not been demonstrated previously. In addition, conclusive 
evidence linking the effects of IGF-1 to Bak regulation has not been reported. Although 
Khan et al. [369] found that Bak protein expression was significantly down-regulated in 
mesenchymal stem cells (MSC’s) following only one hour incubation in the presence of 
IGF-1 (50 µg/L), this treatment was administered in combination with the survival 
factor, fibroblast growth factor-2 (FGF-2) (50µg/L). Thus, any effect witnessed on the 
regulation of Bak protein levels in that study could not solely be attributed to the actions 
of IGF-1. In addition, while Cui et al. [370] observed that in-vitro administration of 
IGF-1 (100µg/L) significantly decreased the ratio of Bak to Bcl-xL mRNA expression 
in porcine parthenotes, they failed to report the level of expression of these genes. 
Therefore, considering that IGF-1 is a proven upregulator of Bcl-xl expression [17, 340, 
371, 372], to what extent the hormone exerted an effect on Bak expression is unclear 
from their observations.  
While rhGH was found to significantly decrease Bak protein levels at one and eight 
days post-treatment, no significant differences were observed in protein concentrations 
after either 15 or 22 days following the cessation of treatment. These results could have 
important implications in light of the considerable evidence for the association between 
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chronic excesses in GH concentrations and apoptosis. In addition to the observed 
metabolic alterations resulting from chronic elevations in GH and IGF-1 concentrations 
which can lead to the development pro-apoptotic conditions in-vivo [21-23, 124, 343], 
case studies have reported that a prolonged history of rhGH abuse can lead to the 
development of cardiomyopathy and heart failure [373-375], conditions which are 
associated with deregulated apoptosis [376, 377]. Significant increases in 
cardiomyocyte apoptosis has been reported in myocardial biopsies from acromegalic 
patients, apparently contributing to cell loss and functional abnormalities in acromegalic 
cardiomyopahy [377-379]. Indeed, the degree of cardiac apoptosis was found to exhibit 
a significant positive relationship with both serum IGF-1 concentrations and the 
reported duration of acromegalic disease [378, 379]. Cardiomyocyte apoptosis is also 
found to be abnormally stimulated in the hearts of animals and humans with arterial 
hypertension, with apoptosis preceding both the impairment of ventricular function and 
the development of heart failure in hypertensive patients [377]. Interestingly, high levels 
of circulating IGF-1 have also been reported in patients with essential hypertension and 
hypertensive cardiomyopathy [377]. In light of these observations, the finding that the 
anti-apoptotic effects exerted by rhGH on Bak protein levels does not persist, at least up 
until 15 days following the cessation of treatment could have significant health 
consequences for individuals who are administering rhGH at supra-physiological 
concentrations. 
Bak mRNA was observed to be down-regulated following rhGH administration at all 
time points compared to placebo treated controls. However unlike the decrease in Bak 
protein concentrations these results were not found to be significant. Our results at the 
transcriptomic and proteomic level for Bak therefore show a “mismatch” of expression. 
However, it has been experimentally validated that multiple miRNAs can target the 
same mRNA target, suggesting it is likely that there are a number of miRNAs expressed 
within a cell at any given time that will determine the overall changes in the expression 
and function of specific genes [94, 360, 380, 381]. For instance, in addition to miR-
125b, Bak mRNA is also known to be directly targeted by miR-125a, miR-26a and 
miR-29b [100, 101, 382]. MiR-125b has been shown to significantly decrease Bak 
mRNA inducing mRNA degradation [228], however not all miRNAs function in this 
manner. Indeed, certain miRNAs simply act to repress gene translation, leaving the 
mRNA molecule intact [93, 102]. Several studies have observed protein silencing by 
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miRNA with or without a change of mRNA levels [383-387]. Thus, it is possible that 
the dual effect of mRNA degradation and translational inhibition, resulting from a 
combinational targeting of multiple miRNAs on Bak mRNA, may be responsible for the 
significant changes observed in Bak protein concentrations following rhGH 
administration. 
Considering the effect of rhGH on Bak protein concentrations, it is surprising that the 
level of expression of miR-125b in cellular lysate was not found to be significantly 
affected by rhGH treatment compared to placebo treated controls. In addition, miR-
125b expression levels were not correlated with either Bak mRNA or protein 
expressions in both treatment groups. These results would suggest that GH does not 
exert its effects on the level of expression of Bak through the regulation of miR-125b, 
possibly indicating that other miRNAs known to target Bak mRNA may play a role 
[100, 101, 382].  
However, evidence strongly suggests that the control of mRNA expression by miRNA 
is combinatorial, meaning that it is not a one miRNA : one mRNA interaction but rather 
a combination of multiple miRNAs targeting the same mRNA that determines the level 
of translational regulation [94, 360, 380, 381]. The combinational effect of multiple 
miRNAs targeting a specific mRNA could have a considerably higher biological 
significance than an individual miRNA targeting the same mRNA [94]. Thus, the 
expression of miR-125b may not, on its own, be considered sufficient to induce the 
observed decreases in Bak protein concentrations. However, miR-125b acting in 
combination with other miRNAs may contribute to a significant down-regulation of Bak 
protein expression.  
An alternative explanation is that rhGH induced significant increases in miR-125b 
levels early in the treatment program and that these elevations in expression had 
subsided at the post-treatment time points analysed. It has been reported that the 
concentration of an individual miRNA relative to its mRNA targets is likely to be more 
important to mediating its biological effects than its absolute copy number [227]. In 
addition, although miRNAs are generally assumed to have a very long half-life, 
corresponding to many hours or even days, such a slow turnover may not be a universal 
feature of miRNAs since they often play a role in rapid developmental transitions which 
require a more active miRNA metabolism [388, 389]. While miR-125b was reported to 
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have a half-life of 225 hours (~ 9 days) in mouse embryonic fibroblasts, the same 
miRNA was reported to exhibit rapid turnover (4-6 hours) following lipopolysaccaride 
(LPS) stimulation in murine phagocytes and human dendritic cell lines [390-392]. Thus, 
it is plausible that rhGH induced significant increases in the expression of miR-125b 
early in the treatment program which, as a result of increased turnover, were 
subsequently down-regulated relative to decreases in Bak protein concentrations. 
Indeed, it has been suggested that a reduction in the availability of respective 
complementary mRNA targets may result in the enhanced destabilization of miRNA 
[388, 393]. In order to carry out their function, upon maturation miRNAs are 
incorporated with proteins into miRISC where their association with target mRNAs 
prevent their degradation [388, 393]. XRN-1, a 5’ – 3’ exoribonuclease, has been shown 
to mediate the degradation of mature miRNA, but requires that it is released from the 
miRISC in order for its 5’ end to become accessible to the enzyme [388, 393].  Hence, it 
may be that in the absence of complementary targets, miRNA could be specifically 
released from miRISC and degraded, making the proteins available for loading with 
new miRNA [388]. 
In the present study, expression levels of Bcl-2 mRNA and protein in PBMCs were not 
found to be significantly affected by rhGH administration. While this finding was 
unexpected, Bcl-2 protein concentrations have previously been found to remain 
unaffected in animal based trials following GH administration in-vivo [210, 211]. 
Cuesta et al. [210] examined the effects of four weeks rhGH treatment, administered 
subcutaneously at a dosage of 2mg/kg/day, on the regulation of Bcl-2 family proteins in 
senescence-accelerated mice (SAM), a murine model of accelerated aging. While they 
reported that the ratio between anti-apoptotic (Bcl-2) and pro-apoptotic (Bax and Bad) 
proteins was significantly enhanced following GH administration, this was attributed to 
a decrease in the expression of pro-apoptotic protein levels as the expression of Bcl-2 
was found to be unaffected. Liang et al. [211] investigated, in-vivo, the effect of six 
days rhGH treatment on a human gastric cancer cell line (BGC823 cells) following their 
inoculation to induce tumor xenografts in nude mice. They reported that the level of 
Bcl-2 protein expression in xenograft tumors was not significantly different between 
mice treated with rhGH (2IU/kg/day) and saline administered controls. In contrast, in-
vitro studies conducted on human lymphoid and monocytic cell lines have consistently 
demonstrated that GH elicited a positive effect on the expression of the Bcl-2 protein 
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[18, 19, 208, 339]. Treatment of peripheral blood lymphocytes including both CEM/C7 
and IM-9 cells (lymphoid cell lines of T and B lineage respectively) with rhGH at 
concentrations of up to 500µg/L for 12 to 48 hours resulted in significant enhancement 
of the expression of both Bcl-2 mRNA and protein levels [18, 208]. In addition, U937 
cells (a cultured human monocytic cell line), previously treated with either 50 or 
500µg/L of rhGH for up to 24 hours were shown to have significantly up-regulated Bcl-
2 protein concentrations [19].  
Variations in the duration of rhGH treatment could possibly account for the conflicting 
results observed by experiments in-vitro and in-vivo. It has been shown that GH 
signalling associated with short term survival, following cytokine deprivation and cell 
cycle arrest in a lymphoid cell line (Ba/F3 cells) is correlated with an up-regulated 
expression of Bcl-2 [339]. However, the expression of another anti-apoptotic Bcl-2 
family member, Bcl-xL, which is reportedly crucial to the mediation of cytokine 
induced cell survival processes, appears to be involved in GH induced long term 
cellular survival coupled to cellular proliferation [394]. Of relevance to these 
observations, evidence of a reciprocal regulation between these two proteins has been 
reported [51, 395, 396]. Endogenous Bcl-xL protein levels were found to be repressed 
in Bcl-2 transgenic mice, while endogenous Bcl-2 protein expression was found to be 
down-regulated in T lymphocytes from a transgenic mouse model exhibiting over-
expression of Bcl-xL [396]. That over-expression of either Bcl-2 or Bcl-xL results in a 
reciprocal down-regulation is indicative of the existence of a shared regulatory feedback 
pathway [395]. In addition, while the expression of Bcl-2 has been reported to be 
largely dependent on the activation of NF-kB, the regulation of Bcl-xl expression is 
reported to be regulated via both NF-kB dependent and independent signalling 
pathways [339]. Thus, although NF-kB appears crucial to mediating the effects of GH 
on the expression of at least Bcl-2, it is likely that other signalling molecules regulated 
by GH in-vivo are involved in regulating Bcl-xL expression. Interestingly, in-vivo 
administration of IGF-1 (1mg) in rats was found to significantly increase Bcl-xL protein 
concentrations from isolated heart mitochondria after 24 hours [17]. In addition, in-vitro 
IGF-1 administration significantly enhanced the expression of Bcl-xl mRNA and 
protein levels in PC12 cells following 24 hours incubation [340]. Thus, it is possible to 
assume that, in the present study, the effects of rhGH on Bcl-2 might have been counter-
175 
 
acted by additional hormonal regulations exerted on other anti-apoptotic proteins, such 
as Bcl-xL. 
MiR-181a is one of several miRNAs that directly target and repress translation of Bcl-2 
[99, 360, 397]. Considering no rhGH mediated effect on the Bcl-2 level of expression 
was observed in the current study, it is not surprising that no significant difference was 
observed in miR-181a expression in cellular lysate in both rhGH and placebo treated 
subjects. In addition, miR-181a expression levels were not correlated with either Bcl-2 
mRNA or protein expressions in both treatment groups.  
The presence of four miRNAs have been identified in isolated mitochondria in the 
present study, adding PBMCs to the short list of cell types that have been found to 
contain mito-miRNA [104-107]. To date, miRNAs have been specifically associated 
with mitochondria isolated from rat liver [105], mouse liver [104], human HeLa 
epithelial cells [106] and human skeletal muscle cells [107]. In addition to miR-181a 
and miR-125b, the two miRNAs tested as endogenous references, miR-24 and miR-92 
were found to be mitochondrially located. While miR-181a, miR-125b and miR-24 have 
all previously been documented in isolated mitochondria from human skeletal muscular 
cells [107], to our knowledge this is the first time that miR-92 has been shown to be 
localised to in mitochondria.  
A MACS technique was utilized to isolate mitochondria in the present study, which has 
been experimentally validated to provide a better quality, quantity and purity of 
mitochondrial fraction (89% enrichment) than the traditional differential centrifugation 
method of mitochondrial isolation (59% enrichment) [233]. Indeed, the performance of 
the MACS method was even found to compare favourably with the more sophisticated 
and expensive ultracentrifugation method of isolation (88% enrichment) [233]. Several 
peer reviewed publications [107, 233, 238] have validated the MACS mitochondrial 
isolation method at the protein level, showing specific cytosolic proteins (Glycogen 
Synthase, GAPDH, Beta-actin) to be poorly detected in mitochondrial fractions while 
specific mitochondrial proteins (Prohibitin, TOM-22, ATP synthase) were found to be 
highly enriched. The purity of mitochondrial fractions isolated via MACS has also been 
confirmed with the assessment of compartmental mRNA and DNA levels [107]. Barrey 
et al. [107] undertook the analysis of two nuclear encoded genes (HIST2AA3 and 
GAPDH) and observed very low cytosolic mRNA levels and an absence of nuclear 
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DNA contamination in isolated mitochondria. Using transmission electron microscopy, 
this group also showed that the membrane and ultra-structural integrity of mitochondria 
remained intact following MACS isolation [107]. In the present study, mRNA from 
three nuclear encoded genes (18s, GAPDH and HRPT1) were not found to be expressed 
in the mitochondrial RNA extract, while protein concentrations of the mitochondrially 
located Bcl-2 and Bak fell below detection parameters in cellular lysate (data not 
shown), lending further support to our claim that the mitochondrial isolation procedure 
used yielded a highly enriched mitochondrial fraction. Additionally, in keeping with all 
mito-miRNA studies undertaken to date [104-107], RNase treatment of isolated 
impermeable mitochondrial organelles was carried out to remove any externally bound 
cytosolic RNA molecules prior to mitochondrial RNA extraction. 
No significant correlations were found to exist between miR-181a or miR-125b 
expression levels in mitochondrial fractions and their respective mRNA targets in either 
treatment group (Table 7.3). As miR-181a and miR-125b have been experimentally 
validated to target Bcl-2 [99, 227, 360] and Bak [102, 226, 228] respectively, that no 
association was detected between their expression profiles is likely a reflection of the 
small sample size utilized in the present study. Expression levels of miR-181a from 
mitochondrial fractions were not found to be significantly affected in rhGH treated 
subjects compared to placebo treated controls. However miR-125b was observed to be 
down-regulated in isolated mitochondria following rhGH administration at all time-
points measured. Furthermore, this down-regulation was found to be significant at eight 
days post-treatment in comparison with the placebo group. Thus, the results from this 
study suggest that rhGH may exert a regulatory effect on the expression levels of at 
least some mito-miRNAs. However, identifying what the significance of this rhGH 
induced effect may be and how its regulation is mediated remain important issues which 
must be addressed. 
It has been hypothesized that post-transcriptional regulation via mito-miRNAs might 
provide a sensitive and rapid mechanism to fine tune level of protein expression from 
the mitochondrial genome in response to changes in cellular metabolic demands [106]. 
Indeed, miRNAs identified in isolated mitochondria from HeLa cells have been 
predicted in-silico to target mitochondrial RNA [106]. In addition, argonaute 2 (AGO2), 
the principal active protein of the cytoplasmic miRISC, has been found in several 
studies [104, 106, 107] to be present in isolated mitochondrial fractions. GH mediated 
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signalling pathways have been demonstrated to directly target mitochondria, exerting 
regulatory control over the activity of ETC complexes and the rate of ATP synthesis 
[187, 192, 193, 296]. Thus, it is possible that rhGH induces changes in mitochondrial 
function through mito-miRNA regulated changes in the expression of mitochondrial 
proteins. 
Another hypothesis is that mitochondria serve as a storage site for miRNAs [103, 105, 
361]. Both Kren et al. [105] and Barrey et al. [107] identified mito-miRNAs which 
exhibited no obvious mitochondrial mRNA targets, nor were they found to be 
complementary to nuclear mRNAs encoding mitochondrial proteins. In addition, all 
mito-miRNAs identified to date have predicted cytoplasmic protein targets with many 
of these found to be involved in the regulation of cellular processes such as apoptosis, 
proliferation and differentiation [103-105]. Thus, it is conceivable that a select group of 
miRNAs are sequestered into mitochondria for storage and that their signal mediated 
release into the cytoplasm mediates an additional level of control over cellular processes 
[105]. 
It has been proposed that mito-miRNAs released into the cytoplasm are trafficked into 
P-bodies, cytoplasmic granules involved in mRNA degradation that also contain the 
necessary machinery for translational inhibition [103, 398]. In fact, it has been reported 
that P-bodies establish frequent and prolonged contacts with mitochondria [103, 398]. 
Huang et al. [398] observed that 50 – 70% of P-bodies were found to associate with 
mitochondria in established human cell lines, indicating that their interaction is not the 
result of a random association. In addition, the association between mitochondria and P-
bodies is reported to be dynamic, with fluorescence microscopy imaging showing that 
more than 80% of P-bodies establish a link with mitochondria at least once within a 
three minute interval, with a median duration of eighteen seconds [103, 398]. Whether 
this transient association involves the binding of P-body proteins to proteins on the 
surface of the mitochondrial outer membrane remains to be determined, however the 
proximity between the two organelles does make possible the exchange of metabolites, 
RNAs and proteins [103]. Furthermore, experimental evidence has arisen to suggest that 
cytosolic ribosomes bound to mitochondria may control a co-translational import 
process for at least some nuclear encoded mitochondrial transcripts and it is plausible 
that mitochondrial P-body interactions allows for regulation of these membrane bound 
mRNAs [398-400]. Of note, while it is well established that AGO2 associates with 
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miRNAs and is responsible for anchoring these molecules to miRISCs, evidence 
supporting the mitochondrial localization of complete and fully functional miRISCs is 
currently lacking [90]. Interestingly, it has been indicated that AGO2 carries out specific 
functions which cannot be replicated by other argonaute proteins [90]. Knockdown of 
AGO2 in human HEK293 cells was found to significantly impair miRNA mediated 
repression compared to the knockdown of other AGO proteins [401]. In addition, 
knockout of AGO2 is embryonically lethal in mice, while knockout of AGO1 or AGO3 
is not [402]. Thus, it is possible that AGO2 plays a crucial role in trafficking miRNA 
between mitochondria and OMM associated p-bodies, where translational repression 
occurs subsequent to the formation of miRISCs. In the present study, the pre-treatment 
of isolated mitochondria with RNase indicates that all identified mito-miRNAs are 
located within the organelle as those associated with membrane bound P-bodies and 
ribosomes would have been destroyed. Thus, in order to determine whether mito-
miRNAs are released from mitochondrial storage and subsequently associate with 
membrane bound granules, further studies incorporating the analysis of both RNase 
treated and untreated mitochondrial fractions are warranted.  
If GH does indeed mediate the release of mito-miRNA from the organelle, the 
mechanism by which the hormone exerts this effect remains to be determined. Kren et 
al. [105] suggest that an increase in mitochondrial membrane permeability may 
represent a mechanism by which miRNAs sequestered into mitochondria are released 
into the cell. Indeed, the disruption of Δψm is known to result in an increased 
permeability to small molecules, including miRNAs [403]. Δψm is a dynamic entity, 
subject to transient depolarizations termed “flickers”, a phenomenon which has been 
attributed to occur in response to intracellular Ca2+ signals mediating an increase in 
intra-mitochondrial Ca2+ concentrations [404-407]. Since GH has been reported to 
stimulate an increase in intracellular free Ca2+ concentrations in cells expressing wild 
type GH receptors [170], it is possible that GH induced changes in mitochondrial 
permeability mediates the release of mito-miRNAs. However, differences in the 
expression levels of mitochondrially located miR-181a and miR-125b observed 
following rhGH administration in the present study would seem to indicate that rhGH 
mediates a preferential and selective active release of mito-miRNAs. While the 
mechanism for such a mode of action remains to be determined, it most likely involves 
the activity of P-bodies targeted to the mitochondrial outer membrane. 
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In summary, significant decreases in Bak protein concentrations following rhGH 
administration could not be solely attributed to changes in the expression of miR-125b. 
That difference in Bak levels did not persist past eight days post-treatment and therefore 
could have important health implications for any individual taking rhGH at supra-
physiological concentrations for performance enhancing purposes. In addition, our 
results suggest that rhGH may exert an effect on the expression of at least one of the 
mitochondrial-miRNAs investigated, although how this effect is mediated remains to be 
determined. It should be noted that subjects recruited for this study were resistance 
trained, which of itself influences rates of endogenous GH secretion. Whether the same 
effects would be induced following rhGH administration in untrained individuals has 
yet to be elucidated. The data presented here points towards the existence of GH 
induced anti-apoptotic effects which may in part be mediated via changes in the 
expression of mitochondrial-miRNAs. These preliminary and interesting observations 
warrant further investigation. 
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 8.  Final Discussion and Conclusion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
181 
 
8.1 GH and IGF-1 mediated effects on Mitochondrial Function. 
Healthy mitochondrial function is characterized by both the production of ATP at rates 
sufficient to meet physiological demand and avoidance of the generation of ROS at 
rates that would lead to elevated levels of oxidative damage [6]. As cellular rates of 
ATP production have previously been shown to be increased in the presence of GH 
[192], attention was focused on the consequences of this putative up-regulation on rates 
of oxidative phosphorylation. The influence of rhGH and IGF-1 on the efficiency of 
oxidative phosphorylation was addressed in Study One, through examination of relative 
changes in Δψm and mitochondrial O2− levels from PBMCs in-vitro. The magnitude of 
Δψm is a major determinant of the efficiency of oxidative phosphorylation as the proton 
permeability of biological membranes increases exponentially at high values, leading to 
a waste of energy and an increase in the rate of ROS production [14, 408].  
At the physiological concentrations utilised we proposed that neither rhGH nor IGF-1 
would exert any significant effect on Δψm and that mitochondrial O2− levels would be 
either maintained or decreased compared to untreated control samples. At least for 
rhGH treated samples this was found to be the case, with mitochondrial O2− levels 
found to be significantly decreased at concentrations of 5µg/L and 10µg/L in 
lymphocytes and 10µg/L in monocytes, while Δψm values remained unaffected. These 
results suggest that at these concentrations rhGH elicited an increase in the efficiency of 
electron transfer along the ETC, lowering the rate of superoxide production while a tight 
coupling between O2 consumption and the rates of ATP synthesis maintained Δψm 
within physiologically optimum values of 100 – 120mV [14]. 
With supra-physiological concentrations of rhGH and IGF-1 it is proposed that both 
Δψm and mitochondrial O2− levels would be significantly increased compared to 
untreated samples. Our hypothesis was that at these concentrations both hormones 
would impose a level of cellular stress at which the synthesis of ATP would become 
rate-limiting, leading to increases in Δψm to values that impede the efficiency of 
oxidative phosphorylation. Contrary to our proposals, neither Δψm nor mitochondrial 
O2− levels were found to be significantly increased by rhGH at supra-physiological 
concentrations, which could possibly be due to the existence of an as yet unidentified 
negative feedback pathway initiated by the hormone at these concentrations. IGF-1 was 
found to induce no significant effect on either of these variables that would seem to 
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indicate that this hormone does not impact mitochondrial function in PBMCs under the 
concentrations analysed. 
Although analysis of Δψm together with mitochondrial O2− levels did provide evidence 
favouring GH mediated regulation of the efficiency of mitochondrial energy production, 
it should be noted that the efficiency of oxidative phosphorylation was not determined 
directly in this study. Traditionally, determination of the efficiency of energy production 
by oxidative phosphorylation is based on calculation of the P/O ratio, which is the 
number of ATP molecules produced per oxygen atoms reduced by the respiratory chain 
[64]. However, this method of analysis requires that measurements be carried out on 
isolated mitochondria for which both structural and functional interactions with other 
cellular components are absent [409]. This includes possible interactions with signalling 
pathways that could mediate effects on oxidative phosphorylation. In contrast, the 
method of analysis utilised in Study One allowed for the interpretation of mitochondrial 
function in live cells without compromising cellular function. It should also be noted 
that as samples in this study underwent treatment in-vitro, any factors exclusively 
present in-vivo which exert an influence over the hormonal effects mediated on 
mitochondrial function have not been accounted for. For example, the presence of 
binding proteins in-vivo, such as growth hormone binding protein (GHBP) which 
controls the distribution of circulating GH and insulin-like growth factor binding 
protein-3 (IGFBP-3), which together with acid-labile subunit (ALS) is known to 
modulate the activity of IGF-1 [410, 411], likely influence any mitochondrial effects 
mediated by these hormones at specific concentrations. In addition, administration of 
rhGH in-vivo is known to increase the rate of lipolysis leading to elevated plasma FFA 
concentrations, an effect which in and of itself has been shown to negatively impact 
mitochondrial function, down-regulating genes required for oxidative phosphorylation 
[21, 293].  
Mitochondrial responses to rhGH and IGF-1 administration were further addressed in 
Study Two, again through analysis of relative changes in Δψm, but also for the first time 
through examination of how these hormones affect levels of the hROS, .OH and 
ONOO- within mitochondria. The examination of these variables was carried out under 
several respiratory conditions, which to varying degrees allowed for control over the 
sites of electron entry into the ETC at complexes I and II, in an effort to identify the role 
played by individual complexes in mediating hormonal effects on the efficiency of 
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mitochondrial function. It was found that respiration mediated by both complex I and 
fatty acids produced significantly higher hROS levels compared with respiration 
mediated by complex II, leading to an impairment of mitochondrial function as 
indicated by significant decreases in Δψm. The mitochondrial responses to physiological 
and supra-physiological concentrations of both rhGH and IGF-1 were assessed under 
saturated substrate concentrations in Study Two in contrast to the endogenous 
intracellular substrate conditions utilized in Study One. 
Variability in the efficiency of oxidative phosphorylation has previously been shown 
under different physiological conditions within several tissue types when using complex 
I respiratory substrates [64]. However, the same variability was not found under 
conditions of complex II mediated respiration [64]. In addition, several studies have 
identified complex I to be the principal site of electron leak contributing to the 
production of ROS along the respiratory chain [303, 307, 308]. Thus, in line with 
expectations from Study One, it was hypothesized that under conditions of respiration 
initiated at complex I, no significant effects would be exerted on Δψm but that hROS 
values would be attenuated at physiological concentrations in the case of both 
hormones. Additionally, values for both variables were predicted to be significantly 
elevated at supra-physiological concentrations of rhGH and IGF-1. In contrast, it was 
proposed that neither hormone would mediate any significant effect under conditions of 
complex II mediated respiration. Such findings would provide support for the notion 
that variability in the level of activity of complex I plays an important role in mediating 
mitochondrial responses to the actions of these hormones. 
However, it was found that neither rhGH nor IGF-1 exerted any significant effect on 
Δψm or hROS values, at any concentration compared to untreated samples under the 
respiratory conditions analysed. That rhGH treatment at concentrations of 5µg/L was 
not found to induce a mitochondrial response under the respiratory conditions of Study 
Two contrasts with the findings of Study One where the same treatment was found to 
mediate a change in the rates of mitochondrial ROS production. As we concluded, it is 
likely that subtle effects induced by rhGH, which at physiological concentrations 
manifested as an increase in mitochondrial efficiency in Study One, were negated in 
Study Two owing to the effects exerted on Δψm by saturating concentrations of 
respiratory substrates. Unfortunately as a result, whether or not the activity of complex I 
plays any role in mediating mitochondrial responses to the actions of GH could not be 
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determined from the observations in Study Two. However, it is worth noting that high 
hROS values were recorded under saturated conditions of both complex I mediated and 
lipid derived respiration which GH was not capable of attenuating at the concentrations 
tested. Despite the findings from Study One that showed significant decreases in 
mitochondrial O2− levels with physiological concentrations of GH in-vitro, this could 
have implications for the administration of rhGH in-vivo, which has previously been 
associated with substantial increases in both circulating concentrations and 
musculoskeletal uptake of NEFA’s [412]. Such elevated supplies of lipid-derived 
substrates to mitochondria is associated with the formation of highly reactive lipid 
peroxides in the mitochondrial matrix, leading to oxidative damage which can 
negatively impact mitochondrial function [113]. 
Evaluation of mitochondrial metabolism in the presence of respiratory linked substrates, 
as outlined in Study Two, is not possible in whole cells as some of the respiratory 
substrates used are incapable of permeating intact cellular membranes [219]. Digitonin 
induced permeabilization of the cell surface membrane was advantageous over more 
traditional methodologies carried out on isolated mitochondria as it allowed for the 
analysis of mitochondrial function under these respiratory conditions while keeping the 
organelle’s relationship with its surrounding cellular structure intact [219]. However, a 
limitation of this technique is that cellular permeabilization inevitably leads to a loss of 
endogenous substrates and proteins from the cytosol [219]. Additionally, the supply of 
exogenous respiratory substrates to the ETC creates experimental conditions that do not 
accurately reflect the physiological conditions within whole cells [62]. Hence, although 
rhGH and IGF-1 treatment was conducted on whole cells over a period of four hours, 
prior to analysis under conditions of cellular permeabilization, we acknowledge that this 
process could have altered GH mediated mitochondrial responses compared to those 
seen in Study One. 
Moving forward, there is much scope for further research into the effects these 
hormones exert on mitochondrial efficiency. Notably, there is a need for these hormone 
mediated effects to be examined under conditions that more closely resemble those 
present in-vivo. Controlled trials administering rhGH to healthy subjects have been 
reported to induce up to three fold elevations in serum lipid concentrations with free 
oleic acid, triglyceride palmitate and cholesterol oleate in particular exhibiting 
significant increases [332]. Thus, analysis of GH and IGF-1 mediated mitochondrial 
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responses in the presence of these lipids, at concentrations that would mimic the 
extracellular environment in-vivo, would account for any interaction effect between the 
hormonal and substrate impact on the efficiency of mitochondrial function. 
Additionally, it should be noted that in practice, rhGH and IGF-1 are often abused in 
combination with anabolic-androgenic steroids, most commonly synthetic testosterone, 
in order to enhance the potency of their anabolic effects [413-416]. In light of this, it is 
evident that any combinatorial effects elicited by either rhGH or IGF-1 when used in 
conjunction with other anabolic agents could have important implications for 
mitochondrial metabolism and should be investigated.  
Key to the understanding of how GH and IGF-1 mediate changes in mitochondrial 
responses could be the elucidation of associated signalling pathways directed at the 
organelle in addition to the identification of specific protein targets. Although 
phosphorylation sites have been identified on all of the respiratory chain complexes, to 
date the signalling pathways involved in their regulation remain largely unknown [6, 
61]. Hence, further investigations could ascertain whether GH or IGF-1 affect the 
phosphorylation status of any of these identified sites on respiratory chain complexes. 
Additionally, examination of the dynamics associated with any interactions that are 
identified is warranted, in terms of the percentage of proteins that are either 
phosphorylated or dephosphorylated at specific hormonal concentrations. It should be 
noted that only in a few cases have the physiological responses to specific 
phosphorylation of mitochondrial respiratory complex proteins been resolved [14]. It is 
therefore important that the functional consequences concerning Δψm, ATP synthesis 
and ROS production for any individual site whose phosphorylation status is found to be 
affected by GH or IGF-1 be subsequently addressed. 
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8.2 Implications for Cellular Viability. 
Both GH and IGF-1 are potent “survival factors” whose anti-apoptotic effects are well 
documented [17, 18, 212, 297]. However, elevations in GH and IGF-1 levels to supra-
physiological concentrations are characterized by the development of pro-apoptotic 
conditions in-vivo [373-375]. Additionally, the development of acromegaly has negative 
health implications associated with increased levels of apoptosis [377-379]. It is 
therefore relevant to consider the implications for cellular viability imposed by GH and 
IGF-1 mediated effects on mitochondrial function at both physiological and supra-
physiological concentrations. This was addressed in Study One through analysis of 
relative changes in the level of activity of the mtPTP. The activity of this inter-
membrane channel represents a key step in the execution of mitochondrial mediated 
apoptotic pathways [54]. Its opening occurs in response to physiological stresses, most 
notably the augmentation of intra-mitochondrial free ROS concentrations [54]. 
Hormonal impacts on cellular viability were also assessed directly, as changes in the 
percentages of viable, apoptotic and necrotic cells following treatment were determined.  
Considering the expectation to observe augmented rates of mitochondrial ROS 
production at supra-physiological concentrations of rhGH and IGF-1, we hypothesized 
that both hormones would impose significant increases in the level of mtPTP opening at 
these concentrations. It was proposed that this would have negative implications for 
cellular viability which would be reflected by significant elevations in the percentages 
of cells found to be undergoing apoptosis. 
Contrary to this, neither hormone was found to have a significant effect on either mtPTP 
activity or the percentage of cells undergoing apoptosis at any concentration 
administered. This was not surprising given that neither hormone was found to induce 
an increase in the level of mitochondrial oxidative stress, even at supra-physiological 
concentrations in Study One. Thus, we concluded that the mitochondrial responses 
mediated by these hormones do not of themselves adversely affect cellular viability, 
even at supra-physiological concentrations. As previously stated, it must be noted that 
the in-vitro nature of this study precludes the involvement of factors exclusively present 
in-vivo which could mediate pro-apoptotic effects. Indeed, noted limitations of in-vitro 
analysis include the lack of a homeostatic environment and an impairment of 
intracellular signalling [417]. Consequently, how these factors interact with hormone 
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mediated mitochondrial responses to impact cellular viability were not addressed by 
Study One. 
In consideration of the noted limitations of in-vitro analysis, Study Three assessed 
hormonal effects impacting PBMCs in-vivo following one week of rhGH 
administration, at a dose of 1mg per day, in healthy male subjects compared to placebo 
treated controls. The potential implications of rhGH administration at this dosage for 
cellular viability were addressed through the analysis of the hormone mediated effects 
on the expression of apoptotic regulatory proteins, namely the anti-apopotic Bcl-2 and 
the pro-apoptotic Bak. Both proteins play a key role in determining whether a cell will 
activate central apoptotic pathways in response to mitochondrial mediated stimuli [349, 
351]. Furthermore, changes in the expression of these proteins was assessed over a 
period of 22 days post-treatment in order to investigate whether the temporal extent of 
the hormone mediated effects on their regulation would persist. Through this Study 
Three aimed to determine whether the putative protection provided by rhGH’s noted 
anti-apoptotic effects remains sufficient, in the long term, to counter the development of 
pro-apoptotic stimuli that are associated with prolonged elevations in GH 
concentrations in-vivo. 
In line with its role as a potent survival factor, it was hypothesized that rhGH 
administration would result in an up-regulation of Bcl-2 levels while Bak levels would 
be down-regulated. Additionally, it was proposed that the significance of these initial 
anti-apoptotic effects would become attenuated by 22 days post-treatment. Indeed, one 
week rhGH administration (1mg per day) was found to significantly decrease Bak 
protein levels at 1 and 8 days post-treatment, while no significant differences were 
observed in protein concentrations after 15 or 22 days following the cessation of 
treatment. However, contrary to the presented hypothesis, the level of expression of 
Bcl-2 was not found to be significantly affected by rhGH which would indicate, at least 
in the case of PBMCs, that this hormone does not mediate its anti-apoptotic effects via 
the regulation of this protein in-vivo. That the reported anti-apoptotic benefits elicited 
by rhGH administration via a reduction in Bak protein concentrations were not found to 
persist beyond eight days post-treatment could have negative implications for cellular 
viability considering the noted pro-apoptotic risk factors associated with prolonged 
supra-physiological GH concentrations in-vivo [33, 416]. Such factors include the 
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development of type II diabetes mellitus, hypertension and cardiomyopathy as well as 
the alteration of lipid and hormonal profiles [33, 416]. 
It is worth noting that only two candidates from the Bcl-2 family of proteins that 
regulate the mitochondrial execution phase of apoptosis were assessed in the study. The 
limitation of this becomes apparent in consideration of the fact that, to date, a total of 25 
members of the Bcl-2 group have been identified, each of which plays a role in the 
regulation of mitochondrial mediated apoptotic pathways [51]. In addition, both GH and 
IGF-1 have been shown to mediate short-term changes in the expression of a number of 
these proteins, including the pro-apoptotic Bax [17, 298, 418] and Bad [418] as well as 
the anti-apoptotic Bcl-xL [17, 209, 418]. Thus, further research assessing how in-vivo 
rhGH administration affects long-term changes in the expression of other Bcl-2 
associated apoptotic regulators in the weeks following the cessation of treatment is 
warranted. In addition, it is worth examining whether rhGH administration induces 
similar effects on the expression of these proteins in other cell types. In particular, the 
prevalence of cardiomyopathy and heart failure in acromegalic patients and the 
association of these conditions with deregulated apoptosis in cardiac tissue [377-379] 
make cardiomyocytes a prime target for investigation in this type of study.  
8.3 Regulation of Mitochondrial Mediated Apoptosis by rhGH: The Role of 
miRNA 
Determination of the effects exerted by the administration of rhGH on the expression of 
Bcl-2 family proteins provides key insight into the regulatory mechanisms behind GH’s 
anti-apoptotic effects. We further aimed to build upon these findings through the 
investigation of factors which may have contributed to these rhGH induced changes. 
With regard to this, it is likely that post-transcriptional regulation of gene expression by 
miRNA molecules play an important role in mediating any effects induced by rhGH on 
these apoptotic regulatory proteins [355]. While miRNA molecules have traditionally 
been thought to exert their post-transcriptional effects in the cytosol, the recent 
discovery of the mitochondrial compartmentalisation of these molecules has given rise 
to speculation that control over their storage and release from the organelle may act as a 
mechanism for intracellular signalling and play a role in regulating mitochondrial 
processes [105]. Furthermore, a portion of the mito-miRNA molecules identified in 
previous studies have predicted gene targets in-silico which are consistent with those 
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involved in  apoptotic signalling pathways [105]. Hence, it was our intention to examine 
whether both cytosolic and mitochondrial associated miRNA signalling could be 
responsible for the rhGH induced changes observed in the expression of Bcl-2 
associated regulatory proteins. To this end, changes in the expression of miR-181a and 
miR-125b, which are known translational inhibitors of Bcl-2 [99, 227, 360] and Bak 
[102, 226, 228] respectively, were analysed from the cytosolic and mitochondrial 
fractions of PBMCs’ following rhGH administration in Study Three.  
In accordance with the rhGH induced changes predicted to occur in the gene and protein 
expression levels of Bcl-2 and Bak respectively, we hypothesized that cytosolic levels 
of miR-181a would be significantly decreased while the expression of miR-125b would 
be significantly elevated following rhGH administration. A reversal of these effects was 
proposed in the case of miRNA residing within mitochondria. Significant increases in 
miR-181a levels and significant decreases in miR-125b levels may indicate a respective 
storage and release of these miRNA in response to rhGH. Pursuant to our hypothesis 
regarding the long-term effects induced by rhGH administration on apoptotic regulatory 
protein levels, observed changes in the expression of either cytosolic or mitochondrial 
derived miRNA molecules were not expected to persist up to 22 days post-treatment. 
In support of the presented hypothesis, it was indeed found that mitochondrial 
associated miR-125b was down-regulated following rhGH administration, although this 
was only significant at eight days post-treatment. Cytosolic levels of miR-125b were not 
observed to be significantly up-regulated or down-regulated compared to pre-treatment 
values, likely indicating that rhGH does not exclusively exert its effects on Bak protein 
expression via the regulation of miR-125b. However, the observed trend in GH induced 
Bak protein expression changes, together with those of cytosolic and mitochondrial 
derived miR-125b levels, suggests that miR-125b may play at least a partial role in 
regulating the expression of Bak and that the mediation of this role likely involves both 
cytosolic and mitochondrial signalling pathways. Indeed, it has previously been 
demonstrated that multiple miRNA’s, working in combination with each other, are 
capable of impacting the regulation of a single gene [94, 380, 381]. Thus, it was 
concluded that it is possible miR-125b, in conjunction with the combinatorial effects of 
other Bak targeted miRNA’s, may have contributed to the significant effects induced by 
rhGH on Bak protein concentrations. Contrary to observations made with miR-125b, 
neither cytosolic nor mitochondrial levels of miR-181a were significantly affected 
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following rhGH administration which was not surprising considering that there was also 
a failure to observe any rhGH mediated effect on the level of Bcl-2 expression. 
It is a limitation of this study that only one individual miRNA which has been validated 
to target Bcl-2, together with a single miRNA validated to target Bak, were the subject 
of investigation. As recent evidence points towards a combinatorial effect elicited by 
miRNA’s on the regulation of mRNA, it has become evident that the combination of 
multiple miRNA’s targeting the same gene ultimately determine whether the expression 
of that gene is up-regulated or down-regulated in response to a stimulus [94]. Thus, 
future studies not only need to focus on whether rhGH induced changes in the 
expression of individual miRNA’s subsequently impacts the expression of their 
predicted apoptotic regulatory protein targets, but must also pay attention to the 
interaction effects resulting from changes in the expression of multiple miRNA’s 
predicted to target the same gene. 
While the results presented in Study Three provide evidence supporting the existence of 
mitochondrial associated miRNA signalling pathways, questions remain regarding the 
role that such pathways play in mediating hormonally induced anti-apoptotic effects, in 
addition to the functional processes behind their regulation, which must be addressed in 
future studies. Considering the differences observed in the expression levels of 
mitochondrial located miR-181a and miR-125b following rhGH administration, it was 
concluded that rhGH affects the release of mito-miRNA in a selective manner. 
However, based on current observations alone, the mechanism by which such a mode of 
action is mediated remains to be elucidated. 
To date, a limitation of studies which have attempted to identify mito-miRNA’s, 
including Study Three presented in this thesis, is that in order to ensure all identified 
miRNA’s were located within the organelle, researchers utilized methodologies 
involving the pre-treatment of isolated mitochondria with RNase [104-107]. 
Consequently, any miRNA which may have been associated with the OMM was 
destroyed along with the subsequent knowledge of any role it may have played in mito-
miRNA mediated signalling. Indeed, considering recent evidence associating both P-
bodies and cytosolic ribosomes with the OMM [103, 398-400], it is plausible that 
miRNA residing on this membrane represents an important “missing link” to the 
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association between cytosolic and mitochondrial miRNA signalling pathways and 
incorporation of their analysis into future mito-miRNA studies is warranted. 
Finally, it is worth investigating whether the effects elicited by rhGH on mitochondrial 
efficiency, as outlined in the first two studies in this thesis, exert any impact on the 
regulation of mito-miRNA signalling. Indeed, it has previously been demonstrated that 
the activation of RNA interference (RNAi) pathways is dependent on mitochondrial 
activity, while the induction of mitochondrial dysfunction has been shown to 
significantly alter mito-miRNA profiles [103], pointing towards the possibility that the 
efficiency of mitochondrial energy production may play a role in mediating such 
effects.  
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8.4 Conclusions 
In closing, the evidence presented in this thesis points towards the mitochondrial effects 
elicited by rhGH being beneficial at physiological concentrations that are within the 
range seen following the stimulation of peak endogenous GH responses in normal 
subjects. However, it appears that these benefits are negated following rhGH treatment 
within the supra-physiological range, the concentrations of which are only observed, in-
vivo, in the presence of exogenous rhGH taken at excessive doses for performance 
enhancement purposes. In addition, rhGH was found to be incapable of countering 
mitochondrial dysfunction induced in the presence of saturating substrate conditions at 
any administered concentration. Taken together with observations that the anti-apoptotic 
effects elicited on the regulation of Bak protein concentrations following rhGH 
administration in-vivo were not seen to persist past eight days post-treatment, these 
findings could have important health implications for any individual intent on 
improving their athletic capabilities through the administration of rhGH at supra-
physiological dosages. 
While the data presented in Study Three of this thesis points towards the existence of 
mito-miRNA signalling pathways under the regulation of rhGH, these findings must be 
validated and expanded upon in future studies. Moving forward, advancement of 
knowledge within this field of study necessitates the elucidation of signalling pathways 
which underlie the hormonal regulation of both mitochondrial efficiency and 
mitochondrial mediated apoptosis. Indeed, interpretation of how these two vital 
physiological processes are regulated could potentially have important clinical 
applications and warrants further study. 
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